var title_f7_43_7856="Hepatic venogram - jaundice and elevated ALT and AST levels";
var content_f7_43_7856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic venogram in an 87-year-old man with jaundice and elevated ALT and AST levels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEbAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFrU0+/s4dv2mxjkIPqeayqv6ZpsuoMwiZRj1pMDUfXbVXJi061BB4LRBj+tNGuq8TRGC3UHuYV/oKgk8P3EakySRqB0Jzg1SksZI8BmQ57g0AXItYRU2NaQ4PUhF/wra8P65YW9/F5tpC65xh4kI/UVyptT1EiY+tSRWkwlwrJkYJO6gD2JvE2iRuZF0ixYZ5DW0fPv0qe38SaFIZVl8P6axkIJH2WL5h+VeWypdRxZaSIDuA2cn8KLD7VIzL5oDdAM9qVx3Pf7DXvC2URtA0kkDBU2cX68V1VsfCsln5h8L6MylsZFpGf5CvnvSLS5Zt73MRAOcFzz713miXAihkgEqOqjOCxwKaYXPTv7P8GtE5PhvR4s8ljbIP6VkanofgmZl26dpaMvK4t0I/QcmqUFjd3MaOZ441ZBgE4JrkfFFvdWDP5UTKuByp4Jp3C47xJpfh+CSU2+n6btBzuECDP6V41qcEbXMnlQIi5O0BQvH0rpdWu5vMKzeYCR371hzsk5X5cEfr71NxGA8ahuKhIrRuIMS9QQeQM1VmgK8jnjNO4FainEUlMBKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKWgBKWiigAoo70tACUYpQKesZJ4BoAjpKn8h/SlNs4POwfVhRcCvRVoWpOPmX86Psp5O5cDvRcCrRUzRYbG4H6VIsXynK4HqaAKtFPbGTjpTaAEoopaAADNbvhyV7OcvtfkfwnFU9EtlubnaTyOQPWt69sGhClTkHpjvzUtgb1lrlus/k39oLhGPJIxnNLqUenMH+zxFAPnIx0BrlVaT7XsfGFGM4x3/AJ1s3EbtAZoSSrLtHPP+eKAKckFgYsoH8wdeg5/Giyn04Sb3WRgwAwcDpUcts7jaOCw5A5z71mtC3z78jBxxQBq6tcWMkrGKJwns1T6Nc2TgkRS4Y/eznFczOSOd3PQAVueGIZJYmVfusemeR2pAd5pE9mLFTJPlXOG/d5AroNFbSzNJK8yGJOrAfeHUdunNcLfeZAIraMJsABJ9TnvV2wLwwyZD7iQNw4/DFNAeoSavaXIJhuVVECgKox/OsnxRe25tXZYfOKgElm4+tcVbh2aQI5wGycnvS6lHdrBOqSO6bBvUZzz1GKYHP61qsd1ayIVCBOY/8M1yX2jbIGX+da93pN3LECdkagcF3A4+lZ39iSpKQ0i4HcN1pAN48neOS3OMdRTvs7ZGfm3CtewsIHi2qHdhwT6D6Vos2m6egUoXcADeetAHLpp7TEDZgeprLu0CTMq8YNdRLMbgsUkC8fd7YrE1W3KhZCQWPYUIDKopaSqAKKKKACiiigAooooAKKKKACiiigAooooAKWkooAWiiigBaKKTNAC4pcDGSfwpuaKAHZUdBRv9AKb3ooAf5jHikDt6n86bRQApY46mkzRRQAAkHrUqtuHzsSB0FRUooAlICgFP/r0ws2eppUIB54NTRxeblgM/SkBWJPekqV4mHaoyuDTAQ0lLSUAamgS7L1Seg6+4ru41jvATHyyAOq4ySK890hWe9VUxkg9a9S0a0eysdxVgZEOMDgfjU9QOajs1kuXJUnB5GOcVqyWrW9hbImP3pbcCOlbuk6JPMCzxsoCDcQeTz/nirXiZ44p1MZ3uo8sbVyMY6/WgCjodpDdIyGEGVRnPTC+tc14lsltozJDblgxJJ/ukda67w8ksmpCHDeZIhUDGPxzVvU4Y7gT21wMbG2gk5z9KOgHjkFlPcqrrE5yduQOleg+HdLbTdNKyo4mkwenQf41s2um2FvAJAxVYXJK4wW9Ke9w17fBi+0KMKAeDjvQBBZ6ZLLMXlXkYGAMkD1+vU1pajpqWunwkhWBPBx9+rsaoLtXV3RthPy9ORxWtbWi3mny75Ge4gAZVwDk+lMDlIvs0URQj51xjb2Pr71NqElnHoMhRSC/SU9XI44960Fs3MkhaEBuuCMZ4rn9YjIu7O2KFI1jDlT0bOaAPMtQm3Thd7Hb6/X+dT20fnkt5rKF/hPes3UJB9vlGflDnHPvSJevbq4jA5pAdOjyx2pwoC7erLjj1rIu5QrgyXELcdAc1i3d9cXXEsrlQMbc8VUp2A3I7m3jcfvuDycZqeWfTAGHns5OeSnSucFLRYCa6EO9jC+RngYxVeiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUALRRSUALRSUtABS0UUAJQaWigBMUtLtPoaApFACUU/yyT04puNp5waAExSg4OamkZGhQKMEdfeowhIpXAYTk81NA7IcrUeMDP4VKihiDuoYEwkUgmQHGKrNIDwBxVpV3KOmc0hgUZ3g/hSuBAse9CV7UkUYc4Oc1Og8rdt+ZM81e0nT/tV0pAJUsBjNAGp4b0VkxeMCVLBE46+te3aS0R06OGaKIgDC7+Mk+lc5pMsVvbQwNEMoNisFyPbNaV/FK0KLbHIZSxVRz0oGQa14hMVtcQWWVIYBiD1x6VyWoXhEwcltrgbj0A6c1cvNMuTdCRFIVwSAe+Byalk0dmhi3rtHUqTii4jpPBMiJJJfSxhlhiO1z/FnjpT2gS/NxIijO4HcOe9WdOgWLR47ePbhjvIVgMitPT7TYJBlleRR93noPX3pjON12EQsIYW3BSe3BPpVPT4ZC2QmCBnJFb2rwSiOX5EJY55wcn/PpUOwiyYyqyMsfPOOaQFuEIIvlO9lTa3y8fX2q5oc5hl3eZ8wk4UcgcdDVFbeR9jIZFRP4QOWJ789R1pYpZIio2lpd+ASfbqaYjsZVsHs5XlyJ+WPOeMda4XxpcWtzc201sg2ogQnJJyP/wBdXPtvnSbCxIZgGAGOB6GsjWIVnWcRNiNmLKduM/5xQB43qdukGrXCtnG8kZ/Sqc0nyFTgnPUda6rxtpTxQ292FOxhtYlcYPXFcUT1oQMKQ0lLTAKKSigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFpKKWgA60uKB1rU0xYLseRIpWU9JB0/GkBmpyCO/rSYOea6W08MzyaottFh3J4wQRj61V1DQ7qz1CW3dOF5LA5FFwMMdcEVNFCzN0JwM8Crxs1jVywDc8MaptcuSQpAX24oA6fQ9Jt7vY1w4DdGVRnHvW5P4FkVh5cMrgnIwmciuV8L6sbW/hWVSVdgpb68DNe76JPdTxmxLyIBjEkXJK+lJoZ4Rr2lmzunjZiAP4fSsRYXdsRrux7V9Fah8LX1q58y9m+yof+WeNzEe/pVn/hHPC3hK0UywoXU4Lt87n8KFcNDwC00HULshbayuJvUxoTXTR/DTxLNEGi0uXBGeWAP869Mg8c6bayL9gsZnQNjbgKD+HYVYf4lXDMxjsLaNMHgsSR+VHK+4aHjN74C8RwD95pcvpgEHFZk2g6hZNm9s7iIAZ+eMgV7KfiZdRuzS2MLIDgjeePpXSaT8R9A1NhBqlv9mLcfvVDIfxp8r6MND5zjgKAYHU45q0bRpItwHzdhX0drHw10DxRavd6LNHbynnfFyjH6dq8b8ReH73w/dtb6hCUI6Hsw9QaWq3A4+G1Ygq64z2PWvS/CnhUSWMdxEudqA++a5qO2jniRggAAwec59K7fwd4ghtgIpwFT7pAHBoA17bT0iASSPcpxggdSOtdTDZq9isu1WBGDxg4qWzudFlUySyyow7gAjt71s2eo6CbcwtMxYDcFKinZgcQ2lCSVVj4CLuXnjGaydStJBIqGTduOAemDXfXviDRLe4CmN2A+XAAXOaxde8SaAsihrCZsjIIccUcrAoWVi0yRlsAAdBxg59K3bawZS0yykkJgHPSsux8VeHZSphguUPO4sQcVvr4j0aVYgiylQOW7f8A66fKBzOp2xDKRgKH785ps8DzwusZQMMbWAzxmrOoa7oDOHxcIV/j2ZPX0q9a3/h94isd88bTgN9w9M+hpWYGdLaspGSZG9eePSoLWwzI7yBipJ/Ouqt10Jsu18XUnOSuOM4rUsbXRjOvl3G8r3J4xnqKOVhocWdMiEmcFuflXGT+NVLjTwI1CI20jAwOhzz+Feqx6VZTF5YLiJg3bOMe1VNQ0wW9kdlusmDwykHr64o5R6HjnifTll06aCdN4kQ4Ur9xh/F+NeAXUZinkQjGDX0d49uxp8M6qf3rjZhlOee/4V4DrNrILl3ZCu455oEZNFOZdvem0xBSUtFACUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFXLSxnuU3xJlM4JzQBUorVt9JmmdURMseOtPvtBurXBZDt/vdvzpXAyFGT1xW74fsmv544LEZudwOD0bn1qPSvDt7qDgRxt8wO3Ck5NdTa+CfFWiL58Nu8by/LnH+cUmwNm98H6vpkdrdWcM0hYlJTFyufrXO+KtC1CO+Eaxzs0gG7dkYPsa7XS9J8aQaIyvqskdrGS32bzMkeprmta1HWLlB++leJDtTd/EfUGjTuBhaVoR88/2jL+7Ck/LknPpU8HhFtQuMaW25T/eNX9D0zW9QvISYnkQsF2YPPtXuHgzwaukW/2i+VBMfnIxwoxyCe9Azz/wv8K2Biubt2jUMCQB1xXr1tDpmhKjQhVkUZwOScVheJ/G8OmRSW9g6yS9MjovFcxaX11fIs4lTzWOSJBnp3zTskFzudZ1a8vTIY9luhXAAPzMK8z1lJRMrybpGI++ckGuol1WWEmWd0mwNvQCo7meHVrJPLRVYfKPReO3vQ7iPP4mMl15eANvIyO3rTVtNkMmS3nElR8v860Z9Mkt7tnUdGweeKjU5uB8rKx+7g5GaQHPPpxMZd9y59TjNVp4EQg4bI+X3+tdmLb7TB5sxG3dkcYBx1FYV9bK8rsDkZzheCRQBd8C+JtW8OXqy20jG3JG+BjlG9a92vLPTfiN4TEiook2kg8ZiavCbCwNyUwdoJAC+telfDu/OhazFDNIxt5z5TDoAex+tNa6MFoeRanp91ouoz6Zd7omVyufbPUVVtLW8XdEm92LkDbkmvoD43eCUuoINXt1InT927Beo6jNYXge1ittMR7iJTdBuXYZOP8AJpW6DON0bT75iIZIpFCnDEg/jXd6fpAW3GHw/IO8YwK6u0nj3v8A6OBH1ywzn6VMZbe4iPPlt/WnYDzbX9Nljx+5LvncrLz+FcbrNtM6hud+cAd696eFLi22bomYDIY4JqlJpNrMgRobaRAcfMoODRYDwCJXW6cZIK8EDoa2WvZre1jQhAWGcYr0eTwnYfbFdYbZDn+dJeeD0aECP7OAvQ/44pbBY8gvb6UNkKpTbyTz36UlpfyyTea2dgAUFRyTXfXfgfCnEVt6Ha3JroNA8EW0WmKZ7WPPqp/+vRqB5vYXN0jFnnkw3C9sc+9dvpMUmpscT7Nn8QH+fet7/hFLCXA8lVfrznitnTtDttNwDbOS4JBU9KauFjm2+22Vs4iYS+Zwu054rm/E2pXNlprbpHM4YHrjaPwr1WDSUlYbIpCqgH05rjvG3h9Lid96Rxo395+aeoWR893mu6pqt2YftUjtnhSxNZt6CqOsj5bPr0rtNc0KLQ7vz7Uj7Q/3TztA79a4XWEl+0uWjZNzZ561O+4jNHzMc5pjJj/CrEFvJI4Vck54qWWzkjDEjJHXHNO4FCkp+DnHShkKgZHWmAzFFOKnGaSgBtFLikoAKKKKACiiigAooooAKKKKACiiigBat2d1JESithWGDVSlQ4IzQBZF7OkgZJGBXoc1dGvX20RSyeZGP4WrKIy+B61OlvnqeOlID07wH4pl0d2m8jzFAUE8cZPb1rtvE/inXdRtBcWhMdvjCgrliB1yK4TwTBFd6cUXPmx8nOPSvbvCi2t1pwRD8qjBLDv/AJNJMaOV8F6ouoztFcyM8rrty3y/pU+r/D2XUb6P+zBujB/eKT8o9811Ft4FY6jHcWoIYP5ilRwBXp+j20VlGYiqh2GSTwGNNK4HD+GfDtr4a0xSdrTcb5G/p7VieOri7vLYJYMq2rDDPnGR9a9D8RQ2C2hN1IQrHGN2Mn2rzHxvdO1qLTS7FnjTBLKeAKdrAeY39qqbhNIW2gkAjI/OpbG5aGFmjAjTZwBwWqHVbO7Nos5kwkjFCjHDKfcVmW9syzBJWYZHODkYqRE1zczzyXLGQ7FXj5sZ/OrGgavJaSLvYuhP4GqiWpQeZLKsQ65+9+lMlSzhYMjFi3JLHHPtQmB34Md3AzxMhRjgkdB7VmNprSXiqwyqH7zelQeFdbsLbdBcvGEcHHzHrW9da1p9sS3Aj6kZ607AZupTPFGIEwqHK/7orDEZJkKxqWQ/KcdRinal4ks7i4ys5Chvu7elS2eoW08nyTI5bqBxjP8A+qgCzYKigb/kYjO3GM++e1XZNWW1MbhAAmCr59OtNSMOS0YDKeSM5IrN1eNHkjC7dxYjBPQnqKAPfdXu28Q/DV5omZXktty88ggf/WryfwXqTiKWORmf5QwB7889a9R+HCNN4DWMtu2K8eCOoryXQrYjUrmJVPy5AGOQN3amxndC+j2jaxU56/Ss7Urn94fLLBx8/Tj8KaxfyiNwHJKg+9Vr4lvm3FARkexHcUCNLTbnzpYyT+8K7ScY/Kppd8V0oVtqMOfc+tZmmea0sjOdxXJzn8q2UYyeSzqDkDr6UDKt0374Avtx1PXNJqUrrEyB88AYHatG+017t/Mh3H5eB3OK5y7j1FbgRk9fvgDBxjilcDC1GedbiKJXfO8Ek967D+2ZrHSVjR2EgXAxzk9Kz4NGnkIunRTkgk5749Kt6haiNN4B3AHCY6GgLDrHUbzciyOVYkFjnPHfNWX1iZ8Seazc4AHpziuegmdpZOVyeMAdcelVZblkjJc/dyxHr6Yp3EdzZazNhyrM3y8DP3a5+5u3vppjMxXyyQQehFY0dzMzMzSsBIg5A5GP/r1XnmeSKfMbhS2AT1zRcCv40bTHghLM0piX5sHhcdvrXmsn2K8lEkKZdc/6wbsV0vjq5aHSkhDKJZn3EDghewrg7dmgydxVsZBFIDUWCM7mCBi3XHGKy7y3CkHIyByRxWnHfF2BPyvjBxnrVS9lGU3BtwxwOhNIDLubELbl0zvJB59Kz3QgqGzXSFlkjCj5mBJAPQ1k3sRAJIOAOp7GgDPkX5QB+Peq7IQM8ip1+VjnkfzpjuCTg4FMCEjGKbT2POQabTAbRSmkoAKWkooAKKKKACiiigApaSloAVTg9M0oyen6UgGQcVPEhC896AJIAp4ZTn1rRs33fIqgL3JqpGg2nOelXrSMl18o8e3epA7LwZDYR3Ua6irpDK20yLkY9+K9u8O20UU1vDaXTNpyrwFbL59854rx+6eGPSrMRnZOV+Zs5Az/ACrs/hvcS3UpgvTIXjBKunHT6daEB7vban9lgVLdIwCvDOOv5GuU17V5F3sSiyc5y5GOPSotTiuUgSfzCqBN3LdfQYrzbxJ4kkbadO2z3CkpKrD/ADmquBW1jVtYubgzPI2Yz8qk8DHbk103gzUpNVDG7MQWJcuUOWLdgefrXjfiHU7y6QLJNIjbdxA9Pr6VN4B8SHw3q8cspMttN8sq9wD3+tLcDovGev6fb6zd2jwNKhfcJO6t3NclJqLzndZ3CEDgqx24Fel+JPDNl4wmabSJAZ1XeoVeGz/DXlmqeFb7T7gvLazKobYw2Hg+9JjsXoob++tPKjkjJLZQ56+wrD1aWZMwylxLGMMpPQ10HhZNRgKxC2fy1cSJuj6MKq+N7G+SV7m9VTJId28LjPemI5e1uGV0Yg49M11uoahs0iIqAWYchu30rj442VFIwQcdKu6jcl7SGEn7o696AIJrlC+XfG70rUsFkykn8G7GOx/+vWB5WEwCSSePatXT/Mj2kSFefunvSuB2sQnCq1pM6DGMDj8/eqc2qXJnjEx4Xq2B1BqSHX5obEpOm6AnBITHPpmsi8ia5YSxk4Y8D2oA+o/g9cR3ngPeSBlnBOcZrkfDNmBq97HImCNxDBuoLcVt/DCBrH4Zx5LJmJ5CQPrzXMfDm5m+0zzXA3xSShd3t1p9hm9JbFZiWID8npxWdPE9wxVeMNwSOgziu2n0tJG3Ry5QngZ5OaiTT4bSJnlKehOMD8qdgOZhga3t3ym1pMrntgetQrIWKo2VVVHT19K0NVuRLKdq4QDg5689KhMEhG4DBLccUAdN4fbz4mhcncF3D6cc1JeWSFgzJhh69Kq+HUdNXmBcsPKI/HFX7t5t7K5UoAOc4x7YoAy77bbW46BW4GBxmuY1BwN2wksBvbJra1BiZFRjlFGVDdhWDqcSmQgyYQ8YXkn0oAoadDIzRM5Q7zu3egqhqFs6AwksHZyBxwB161qIwhiCbHBBIGF6L6itqS1F7pzeQoMseMZ9P8aQHCXUxjuY16x44wvBrSjgee2gLs2Bl3Hp6dOtXdQ0ediisoJQcbhwfpWlLpXl6K4Y+XJ5YO0jAYHsMUXCx4H4k1OWW/uPNJKoxUd9oB4rBe/GTkYUdvWrWupvupguPkchiPXNYEibicZ/CgRu2+sWkSkGHdkYJU461TuNbRhhbfI6Dc2cVlqh/unFNljI7YPvRoBoR6y0e3bCmV5qV9cWTIntkcE5OODWHSUWA1RNZykgtJCPcbv5VE9rG4zDcRNx0zg/rWfRRYCV4nVsFTmmEEdqAzL0JH0NDOzHLMSaYCGkpc0lABRRS0AJRRRQAUUUooABSiilUc0ASqq7eQathAWUgH3qrH1GRnNXIWVep57j1qQLtpb/AMXAPce1bWn2XUhVIDA59qzbeVdmAD7+1bGn3ccEom89ECpyoBO/2oA6PT4VjaNZfLkiC/MGXj869E03U9K2WktnEkVxEu1irEZHt2615iNbil0+LcvlspOVxxj60aXfS6lN5KHZGvIGcZ59aAPa9XuRqujLHDdFE2n7w+8Se9edeJdJuNGsxfF48S8PIR2x0Ars/Dl+I7QMQHUYQhznr3z7Vz3jPxNFdWzaXJFHNb+bhieuzt+RpsDz3V9OuNUAksY5Hk2/NGozgduazp9ObSGjj1NQ07YYxA8ge5r0zRrmxsbRTp1xbIQAuXOCCfWszVvCs+rPLdrLFNI5JPzc5pWA674e+IdN8LW8M9zCxhCbwmck59Kn8SePvD93I8yxks3JCjn8a5PWvD1/H4fV9jDZCoZR6gYJrzFTKWlyMkHkHsad+gHpB8c2jSrFZWUjySNtUMOMnio/iFE0+gF51VJEYKAOmcdAe9Zvw00tb+9ku5FULbDj1yeM4pvxUvp/7S+w7x5UQDFV6c0DOCgj5HHynioriIlQRzzgitC1BVAVORgBhT2SNpWYh0A5IPbNIRnxxDyCSCucEH1rpPCmjm+kae5fyrWFdztiqCxgSiM8jHHPau2ktJIPDVpbRq6RuDM7HgkemfTvQBT8RaUlt4biu0EptWk2jPG5T3PvS6bpNo2hW8vmsJ5CQsOM/L2OfX2pNJGq61EumI0k9nHyUY5SMeprdsNNca/aWK5ZNyohxx1GcYoGezfYjp/w1jhjZwwtQoI6nI/+vXPaJYfZI4IOAqBQccYr0HxTGI/D0NvGmWLohx2ArnDDsjbcTuZce9UBAL90Kr0QNgZ56VWv7pktwuCWbDHHYVFISGOf9YDwMcYz3rOnleWZznlTx/hQInUo5kaQMGyMA9M1owiMKNx4ziqQjClS5AJwSD0Bq+qKyKNxGeASMZoGbHhz93LOxXJHAJHWrU7KPNOCC/btVLTpFIAjYsVPzetWJlMjkjOAck9qYGHqMp+1kLFyyjvkfhVW4tll27iNxO444Jp2pShLgd8H5j6e1S6eBIHcgsCuPoPakBj3FnCJFc5AUgZD5wKsQXqxMyxcAds9TVi9g2kN36jA9O9c1IZXuZGdQqn+6epzQDOiOtMZVV0UlRkAgYFYniPW5WUFhmMjBA6DmqkYeVJVblc/KRyT61lXEcrQtC78dVGfumi4jyTxRbmz1a6ycrM5dWHTnnFc8/BLn5VH613HjKzY2kcjHMiOc/7INcBqEhdwM9OoqUBG9y3O0YqFnZupNNNJVALSUtFABSUuaKAEooooAKKKKACiiigAooooAUUtIKWgAFSKRx61GKdu56YoAkDAcdOasxkB+23p65qmMkZ9KnjOMFj0NIDVtVJjbGPTrVsCO2AMvzsf4c/54rNWVo1DKfcU0MxLNu69N1IDfslF3KFkbaD6nirltJ5dyGtmG1W5wKw7aUhlDkDvlRzV/TbtY5Gzgj+RoA7vR/EsulGCO5UTQF8sv1P61r66NAaItkxs5EmY1yWz2+ledapdB3WQbdxIwB6CreizM9xGjksCc4b+lMCt4guIg4gt84LAuTxj0FVbXWtQgdBBeTKoPGG6VHrjD+1Jl4GTjIPSqNnFJJcoFLFice3WgD3LwvqjDw/G2sXZZ5/9Ureh7GuQ8W+Gdglu7UY+Y71Xkn3FTaXp9xqRNvANzxAeuOgNdt4dtZzB9m1JF81Pl3DlWHoRQBi/BWxlUXfmoVSTGMr+tcJ4+3f8JLqDbjkSbQGHJ7V9Q+E9GsdCsjcXSrHu+bJGABXmvjjQ9JutXnuVKssj7hkZzmi2gzxe0gMojWJDI7HAX1NXbfRbuS4kUKjOp+aPrj617PongfT9OjgvpYwSDvVT/M1Jf3OjLfM2jCEzR5MsUQzk+tKwjkPD3gC51XUoB5YUKRkDgkfjXrGqeDNInt0tyzD7PGI8BuF4rmvCviSRNcja3i2yBsNvHGO9drrmsQw3LGzQvdSJuwDjk/0ppIZwlz4VPhBSltII575CVI6lQDgH0q/4D0SW41PTpbhFPlEycHO36VQ+IniG+uZre8ubYRFCtttOeDjk/nW78Imv31O9mnctaoFEffBPUU+tgO58SEvJbwxqzFSCdoyfassadK2XMJIxgDqc1jeLtentvGbJaOEKqqfN371atfFN2hG2OFwWwTg/nT0AgutImNw+YyNwyeMZNZx0SX7QWRH+UkkYwDmtseNGaV4jYq+0kZLE/lWbc+MZvMA+ysiDrhhkHtSAdHpdxuVHt2OeM449qsXunSogTZ86YAwOlEPitk3OB1+bBIJz9KaPG8HmFZcBh1ymcc+tADtPilt7gM0ZUOMHirmoStAw8tGZ2+U4HQUyw8W2k8wRfKD7e6nIoufE1msh3twvdR1pgc7dxSG5PDsGJG2tGwGFKhOcAD2ok8UWfnKxWJR1BYY4pX8Xad5sQLwJnklcHNIDJ1cTsNo3M2eSR09qwvsUoJIDE5rpdZ8S6fHOWNzAM4O0DH41LY6/pNwuTNCVyMENzQBh2thvsVwCSQTuUdPasy705wkyuQckbTnJOB3r0eG40RQQLyBAM7gW/wA8Vn3/APwj6xu7XsG3+9mgDwrxUhawlDkD2+leRXwzIxPr3r3Dx1Npctu8kE6vg8KqHJ68ZrxTVcCVgMdaQWM+ilpDTEFFFFAAaSlpKACiiigAooooAKWkpRQAlKKSigBaWkpaACjHFFFACjkir9ug8sZxuzmqcYBxkVYJJHQfLxxSAkZSCd9Tx8RkYzyOKijG9ACTxzkdqt7AEXGcsM4pALEPnzgkirMJ2y4IwSf6VBGuWwOO3NWV4kJJyQfzoYGq8CpblzncF2jj170/w64OqoNwAJ2jPQZ70TLuQLlQQAeO9JosSm/j3Lkg5waAINWBTVpfuMNx5WvTfgv4EtNcNzqmoS7YbeQKkXTc+M5NeX6iCdQnx03ZFdL4J8TS6JdKN0i20v31B4znrTA9Wn1jTNL1mbT7SHEynDIF7+pJrCufEF5peqLdeUskRfcQfTPWuZ8Qaotzqr3FsyefKAS+fu9q6LR2stU0p4ZXDSgYIc5Iye3tSuM9PXx5oPirQzYB/LllXZIj9fpWND4fmhdkgP2q2XldxyVHp7ivKNU8PXWi3cUkfmGNiCrjjbX0N8FI3uvDc098pco5Cu/UrVLzBnH+Lr7ULXQwY4QpOIhhcbfeuM8AJHavcFWSS9lzywwMd69B+L+polkYrTG526Y6eteVaDP9j1SCSJVRh1PWh7geleHNLheS5ukiVGGAxHTcayrkuPF9i0xJTzMEhscV2XhO4VUVXhTBfbJj1NZnjq1tG1v/AEZcmAbjk8DGDTtoIt+PNMk1XRbmy+ytPsYTxBOCuB6+9aPwbsZLHwdNd31sYJZWJMbZzwMCqGjeLmQl7xV24xuI+bZ0xXZ38sMegTyQ5SF4iy7uOvShWGzxmK5fVvFs7vC7M8pYEH0JxXTpDdRMCYMLjgkda1vCWh29mFmePa8vrz7Gu2DQImfLjYDjaRjNCQHmVtbTSMCUOd2MqOtM1DRHWRriEAr6MccdxXpMr2JTY0IiLcnYelZNzplrMXEV1tVuzfpQxHGSafCLddsg39z6/WuZvdLnhu5NyEKDgFeRntXojeHJo5hJb3kZG7OD0PtUknhu6ciRWh3nrhu30pWGcNo9solJUYdBnJ71k6s0iXbc7lLflXrTeGnEHzrHuzjjvWHf+DPMuS+1sem7j60WEeR3Ds0+M7kHRW7jFV7a0up2KxxHgZBJ4/CvU5vA0btkq5OOBjFMm8PXFrbulqiIGHLFen0osM8m1+KAIEYO7r95z0x6Vn6fPNAUjjJYAcnHQ1283g6/a6kk+0hmcfxZ79q6DSPAMfyyXMqBgT2POP6VOojloFFxbxEgiXHzc54pmoQ7kKKUVV969HXwWu3ab+3jAXBITsfasDxB4VskUt/abMBxhI+OO1MZ4p4vuFs49g+diOMjtXnl45d8k5r1jxv4fidQLeV5GRSQSOf/ANVeUXkMkcpVweKSEVqMGpFjPccmn4AK4A4pgRKhJxSMhXntVnbxnoM9qZIQCCCaAK9JT2XHPrSbTjNMBtFLSUAFFFFABSikpRQAlFFFAC5ooooAWjtRQKAJVB4IxxVxSHILAcjjFVYxz61aAKnAGD3pAOcKh2ZwTWhEv7jCgsVPBqoE3Kpx16Yq3bgrjaMbs9aQDoiPMBxk9KvxJ5gLqBvB5JqCGMBjtYDjtzVyzbMjZBJ+vegCa4fMjODnAx04IxWhp7pHIXjZd78Y9OBzVSVCSxGGbHCjils1b7ZC4xuB5yOPegCPVAUvpJF2gsTj0B9TUcC52hVITPTHQ10XiDTJI1WYR4R8cism0tvNnKcYHSmAsERNwu1fmPbsfauj0UNZy/aBy6gfQiq9lEkd2hClgM7zjPetzyneLEYGwLn5evWgD0UeRrWjKiAHeu36V0fgC91Wy06axuh+4jBC7RzjHevKdH1G40+QJbZMYOSD0B9TXa+HfGEtu6i6hGXPYnp600xmV46064nne6+YIfl2HOB7mub0yMWt4hYK7PgE46jPavetUi03W9BM0QUBkz7iuH0bw5Zz3kYLlSrZHzAGhoDofCto1raxTSQYadyCp9PWneK/Ds813LLF5e2RBwp5P1q/danCt1bWQBPlk5b3ArVs5YbmSR4RvEYw5IOCRVAcXpXhhHeCNixIcbuPvV3viqFIdG8vZlThQAO1UdGYz60Fhkyq5crjHFXPE14vmx2hceaylgD60AZ2jy2ywxAREfLyOR+VLd4jkd14T+pqihYGPLh8cEg9PanalukhU5JKjJGe2KQFK5d92dxfqTzg/Sq/mEv5eTnABqNLh3QBsgcgE1YSNZMSBTnrxjOaQFoAyGNd7BgN2OnHvU8MzxzgE/Jnn2FTfZthj3csE7j1pBbMy9OmeBTAvXk/l2cTEjb3NZUjuzbwx3KMcd+tWQxNs0cuQOq+9Yeq3f2Oy8iJgZ3JZuM7R/jQAT6g0RyXI5wQD0NVLq+mZEk355zkHgelZ+nK0xZ2ywzkgitO7tmWNFVRtIOTj9KQGLcXchdGDtjOCC3brUkUrOoLhj2UA9B6VMbBRHISeYxnaep4qvDMsaKgwQQQSwpAW0R5gSynJbGAT07ZqG80+GNmaS5TccAKDuwT7CqN7euse2NiFz+JAx1qs0vz/uyOVz8vTOO3rQA3VNKtLm0mLSKZV6gjAbH8uteJeKfDQWcrb7GbHKhq9ou2LWkmQdnCEg89K881PTZPL89lG85brgn04oEeWmw2BtwII4wRxVO5s3QhwPkPSu71G2KRIy5VHODzmsq7gWKDawG4n5c9/rQByjIqcE8Hpjpn3qttxJxWrcR7S2MYPbGMVSEZByQCRQBWlDEDinxcjbjtUsmdocAEdOlRqDu3Dii4ELoecCo8VqRorJz3qpPbkE7aLgVaKcRg4NJTASlFJSigBKKKKAFpaSloAB1p6jgHtSAYHPapIueB096QDkXbzjmripuUEfeBxUS5wD36cVZhHyALyc5zSAnQNvUDgdMjtVqIDOfTPU1CFUlQMkkdfpVu3VcZYHHPagCS1QF2yM57jtV6ONQpJ52+nrVeAfOflwvr71aUHcMfxAAgUgL0MAlkjKEb2HG6hYwJexLHv0qzp6N5ylUHGSDWhDZsJY5Sobng5yOTVAbukXkF7pJtNTYRsMJlh94duansfCaOyvZzhueAOg4rGWzJfDAFs7ip/wAa6HRZZbFl8mMA8HCn+VAFdtDmtbtkkiMeMtgjIPvWoltFHb8gLjgEd66q2uo9XtDBcoscgTKnGDnPWsfUtPNtAVBB4HO3nrQBheURKTGRjABOM806zjuJJdigsFbJOOlXba0aKR5biQRRZ/i6A5ottWhgMqwKZpiDyWwDQB0egXrWg+zXJLQOPmAbOPqK6vw7odqmpJdrNm2RdyAN3968OvNW1GcylZNgQ7QqcAe1aGheI9T062khjnbypuWUgHFAz2fUNEjn1V5bWYh3bcRuzx7Vv6aUg0yXTY/3T7sAOOTnv9K8b8M+Kn0rVxJLO8tonBjHJHFejS63Frdi2qW+VWCI4J4bjPUCqTA3/ClnJBcXE84+b7qv0yBXP6vqgm8TzBxu24jAPQGui8JPMvhCK5vZhI5DS7hySOteV3PiKyk1GeQu2S53EducUMDvYljthlixVwcIBUnko6AKzHg8NVvT/Lu9Ms3j2kNHwc81LLpsnk9j3BzTsBzdzYmIopwAHyM89eat6fbb7hQwOM9a2oNNkmtAH++rd/Wpvsq2tuu/7560rAZc0pVt2e/fqRVvTpVkbaepHBIrPuY9xLMWPGcY6UaeWQlmLEZ4xQBoXkJYMqkbhzmuZk0lppWkdizFi2Dx+ddAbk8OnzbjjkVFJOUiEgAEjHjjtQBl2FkkH3gASe9QajIyyKikMc8+wq9duwG7bhmOTWRdQyGQS/djJ6DqaQFaYFbadiDIHXKsD0rElIWJQCQX6YGSK6OxQCQIyksRg+3ao9S0g2/3RhSM7sUAcddK6ISob5sg7geTnrUccjyrCFBGOgHGK6B7N5WVthHHXOafZ6UvnIQnAJyO4J5pWAxZVYGFBkI5IOepOOP61xHiPUUjnMDEKE+Utjgn1r1fxlLb6Rpdu1yyJIwIQnqK+dPEeuw/2nNMz+cCeFXotDA2pZoxbuSFwBlAe59a5rz47gyFQVw2SWbK4rCu9bmmyPuk+jGqn24pFsViB/Fu6GkI0bqMTSZVlwM9fWqltGfNbft2Ed6qG9i35YEj/ZqWPV0jQBYRuAwCxzQBNeRKCQqkLWe6bDjJxWg+upOFW4t1AHGUGDVeR7aRXeKQD/YJwaLAV7dgkmDyM5qw7xSLnGOePeowowDsAPpTVXLlePXnrSAbLEGGePb6VVeIquTWiANmMc+nao3DEH3HQ800wMyl7UUDpVAJRRS0AApy0lOVc4NADlyetTRpjDHt60wAh/lPFTxrlRnrUsCVFzk469KswKQcOBgc1DGApG7OKuRA7sEZXPHbigCUDdLknjFW4VOw8g57A1VRdz4yBj1NX4oJWQlAxVeNwHegBLbPnqAMpwD6/StvT7VpupPXOCeQKg0y3KyZKEuOQMYH1rpNOsxsBlCsCDl84xmgC5pVm2xkwiY53Hqfar9rYqj5J4HXI6kegoiQxRqyR9OgHPFT2krvNv8AmJB4yeSfQUwHJamNt4TknPzE+npV62VVkQRDoM7gMZqL7UBtXqe+TnirCTwfOZJI1AHGPSgB9k7xzl48rxnzCev+ea6VtQtLqz8slfOVep4Ga4G61H7TI9vAVUcfNkjinxhwyFZWEiHOecHNAyDWZLt5288kRH+HqPpVHRAVuUwQoYMMnpjsK7S3hi1GB47nasg4HHX6elU28OLFejyZB5XbHVs0COcniNvNIu75T+Ap8QHnqx+YMwwP6Vb1qKKK4uS+7g4J71VjQK1u6YY9xjk9utAFi8g2Xh6c9Qvb3r074XaZJe6dd2qttSRhuPoMc1wE1j592uw4LEENmvT/AIaTSRakLaM5JHzHtTQzutRs4tE8JTxQtkRQlQW/ir51utGefWLU2qnybklpMdVx15r37x1qsmn2MSFBJ5rYIPQV5zZ6XHGzXw/eb5coAOMH/wCvQwOj8MPJAwiB3R7eA3GK7mxlAX58Eehrk9IijQ9MsOC1dHCrFcDiqQGr5iBW2Yzisi4VpiwJPUjp0qzbMTuOeBUWcuRyQc0CKDQAtk9B2qKSHYpCjkj8q03hGw8Hkce1ULgZJCdR3oaGV0UsoXBAXsTnFNukKwscZYYx6VOiHzFBOcjii+z5I9c/5FIDEaYsRGxDHGOfSoJkXjABHOeeBVuCAeYzYGTnHtTLqFt6kAZA7GkBDDbiMfMxDHBHfit218maHypQG7ZNZqKGJBPpkkU6RxGCQfu4PXvTA0n0y2CAqqZHcc1i3iQ20ilQVPLE+tS3F06xFo3JB5IxWPf3RmEgc/OVxQB5T8e72a60y12EskbnJ9jXzvdTbmOPXr3r6N+Jdok2mmJ+WbJ+hxXzjdxGOZ0P3gSDUgQ7j3NDMT1NJinAcE0xDaTFKetFABSGlpDQBLBM0Z9V9DUqSgDjqTzVUUtFgL0MmW5bGallfMeGBBz271nI205NTrcA4DjcPWpsBVb7x+tAobljQKoBKWkpaAHZ6DpTww4qOnL1BpATDBwD39KnHGKhxyKlTt64pMCzGMoDgcmrEWCSBuPPAFNsQx+XuTjBHP1rWtbNVKuzHcBxjpQAun2plZXG7KnqOmK6C0tSq8YAAPfrUVnCIzhlOcdFPGe1bEMJEZGVLrwG6/5+lADbVMAHAxjp2/GtiyiCopwSX7ngA1Ut1ISRWAUEfewQCP61YhlXzESLOf7+On09KYGqsiIzK2Q2Mn3NUWlfDiMFUwQqHjJ+tVZZ1jVl3k85J9qo3erGZXRBjGQAOuKQGvc3y20BDhlBA+Tqaym1B3LLkgY5Hc1kOWkYsGLMOSegI/xqxCp2FgPlUZGeKAJ7ZgJMMxOD1NbdvcylS2847KOc1jadHiVhkBjgBj2rYg2hvnJYevv70wLSX0rl4iXB4GTwa7vw9phk03Mzs64yB6GuFs7fNxuk5G4Dr+teh6VqcVta4RDwBu5oGc74pgi2ucHzRgDK/wCc1y0EjfaXaRTxjgevrXeeIprS9sJHf5CFKYXrntXCrB5KTO3LfdXJ5Hv70COq09kZS8YJYIcnPPuK9G+E9rvvZrk5wibR3FeV6HeRQeWZsDzARkEcivbPhUETSp3wuwthT6gU0Mb4+sLrVL6CBJUht41Jdm6EkVTsIHjtTaqPmgIOCMZ+ntWvrjXN01x8sfkF9oOeo9Pak06wZ42SIOBjADHdj8aYENk6ooZlz8vT3rZjbcny8GqUVoyNuKgN0IatW0gBAGR60AR24PmYXjI65qIh1nO/kZ656VrpHHG45U/zpsqoz/dBz3x1qkIpJgxPkcdKoMGZyOPc1tnyo4gGAGTzkdagMEZfO7GOnvSYzJhztJ7026yw244PPFaxs18wnzOD7VFPbRgZyxwMZNAGDAMSf7XIFPuIgu0hScDtV/akUgOz7wp8yRsDnPPNIDnDkGQBcHsc1HIpLYx7DAzXQi1gbjnnr2pHsYV5TPXjmgDnJAAqpyCSc8dRWJqZAYyL1BwRjt7V2cml7VOAQ2dwPrXI+IYJbcEjLY7dc/WgDzjxhia3dGkJJ4weDXhHiqyFveFhkE/ex0zXt3i1JVVyAFHcMeRnnj8q8v8AF1uktq8kefNGN4NSB5+D81Px8pNCjaTmlOQvNAiI9aKKKYBRRRQAlLRRQAUUUlACUvakpaAEpaKKAFAqROWA7UwAnpU8QyxBpMCRCcjgZA9OtWYY/MdeDn2Ham28BJyRgZ4PrWxaQpGcBtueC3ekBY0q3KqdmC56/StWOIKBvXK5qvY/KwCnbnv6VcjUlQVLHBPFAFqL55v3UbjAJyfT+la1qWAAX55MYAJwOe4/AGs6zZzI2Uym3GAeT7ZrXUqMMeV7A98UICXCpwpOCuAT159Kpvdraqy7cSFw2PX/ADioru+WOR1jY57Y5z/tVjt5ksgkds7j8pPGfagCae8kkuTtyyvzgdqdtX5s4DEjkjNQIcs2wjcc5yOB6fSrcYPlEMdik4x6UIBoX9zsix9/NW0ZY4mJB3Y5A6f54pjLkI+RyMEjjAqSMjEhyF4Gc96YC24Zcnn5iMH+f0q5cSldoUuqn29qqCRJGTG0YIBx1qwHYvuKn5MHAHNAGrbSGO0A2fMfmIOfwP6VoafrLQShpgwXgLxnj3rIt5GkUMgK/Q9RSQMRI8rZwMYHXB7YoGauo3hmYqoxGcOPaqk7hkJwy7RnJ6HiqpkD7jja2cZ5GfepGztw4AywwCc8+tAAfNCoAASvTA74r6H8FltN8EQvNw3lFycZ7V4Pplu11eQQjPzuFIA969w8aMNN8DtCpYFoxGOMY49KaA5rStfkh+ebzpYZ2JCgdKv2PiGaBhAI2EGScs2STnjkV5zY3twZEhkkYwrjEQOPr+dbtjmMBGyYWPy4OStAzvbS+mklk3SMqs3yknp/9atq1ubgKBI+45zk1y2jqXVY8ZX1PU12llE2wKduAMfSmhDBdyN1xnGKswyzSRJtIyvQe1VpbWVM7l4qSAmHJJCjHQU0BW1DVJ4SAr9+hANRWusXLzkbY85xgjoPWsjVjKbolQNvfFO08OE8wKVIxn1NIDop9ZkS5ZTGhToPeoLvWAmWeMAdeT1pjQGa3WRAfl4PHeqy2bziSMqSAueR0oAqTeIMSj9yueuTTYtbnnmZDEuDxkVj3cQScjafLUks1Zllf3Ut+32dG8sHaAakaOym1KVWXCgsPXvUT6q6jIiBI96zXMj7WIAfHTPU+lKdyDawOeucdaYDLzxRNCwUoWz0APpXG+IfHJhWVvsu9xwMttrQ1iBlLNl/mOM/0rynxgWJlQMATgjrnFSwZn+IviHJPJtXT7Vgp+9ICxNcRrPiC61G1KSpCsZPREC1DqKhWxuPHBxWXMT5fK8MKBGbJ1zmmsxPenPy1RnimIKBRSUwFopKWgApKWkoAKKKKAEpRSUUALSgZOB1NJTkXLY70AKqkPg8Edqv2sOcF8ehzUUEB80BulX0jyQDx9al6gTw84yAVHStGAIsgUnqPSoICqndjtjHuatQqBKcc4HagC9AqncM44z6nHvUykBlx98jPBqtEdq4wDxz2zQJFBVAfl55oA1LKUFnWTllHXOAfSn3GpZUxR7WcYXJrn3vBh1iPXGTu71YjJlUsVBxxmgCabIAKMCxOenb0qxZsoJ3Lzjo3I/L1qmTlFAGcnkY9au2yOrbs4wA2T60ABRhMMYzxwR098VZ2MwRS3tyO9DOxn+ZeM7sg9TTZQq/xbCuB+HtRcBzOxQg8seMEdPp68VGc4J4VCRwe/Sp5z02Z3AH8DjjmmNCzWrMN25TjrnNFwJ7bKThucD5uvX2P5Vp2oUnIzhjkDGcAms2MOsIPLSZ6H09a07cbpMKwKgE4K4GccCmBYjzDC67OcjG09ef8KWOT90xwMg4+nFSYK26ElhJyTt4AqPdG0hQqQp5XnFIBqPKEXKZjP3WzxVhABMrkjjtnp601mPkpHjCKcqOo96fp0b3V0fKwZG9O496YHdfDrTRqHiG2JAMafP04xXV/GK5Oy1tEIB6nmrvwo0ny1uLmQAFQEBIxj6VzPxKk+1eJmVgGWPCjtTWwzB0TS0ZwxRmLkDcT0Br0nT9JtUi/eIu71+lcZpzvHKhxzkGu8sfniGG5PP/ANaiwbG3pOm2YjVfKG4Hg5rcis4YslVxz3Oay9LiOQRwRx61rmPIznBqkBLJEske04zVC4somChnP1FWeVYEfrUV3nP1GaLCM59IgdSPMyfXFNTT4IhxLyevarcZIbgcHiorqMrubqRwD6U7DLFmIFjZDJn1pJkjUkROAT6msFbgQPjcQW5z6VI9whxtfk9eP1oQinqeklxIpnTLZyDzVaw8ONDES06Fm5ORWlMQ245/+sKhluTGy4O48YANTZDGQ6K5A3yRDB4ArXg0ZEjzIVJ7Z5qlbyNI2G6D0HSpr25YrjnC8ZzQDZl6x4fNwhS3eNGPdzxXm3ib4c6ixkZGtXZup8wAj3r0x3zPhsleuKy9Uk3K5+YkDjBpNIZ84674B1O3Rka2V2z1jbPavO9UtJ7KWWG4hxIV2/OvQeo9DX0bq7MWdpm28E5HWvK/Gdo9zAJ5g2VYBN3VvaoCx5tDZZyWGF7Uy9tAGzHW75WGYzDaPX0/Cs+VR5jlce3PWmSYTqVOG4NMrSvYw5XAxgY/GqLoV69KoBgooFFAC0lLSUABNFLSGgBKKKKAFFTwLznpUA4qWORgRz+lJgakABk74B4q3GvzL8px271mWsz+Zjdx9K0/MbahzyMY4o5WK5diBUsucdMkVJEpEnyjAxzSRcqSfWrsLsbRgT0B7fSjlYyrI6hjvJKk9D2qrLISx2nKDk4461WvpXYLlu/pSIx8vHbHpQkK5PalQxLnOcZx2rVj+7+7IVSfrWVaE7WHZSMfpWsjEuPTeB+lFrhclhCrImc5bBB7CtK2UFsY5HWqS43JwODxxVy24lfGBgjHFHKMsoh3uQpGP9ntSsFYcgDB6kc4+nWr2kqJWlEgDYVuo9Bn+dMvAImJj4Jzz36GjlYXKsitsEgwAcgL16cVbghT7Ku846/OcntxUcvyIhTAOB/SrcrERRAE4w1HKCY2COVgwLYUDPA6ntV6C3xMpPA2ltuOlO0wkuzHk5A5+mauxkmRVOMBsDjsOlDiFxskLOiIm8YAOA2MVBbWxefEqkBQWO7v9K34FEnDgEbG/pSoil0UqMHGePc0crC5kSaZLIQYivkA8nPNbWi2iWckMcaZAPzt35q8iKhwqgcHtSWDH7WnP/LTFPlYXPcPDcK2WgCRhwy7yMe1eVakFudYnmbLEyZ4r1y6Pl+FTs4xAMflXkCnLkn+9iqtpYXMi/Z243IxJOCflPNdtodizxxk/KAefpXLaYd0q7uecc13+hErbsAeKFEdzViVIlwq49z3oVzuNRzE7F9wDSRk7GPcrVWFe5JnfJ8uCBROnyDPpUdqxK/manmY/pSuO5nkAMSG46mkmOV46kY5omYgADoRzx71HOzEEE8HFAGHfD5yEAHNRuSGAVeDgD3qW5JJY9yTzVUEhAR1DHFILlrKKh7HHT3qqiA4LDBHHTFWMkiMnruxUbqFmQDoRn9aB3LVsMRFh97B4FRuNy57/wA6ng5glJ5xUcvKAnGcdaQXIIwXkJPPfFR3NoGiODgnrxzihvltnx3Y1DbSO8JLMSQSM5+lFgTOZ1HQt6SlCdvJyOprx/xijvL5TgoiZCnGa+ipztguMY/1RPSvF/EsESwTMEUMSefyqWrDbPILm0kAZuignkjpz1rJmtj56jg+nHWu3v1GBgDlq56YYuHx2Jx7cUhHNzQsWIbGCeO9VpYsRHP51pv8+C3JqGX5rWQkAkEAUCMMqQ2KXY2OnSrBUB1wMZpxPB+uKLgU6Q1ZIAmwBxUUoG8e+KoBlJS0UANooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hepatic veins are not seen; rather, there are small tortuous veins in the liver. This is diagnostic of Budd-Chiari syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7856=[""].join("\n");
var outline_f7_43_7856=null;
var title_f7_43_7857="Modified Martius fat pad graft5";
var content_f7_43_7857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Modified Martius fat pad graft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 405px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGVAZUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACorm5htk3zyKi9Bnv7D1rK8X6rJpGhzTWsZlvpCIbWIDJeVuBgd8cn6A1TbSYbPw/bw3oElyowZ8Fish5JBPQk89sn60AdDb3MFyhe2mjmQHBaNgwB9OPrUteY2VnPonifT9YsYobSzvJ/surJGoCTmQYhmGBy3mFRnriVwfuqB6dQAUUUUAFFFFABRRRQAUUUUAFFQ2ksk1ujzQNBIfvRsQSvPqOKmoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACud1HX5P+EqsdB0pIp7rAuL9mPFrb4baSM53Ow2qPZienN/xFqg0jSpbkIJLg4jt4c482VuFX8+voAT2rL8D6RJYWs97dOJr3UG8+4mYfOznPH+6owFHYAUAdPRRRQAUUUUAFFFFABRRRQAUUUUAcdqEr33xKsLRHQw6faGeRTnIaQlQR2zhPyY10+qRefp9xHlQGQ5LAkY/CuN8FwLq3izX9flhj+S5eztpQQSyJhCM9QMx7sf7VdvchzbyeVu8zadu0gHPtnj86AOI1zTpNY+HniDT1ZzeGB5YSGwRKo3xNkd9yqSRweveuq8M6quu+G9K1ZI/LS/tIroITnaHQNj8M1R8OsRcTI8YQumcY25wcHC9sZwVP3T0yCKy/hEv2Twcujs5aTRru40056hY5WEf5xmM/jQwO0ooooAKKKKACiiigAooooAxtbtZlvbLULGTZcRP5UiEEiaJjyp9wQCD259TWvFIssauhyrDINKRkYrNiu7ez1OPTeFadWmiUA+pLfTrQBp0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVm+Jb6bTdCvbq1VHulj2wLIcK0rHagPsWKigDlPtTeJPG9zGFD6bo8q2qej3DKWlY54O1cIAOh359K7uJSi4Y5OTz7Z4FY3hfRI9H0y2hdUe6WNfOlA5kkIG9z7kjNbdNgFNLgSBOdxBP4U6uS1fxpoukza5HPqFl/athHuFg1wizSARh1ATOfmLYHFIDrQc9DRXPeCoZ7DRrXTrsF7u3gR7qbPDXEmXkA/wCBHP8AwIV0NABRRRQAUUUUAFVNXvU0zSb2/lGY7WB52HqFUsf5VbrhvjPcvH4DubGAObjVbi30yNUbazedKqMAe3yFz+FAFn4R6VJo/wAPNGguABcyQ/aJ+OsshLuff5mP4YrrpEEkbIejAg8ZpsCLHDGiABFUKuPQdKzPE+v6V4d0uW71q/tLKDBANzMsYc4+6MkZPsKAKNpALPWooWyRnCYY7VIU9BnK8Z46HjHAwtLwvG1p8RvGtvu/d3AstQVPQvE0JP4/Zx+VVfDutQat9nubQq27/VgSmRcD+6xAPbO057lTwQd37OIvHSXQJBu9NMTDjnypMj/0c1MbN+iiikIKKKKACiiigAooooAKqXtssjRTqhM8BLJtOCeMYz3Ht9Kt0h6Hr+FAFbTL2LUbGK7t93lSA43LtPBwQR9QatVzejXkdjrc+lTP5YuN11apI3zEkkyoPoSGHs3tXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxPjOc6h4w8LeH0jMkRlbVLpgxAjSAr5YP1kdSP8ArmfSu2rj/DUbX3jvxVqxlZoovI0qJc/KPKUyOceu6cj/AICKaA7D8aKKKQEdzKILeWZgSsalyB14Ga878e2FrrF34Z8LXVvDK2oXJ1DUPMQN/o9vh3ye26Qwp9CcdK7rWozc2Etksjxvdq0IdPvICDlh7gZI98V5VZW3iSfxhqKprEOqaOsq6B9ovYQt0gMXmTMjRqqE5IU5XqnX5cMAeq6JZw6fpdvbWsrzQovySPIZGdexLEkscY5JJNXqbGixRqkYCooCqB2Ap1ABRRRQAUUUUAFcN4vabUPiD4P0uF18i1efVrtckEqkZijGB1+eXP8AwCu5rxvXdestO8ZeLPGEnmT/ANlxW3h+0gt8l7mcN5zxLjPzM80SZxxtbtQgOt8Y67qF5r0HhDwtKYdWnh+03mobAy6bbZwGweGlcgqi+xY8DmbTvh54RsFRbjSLPUL1xh7zVFF3cznuWkkyxPU4HHoBXJ30978MvhlrfiPVEivPGmryrJMI+Q93IRHDCmckpEpUAZ5CMe9eLz/BTxjqvhWfxb4hvR/wkLbb8GWWQ3O3bkKcD92y56c4KgfLzQB7L4/8GL4PUeK/AdtDY/ZZFk1LS4VKW91DkBpFReElQfMGUdjnNdjca5bX9t4U8QWBJs7q4WFi42sqTIVCkHoRIIwR6iuY+AXiu68c/Dyez8SMs+qWLGwvHDhvPQoCrkjuVbBPcqTVXw7Hqtx4M8Q+HHVhq+mSNLZscAvNE+9BgepWN89xMPcUwPYKKraZexajp1re25zDcRLMh/2WAI/nVmkAUUUUAFFFFABRRRQAUUUUAc74lsSyRX1rA0l5px+0w4HLEKQyA9fmXK/jW7Z3MN5aQXNtIJIJkWSN16MpGQfyNSmsLw1GbCfUNK2BYLeXzrbAwBFJltv/AAF94x6BaAN2iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARiFUsxwoGSa5j4cRH/AIRlbx1Cy6jNLqD8AH98xdc46kKyj8BVrx7eNY+C9bnjJEotJEix/wA9GXag/wC+iK0dGtBYaZb2oUKsKCMAHPCjA/QCmBdooopAYHiTV7nSZVubfTpdQt4IZHuRFJGjQrjcG+dlBztYYBz0rN8CT215bp9isru2jSSW8mW8i2SCa4PmjB3EH5ZGyQSBkDjBAzfE3iXSJ7PW9Eu9Vg0+9ln+zzG4Vo0SIsqsPMI25MeSOf4q7bSZ7e7tjdWiKIZTlHUgiVRwHGOxA49sUwLtFFFIAooooAKKKKAKOu6pbaJot/ql8220soHuJSOoVFLHHvgV4X8DrKXxw+ma7cROmhaXPNfL5iYOoarMWaWc56pFvKKcfe7/AC4rvPjFDN4nsLfwLpc4jvdZZXvHXk2tijAySn3YgRqD94sfQkS+N9csfhn4EtdN8PWiNqDRfYtG05eTJIF+8f8AZUfO7EjjqckUAeT/AB+8R2/iPxhFpvyT6B4RuLe81NDhluJmkXdFgjBCQiUnnqWBHFes6/r+/S10sh1mDLC8qv8AK+39cN0HfkV5BD8P5dO+H0VrYKLnxv4nDo5ueTPkuZpnz90IshO7nO5V5LYrS06Xxn4ct30mPQLHUtTs41Wz1K81BojGqgRo0kGwiUoCoJU/NtDdadgIvhDdR+FPj94n8PWgm/se+AtUlcF995DGJSC+Ou1pvc4HtXpPxIsbzQdZtvGOj7hHGoi1WNckNGvKTED+7kqxHOxs/wAAr50g8P6p4a8Xw79Wup9YsrtPEUayA41AFAZ2wO+5JV9cEjnNfZGnXlprOk217aOlxYXkKyxtjKyRuuQcHsQaAOL+Ed15UGu6IHDwWF809jjn/Q7j99EM/wCyWkj9vLxXoFePadY3nw++JtlHceZL4X1SI2FteHn7M5ffFBK3s7SKjHr5uCcjJ9hpAFFFFABRRRQAUUUUAFFFFABWNcB7LW7WZm3QXDNCxPGwkArz9VwB6tWzWH4stpZdHmkiKh7U/aYz/dZPmH6g0AblFNikWWJJIyGR1DKR3Bp1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBynxEjF1p+lWBnEK3eqWqN0y4R/NKj6+XXT28aRQqsQAQDjHpXJeLytx4z8F2TuwC3NxfYX+LyoGQZ9szA/lXYKAAABgY4FPoAtMncxwSOOqqT+lPqrqMojtGxkmRhEuBnBY7c/hn9KQHNX9oV1vQhPtTT9Ot7m/uZTwhlKhATn1EkzfhXUWMKW9jbww7fLjjVV2jAwBgY9q8s0XRtVl1PxHY2eu6tdaRpl5aWAt7kxzfaEEUbzJv2Bl4lUZB42n3r1qmAUUUUgCiiqGs6xpuiWv2nWL+1soCdoe4lCBm/ujPU+w5oAv1zPiHxJLFdPpPhyCPUtfOAYi2IbQEcSXDD7q45Cj5m7DGSM43+t+MCY9GW60PQjw+o3ERS7uV7iCJhmMf9NJBnn5V6NVrVdQ8O/DTwsG8vyIN+yC2izJPe3DnhVyd0krHqxJPUscAmgDNvLjTfhpodzqWqTz6rr2pSjzJAoE+oTgHbGi9EjUZwudqLkkk5J8/sNC1jWfEx8S+LYftWo3FuUsrGKcQorq5ZbWFmGCpVSXbqQGOMYFdd4W0m+1PULrXvFZ8zUZ4lTyI13R2Ue7P2WI9CSdu9x94gdAFx3em6dbhoJp/Knu7UukbAA/ZwwGUX8AuSeT+NPYDD0Kw/seee+1OSC88R3KrHPImRDbJ1S2i4yEHYAbmOWI5GLVxqSyNC2rW6vYH77yWU0fksP4iWBAXjqcda32s4zHIsTNE7byJFwWVm6sMgjP1B9OlcR4D1TxBqus+ItP8AEbWU1joyx6a7xICL2cp5jylcfIDHJEDHyAxbnpQBc+I3hS31ixt9RtohHq2mBjbTLkFY2I81MDg5UcZB5A96wPh7qz+H71tI1F5f7OvJZJrWSRQFtnLgGInoFdnyvo25e6iuw0qcppr6dYTO8kUZltpGG9XhzlACeo2kLn2rjvH3guTxPo1xb6LepZ3F1G32SeQboyGUhonBB4KkggDPQjlTR5Aej6zplprOl3On6hF5trcIUdckH6gjkEHBBHIIBFcxpniCbw466T4xmeNUYR2mszYEF4p4QSOMCObsVOAx5XOSq0vhr4wfUUbSNZWW31O2cwD7QRvZlUFo2/215wf41w4zk47u8tbe9tZba9giuLaVSskUqB0cehB4IpATUVxKeHdW8LfN4NmjudKXJOiXshCJ7W83Jj9kYMnYbBW1oHiaw1ljAPNstTQEy6deAR3EWOpK5+ZfR1JU9iaANyiiigAooooAKKKKACobyNZrOeJ13K6MpHqCOlTU2VQ0bqehBHTNAGT4PguLTwxptpeAie2hFuxPfZ8oP4gA/jWxWXoNwZorhW8wOkp4fPQ9COOnX1xWpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByc/xB8OW9p4kubi9aKPw9J5Woh4mDRE/dwMZYN2IzntW/DqtjLbrMLqFFLKhDuFKuwBCMD0bkcHmvMPG3wsvte+JltrNnfW0Hh+9+zNrlm+7fdtbOXiwNpBBwqnJGAOM1S134aeKbnX9VFjdaIdEvtftdcLTNKtwpjKb48BSvRODnnvjPAB6V4X8W6V4k04XtjMYkMk0YS4Ko58pyjnGTwCp5q4+v6Mlzb276tp63FyAYIjcoGlB4BUZy2favHNV+D/iCXwRp1lpmpadaeILS+1A/adzmM2l2ZBImdud211I4wCvXvSfEH4Pa5rN0LbQ59ITR7e1srexWeR4ZLbyGBbOyNvNyBwWb5cnjvQB7fDfWk8zQwXUEkylgyJICwKkBsgehIB9MirFcL8N/AyeGNQ8S6le22mvqmp6teXcd5AmZRbSyB1iZyobgjJUErn1rrNT0yPUDEZZ7yHy84+z3LxZzjrtIz07+9AF6isV/Dls+N15q/HpqM4/k1C+GrEMGM2psR/e1K4I/LfQBj30txL8VLKFFVreDRpndv4kaSZAuPr5Z/KuxVtyhh0IzXnB8O6ddfFPUFdrpng0i2Kg304I3S3HPD+36V1zeGdMdNjpdMvobyY/+z0+gG1WD4gtZf3P9llU1CWVWRZC3k5U7i7qCOw7YJJAPFN/4Q3Qu9kSfVppG/m1YOqX1p4P1GGVdFu5ttvN5sljEGxEAG8xiWAUDYQQTnJGM84AIvh/r2oeIoLG+/s+0sbC9nup/OtWP78xyNEN6lRjeAHByeFx712sB1GNx9qFtMhzloQyFfTgk5/MfSuS+FbxR6LY6XZwTxWOm2EEUZuoDHLKWBJkGeqHA57sG9K7ukAAgjiiisDx1r7eGvDF5qEEIub35YLO3zjz7iRgkSfQuy5PYZPagDJ8VeJNTm1aXw94Qijk1ONFkvb2WMyQ2CN935AR5krDlUyAB8zEDGbPhrwXZ6dff2rqbz6trp4Goag4llRf7sYChIl5PyxqB65PNS/DnQH8P+F7eC6YTalOzXN7cnBa4uHOXkJHqeg7AKO1WPEHiFdOSWOzgku7xRjy40LYbGQMD7x9hz9KALWu6j/Z9gWeTZNJII4liUO75OAFB74/Ae9eYaFCvjv4grrdtKtzo2hytY287t5jy3Q2tNMjYACDiMbRgncRwa5XxZ4iuvEniUeFtOvTeahclYtVvLQgiwiJO61hIJHmEbi7DO1QV5PT2/QbSx8L+F1DRW9hY2VvlvLyESNBwx4B+6Mnjjp2pgT6vfrZyR2ttLDHdOplCupbEakB3wOp+YAZIyWFR/Z7m20i7kLGOW4m81kQ7fJVmG4A+uMkn+8SR2rK8Fpc6jdXmsalbsk10yuFc/wCpUZ8uHHqinc3/AE0kYfw8ddNGs0LxvyjqVP0NIDOtpnuNZLkOkSwMqKT1YSEMSP8AgK4+tcN8G9XsNQv/AIhm1uUlaLxJcGTkZCiKJA3+7mNgD32mu20rSP7NuryY3LSRzSmcKwx5TMB5gBz91iobHYk9uBhRaPoEGtrNoNr/AKUti2lmCzXbarCW3gSBRtBUlsYOfnbg5pgX9Ntz/ZOj31vBuuIYRlFPOxlyV/8AreoFX7mFIRJMvzWEv7yQL1ibr5i/19+fWobS1vLCyNnFAxQEsLiKVd7MSWLbWGBkk8ZPWrOlyBC8crBJWJYptKZ9SFP64JHfvQBzfirwVY67P/a8DtDqbQrC9xbS7TIqtuRwem9Dkq3UZI6UnhTxRdWkcOl+MpYY9RU+XHqCDZb3v91vSOQjGUPGfuk5wN3WlutNR9R0qCS5ZDuuLKM8zL/EUB48wDkf3sYPUEVDaaL4x8OrdWhhu9Nv4t6kr8rZ74I+Vgc5BGQRgjORQB01YPirQ4Nbt0jurNLgRHfFJHKYbi3kH8cUg5VvoR7kg1xT+ILnwBd2en326fS5sJGHYAxkttVUPbPZW+XPAdflU+iaJq+n65p6X2k3cN3auSoeNs4YcFSOoYHgg8g9aQHMaTr97otzBp3iSSS6tZZVgttW8oIQ7HCw3KrwkhJADgbHyPukgHtqxvFOm22oaXPHdwedbyL5NxHz88TcMOO4zuB6gjiq/ga8ubjRGtdSkaXUdNmexuZG6yMh+WQ+7oUf/gVAHQ0UUUAFFFFABTXxsbd0xzTqKAMTTZJ18QXsUhzA0SGE5yW2/eJ/4ExH4Vt1x6TSQePYXZi8d0JrXZkgRlFWQHB65Gc49q7ChiQUUUUDCiiigAooooAKKKKACiiigAooooA8a1X4g6npGv8AiC2061S6uD4jsNHhS8un8pfPiB3AAHYAeoAPc4qKx+KniC6u7bQ5LHRbXXpNZvdKkupZpPsS/Zoo5Cw6MSwkAC5H3SfavR9Tj8KWuoMt/Boo1KWVb4RSJF58ssY+SUA/MzqBgN1GODWVpl34G8SeGLG8nsNGTT9elN7HbahBCpuZjwXKNkNJwBnk9KAOGuviPrmn3/ip7OyttTv7ddKQJBetNbZmjkLvChwWA2E7VwzdT0NRaf8AFia4uYNWli+1iDQtRvZYLR5oY2e3kA2NFIMhvUnO3nBIr0280nwStwdIvdP8OCe7WJTZSwwbpljBWIeWRlgoJC8cZOKs6XB4VWdl0qLRBNpsTWxFssW61jJy0fy/cUkZK8DIoA8ul+MGt2em3/2jTtHvL+KHTrmF7Sd/s+27kCCN2wSGXrkZyOcV3fw58Uatrl94k0zxBa2MGo6LeLbs9k7tFIrRh1I3DOcHmovCk3gbWb7XPD/h7SdIkt9Pe2uboW9rCbaV5NzRsu3hmBQ84yCBXZWthZ2lzdXFraW8M90we4kjjCtMwGAXIGWIAAye1AFmiiigDjtC/efEfxRN5SEIlrbeZ/ECIy+36Ykz9WNdjXIeGFD+NvGDl13pdwIEz0U2sJyffOR+FdfTYFW/nlhjPkxSMxBIcJuCkeoByfwrj/EWsaTc6f4g0/V9SttMubnT/JZJXCuqujrlVbBb5iw4HOK7quE8a6Ha67aT+baWt1cNqdnAZHVS0cKzwu6gnoMBjgdSaAOm0a9gu57hLMRPa26RRpPEwKuSu7AI4wAV/OtWs3RbGx0/7XDpgt44WmMjQwAKsbnG7gdCSCT05JrSpAFcB8Q4Tqni/wAF6QJduZ7m/Kc/N5UWwEntgz5Hviu/rzPUJbmb9obSo/nFlaaBIdwPymWaY4Uj3W3J/wCA0AehX1r9pjSMMyoCNyhioI+o5zjpzXkvxekNtok2j6ddE3+p3C6PZwW2U8kyJukklYHe5SMl+oGSuQc16L4t1xtKggtbCI3OsXzeVZ24GcnvI3oijkn8OpFeTaFbQeIPizNAhbUIdDgZHuJI/wB2b2Z98zBs54jEKZHXntmmgOn+EPgmw0O3jktLfyIrSNYIlKqHkyiOZHI6tlmH6V0fiEjXvEEGhxlja2ey7vcfddyT5MR9ehkI/wBhAeG52ta1GDw/oF1fzqXS2izsjGGlbACoo/vMcKB6kVj6Wy+FvDzXetSwi+nY3WoTs4RA5wZGLHgRooCgn+FFHUihu4G493Z6ZZzh5ooLe0jzJNPIEjTv8zHv3J989681k+OnhCC9NpJr+jyuG2mWNp/LUkHHzCIqenUN+VeS+M9Su/jX4titfD4uX8N2pb7MjuYftc5bm4ZcZ8tVyATyAp5VmxXWeD/gXpcEb2+preXs8cnmSv5HlW+/ptUOcSDgZOwhu5xjAkI6/Wvjn4E0vTRPdeI4bu5Rt/2bSkaVpfRASMfiSo4/PyzUf2jPFuq3M8nhbw7Z22nqAyC5hmuZmU7v3hKEKqjac9cZ6nrXs9n8IfCcU8NxLpNtLImT++jViCTn0xnPU9+frXSWHhi1097g2UGnWyzqA/2eySNmIzgsQeevp60aBqeUfD749yX9jEvjLw9fWVx5nlyXdhA0sK8gbmjJ81OWUcB+o5HQeuaDr+g+MNOefRdQtdStkba7Qvkxt2yOqt3GcGi/8P2d9DsvbK1uCgGxiu1t2OvTHpXnev8Aw81PR9QHiHwbfz2mr4USlsyiVAMCGSPO1k6E4+YEsVI4FAHqlnLKjm2uyDIv3JP+eq+v1Hcfj3rkIwPB/j8RD5NC8TSFkHRLfUQCWHoBMgJ/34z3es/wx8SINX16Dw34js00nXZoRPaPDN51vPwciNyqkONrZRlBwD1rrfF+iHxJ4VvdOL+RdyJut5h/ywuEO6KUf7rqrfhSGZHxI0dNSt7aR9rSRkiMMcYJGSM+hAH0Kg9Aa4r4K6VbR+JPF0aRvbTg286TwuyNKJA4LEdGw0ZHIPIPqa9C0S+bxf4EtLua3MN5NF+9hyVaC5QlXUHsVkVhn2rkrfVrXwzrNjqeoGOG0lb+zru6+6q+Yw8pmHYBwVJ6DzTnpmn0A9OiheGz8oTSSyBSBJJjcT6nAA/Sud8Mb/8AhIdSlk+WS7sbK7lTHAlIkRj+Uaj/AIDXUkZGOxrmNDnR/HGv20YYC0s7KIA56EzHIPfrj6g0gOnooooAKKKKACkY7VJwTgdBS0UAck6SnVdKkdD5sd64LqOzRMDn8h+VdbWDqDxrPbOqOZGmhkBL427n2nj6Ma3qBIKKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAeWS+AdXg8Z67qFvbeHtRstXu4rprrUA/2u02IF2R4UhgNuVO5duehrkJPgrr40CxsRPoVzK+groty915jC0IlZ/Otzs+Y4bodnIBz2r6CooA8T1L4Ta3P8QRq9hf2VpZSSwNc3LSGaadY4gmfKeMhZeBiRZBjrtzWHpfwL1q30LU9MlutMhml0mTTIdQguZd0qmRXUPFsAVSV+b5nPJxX0RRQB5z8MPB2reHvEvibVtWttEs49Viso4bTSXdo4vISRW+8i9dwIx7/j6NRRQAUUUUAcT4UKHx5412qodry3LENncBaxAZGOCDXbVw/hW2VPHPi2ZdyO18gbCjDf6LBgk47DHeu4psCG8tYryAwzhjG3UK5XP4givHvFfglzqum3sfiTxZpf9q6yts1pbarJFFHGscgG1fVhErEknrXsF68kds7QECQDgmMyD/vkEE1474i1fxMbvQFNlYC2HidYbaSaWeN3JSU4O6P7o+dcjPakgZ2fgvwJb6FZSLeXN/eXkxDz3Mt5IWlfJ+ZsMBu554rsbe3SBcR78f7Ts38zXE/Cu817U9ON14lLR3Sp5fkDO1TubcefvYIwD6Cu7psArifD0DXfxJ8Y3F3GjpbGxhtmI5XbC7HH4zt+Zrtq8/8AA13fT+PPGc0yg6dcXwgttq8o0EMSPuP+0WOPTYfWkBueM5bKw0XUJriYQyywsWk34YRp8z45ztVckj6+tcb+z/aTyaBe65fwrDfavcveSRgHCq+DGo4GAqbFx221H8dt9h4I8RT3rtPFd2M8KeX8pX5GKhufujjp1PJ4AA7zwPaRWfhfTY4FZUS3jjVWYsQqLtAye+B9fWmBV16NtU8YaHprZNnaK+p3C44d0IWFT/wJmf6xivEf2sNZu7mLRvDunq7SXzvdTxKcmZIpAkcYHcFizkYPKjg4r2fR7xpfFPivUCGlit5LbTYUTGSyIJGx/wACuMf8B9q8Q8U3dp4j/aj8P6XYMtzFolo0bssfmAz4eRuhA43oOTgEHPpQgPSfgp8NbHwV4es7i5fz9cmQSzyxs+1QRlY1VuQiggc9SoJ5wB6W8jGZHRLjC5UqAAGzjk5549qSxgeCEKdoY8sc7mY9yTxz+FNguYppJvJvkmMBKypGVYoc9CByDx0pMRL9ofaT9mn4OMfLk/rUF1eR73hL3FuwH+tEXyjI/vEFantLuC53eTKrkHlcYYfUHmkkvYYy+8yDZ1PlNj+VAyjbWtvJIyHU7q5nXhs3G0/98pgfpUwtLmElrO9dx18q4+dfwb7w/En6VNI9jcuY5Wt5HXDbWKkj0OO1RXOkWV0mJEfOMLIkrq6j2YHI/A0AeT/GDwsviOW2a1nOkeJLIfatOLECJZY5FYShgOQTtDZ5X5WK4Bz6X4I8QJ4n8MWWqCPyJ5FKXNuTzBOhKyRn3Vww/DNcZ8VdFs4NO0ua+e8uLeO+hW3lkupGayuCdsUvX5l3EA5yRuzzyK4n9m7Wvs/iPUtLkM6pq0D3673Uo11DO8M5XHdl8hiOehOaYHp+nl/DvxIudNLn+y/EET39qpPEV3HtE6D2dSkgHqsh71wfx20m5Zbm0+z2p0rUUU7pHOFcyIkg2/3sOXU9Ayg/X0H4lp5EPh3VVyH07WrRtwHISZvsz/htnOah+LWltq/h37IFG2cPAJD/AMsXZT5cn4OFzjsc9QKEB02jxzWMC2N1KZREfLgmkfLyoBxnuWAGCe+M9zjC07/Q/iNeWsUPlQ3Fk0o4xuKyKxI/4FO345qT4Z6+3i/wLomtXsKLfSRfv12Y8udcpJtB6DIbHse9PiaeTx/C08YTbp9woAOcr50W0n64JpAdRRRRQAUUUUAFBGRiiigDmPEjG2mjuFDsxvbNMcYCtMinHt82fwrp65HxvMbaz06Ly98k+oWe5s8KftcWD/48e3OK66mAUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOM8MW6w/EHxtICS00lnIQTnA+zhcgdvun8q7OuJsNln8XdaUyqP7Q0uzcR9y0b3AJ/75I/75rtqbARmVRlmAGccmvLfiZq2htdeGbO41fTNLnsfEcFzLHPcIpVVEj5IzxvB4J/vV6ZcWdtcsrXNvDMVOVMiBsH2zXC+O7IWOiWdysEBdfENjLIFAxsa5jiGfcIwGKQHVaFq9lqVtBNHPafa541Zo45QzYxke/Q5/GteszQ7OztLYxWEFvFawu0cCwoqqig4KgDoA24YrToAK5jwLHHCuvxpu3jV7lpM+rEMMfgVrp647TMaX8TtXs8ny9Zs49RjB6CSIiGXH/ATbn8TQBw37Q14b/wrcWUM5VLu+tdHhKkcTvKryH8I1Iz25969U8JidfDtiLyJoZxGN6OxYg+5NeXfHrTRaaDp+pt/q9HvoL/5QfuiRI5pXA6tiXPts9yK9Y0QCPRLM9vJVjls9RnrT6AedWOr3Vl8NvEWt6W0Zu5xrOpQFhuBeORxEfptVeK+YPg5dPpvxT8JBp7po7iMpI0EkfnPJPGxCbmIC5O3nO7ryDwPobU71dJ/ZujuJWS3jPh2SVm4A864iKoo+ryn8q+cHsLyLxXLBbl4tVsLOztrMF13RzqEaM55CfOoxgDccfdD0ITPtezsLORzKPD0/nkZ829ZHb1Cli7NjPbpW5AJ8gtFBFu5cKxY5/IfnXnPwy+JFz4z0OzurnT1t55gwP2OZGAkTiSJlkwyuvDY5+UqQSCa7+2Wd5nZhcBCx+WSRMD6bf6mgZbkidx/rnQ4xlQP6g1XuxeoYzZtBIFHzLMSpb/gQBx+VSPZxSCLeZSY8lf3rdxjnnnr3qR44FjKusYjK7CCBgr6fSkBRm/tKXYjWdkVIG8m4JH0wY+R+VVri1v1KvFBCqgDesEzKxx0wPlH8v0q/HFbNvW3EihhtzGWUDHp2/KoLyWNfLJuJ2jcZBVgFPTqRzk9evOCPamBxPxX1eTQvBdzq817MI7aN5TbzRqBJIMbF5HHzlcYOR94E7efA/ga1zpreAbtvNd212e2O5twCywOG2kfwnCtnPJGee2n8bvF1r4v2aTYeXcaFp/mPfXCyEh50DbYUI4bYvmOr8q+Qp5BBT4Pwxf2t8PYLcKLJ9ZvZFABG4x20hQ/NyCNxDAcA4HYUCufQvxdiaT4aeIXTG+3tTdrn1iIlH6pTfiXqcGn+HLm7cgNFazTo5GR8qZH67Tj2ro9d09NX0TUdNlOI7y3kt2PoHUqf515J401KW/+AejajdOR5tjbfathO/JCb8e2Qc5HShDPTPA+ijw/4T0jTcYktrOGGXH8TqgVm+pxSaPIb3xJrN0Avk2/l2MbDuVBdz+cgX6oaf401R9E8L6hqqEgWKC5kAXcTGhDOMe6hh+NSeE7CXTvD9pDcnN24M9wc5zNIxeT/wAeY/hSA16KKKACiiigAoopGGQRkjPcUAcd4yjkvZLLylOI9VslJH91JkkJ+mRj8fauyrnNVBhutCtyM+bejcQCTxHI559MqtdHQxIKKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHGakqW/xV0mZ1Y/adMmRWC5AMcidT24mNdnXFeOA8Hi3wXdqCY3urixk29QJIGcH/vqFa7Rc7RnrT6ALXmHxmt9Qh8Ma1f2Wpz6fDA1nLtWGKRGcXEZaX50JyqhcYI5UHmvRNQuxZxiSRoUi6FpZNgH44Iry74teKoJPDuoaTdadqV7a6jYTNFPoyC8EbwlSxbBG0Dch+bA4IoQHpmhWUmnaZFZyzPO0JZRM5G+UZJ3NgAbjnnAHOelaFeaeGvFHiPxLrepS6T4dfSrNFgRn1uba7cM2+OKPcGBVlG7cBweSQQO601dRDY1AocD70bDax/3duQPxNIDRrivGdtJ/wnngC9ibbsvbq2k/2ke0lbH/AH1Eh/Cu1rlvGsiwap4QuHJwmrhOP9u3nQfqwoAy/jfbJcfDTxMZIyQmk3bbx/DhMgfiVX8qgtNTurL4FT6hdSYvLfSJjvXu6owUj6kDH1qX483z2fwn8QRwL5lzfQjT4Y8gF3nYRAc8fxk/hVbxHF5vwp0yw3A/bbmwtBtAGEe6jBGPZM/lTA83/aEN5pmkfDzwjbTPDZpGZp5I8jm2jjWPOP4QzZx67e4FeSpfLD4tv3FyB9mIWRNw2zQQIm5VA5PzA4PPAB/gr2L9rM28OoeB7q4MQMcl4uZcYVSkeWwSM4wOPevHPB/h1fF+rvPb6bLqOlKr28Ucm9PtrmXccMo3hUVkORt52hjg4LRLOU8EazfaZvazuZVuzdCVna7YQggHJIXJMmARkbg6M64Jr2W08a+I2SUpHbLZCQxzQjVriJj0CkSbMAhDGwkxgjDZO1q9J8KfCL7E3nSiCBHTY0USiE/eBBUKp2EdQckg55YEY7/RvC+k6XOEs5JEuYgW5uGcqCSduD0UMSwHQbmAwCRRoM+dbzx/4l0exfV73w3qCQtFuMkXiUTeYS4RxsBOOWDYCna3ONrYGVD8fri3+zXFvp9/EdxFzmGORS4HPlsQCmRyVHQjPIzX1s2jWTxCOeGOQZBAI4BA28enBI+nHSsCfwFo04C28ENtbqnlxiFcspA+VwSSAy9jjpwcjilcZ41o3xL8Wapazrpeg+IZZAJJvtE1nBaIHQ5DKzttJKkB0GepI61j+Obz4p67oGrPHp+l6dasm+a2j1Fbm4VD95owrFCp+9wpIKkgg17nH8OtMSVXCbjGVZTIEOWXowGz5GU8gjsdv3cAbMWgEvE1yRKsTs6IpC+WT12EAHa3UqTwcc09APiXRoVttNh0m5lZr50UPZXEZjmXzDlwUbBxghu/BDLzmu98ERNodp8OrtnRrpPFj2TFSQNr5hIx3xjH02+tej/HX4cWmoWcOu6JJ9k8QaYN0C3LHy5YweYwxyMcsQM5BJxivN7PUdnhnw6brEb3niPT7vauf9GlL/MOR38uQHpho2HbkEfYFeO6nZmT4GahYzRrOLWa+tfm4yI550XAHcgKPxzXsVee2FmL74dakZMr5eo6hcKcZOEvJjx9VBH41IyXxxqMl78J7m9hHmxX2kSs67eGV7V2BPoM4/Ou4tFCWsKAkhUAyTknivOmnjn+BVtIuWR9BLRlfu4+zlV/PcMV6REuyJE/uqBQA6iiigAooooAKKKKAOQ1dlu/iH4dt0eTdaR3F46g4XlPLGR3OH/CuvrjtKb7Z8QbqeNCYYLNlMhbO52kAIA9AIgK7GgSCiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBy/j+Vraz0a6VGcQ6vaBgpwQJJBFn8PMyfYGuoHTiuX+J9pPeeANbWzbbdwwG6gP/TSIiVP/HkFb2lXcF/ptrd2h/0eeJZE/wB0gEfoaALVYXiJ9OtIidSaC1tJ4Jbd7mRgiR7gDgk8AHB5PcD1rdrE1/QNK1eK3XWre3vLeKYSeXdoJUJJOBtbjqRjjsKAOR8AeMNDvGsLeHWrC9u4NKhivpraQPGkiHaAWUlRuJkIGeccV6OjrIgaNlZT0IOQa8+8N6VaaFPfrbWsNlLZ6wYYzbxhfNt7hlkCMBjKgzNj0Kcd676C4gnMgt5opDG21wjA7T6HHQ0AS1yvjoubzwpEgJ8zWo92OwWGZ/8A2WuqrnfGmYbfSr3ICWepQO5PZXJiJ/AS5oA4z9oSNJvCDT3EkkdtpU1vqUnl8/duYxnHfCGXjpnHHArQuYHm03wBbXTEF9XEjA8/chuJFX8Ci/lWp8Xrbz/ht4jMaJ5wsnZWK5+783PtxnFZuo3Ci38Azu4dE1ny3dR0Zra5jH/jzAfjT6AeU/tom5tbfwtexKTb4u7ZyG27WfyWXn1/dk/8BrufgR4Si8O+FLVIcXNwsSeaYh5cPmkEuC/VypLLznB3DA6DR/aQ0GLXPhRqjyQ+bJpjR6jGMZwI2/eHHf8AdmStfwJqv27Qt8IXTrGB9uCmGYbQV2gjCrtIwCCcY4UYFAjrkiuWC75UiGclYlz+GT7+wpZLdm/5ep1x6bf8KbFZwbVLK82RndMxb9D0pJJ5knIjsJXBODIGQcevJzSGNuQI4UhN+8MrAhJDtLE/iMGqhUMQDrZOw84EOfT+7xzV03bod1xCLeEHBkllUDngYwT1Jx2oGo2Aa7Vbq3L2hC3Kq4JhJAYbwPu5BB57HNAFcQR3cKeVqdwVUbd0bqM/XApLTY8wihur99ucu6/L/wB9FcH8KuXpu9sf2EW5O75/OJ+77Y71Kgl58xoz0+6pHbnv607iKt3ZtdWkttcmG5t5VKSRzR5Dgg5Bxx6dq+VJPCF14e+LnhzwrHO8uhXuupqMTMTmNoCzvAQScqcqwJ9T1OTX1ffSpEq+cyLGxxliVAP+8OleA+LLS8Hxb8MmzjvGnk8QxyBZnLxiPZJ5xRj3CIxx0wwyOhoGfRBIAJPAFcN4ek8j4VaVJMW8y4tY5OO7yHfzjsS3PtW/41vJLDwlq1xBn7QLd0hx3lYbUH/fRFU9Yj/sjw1pml2bwo5MVjAZFyuQvy/+g/lSAwLKxNt8P/CPhh0YmWOxtXD8EJGvmOG/4BCw+pr0WucNu9344t5HAMOm2JP/AG1mYDI+ixN/33XR0AFFFFABRRRQAU2QgISxwByadVXUT/orr8xDcEL1x3x/L8aAMbwy0Empah9lKeVbpFBtXA2N8zlTjvh1P0Iro65b4eIX0q/vXZGkvdQuJSyLhTh/LGPUYQc9+tdTQwQUVwvxU8U6j4OTQNVhWBtEbUY7XVTIp3RQyHasoOeArYz1zkVzVv8AFS/TRrvW2sbW9sb3V5rLRoEn8qSeCIFTIOGaQs6tgKvAxn1oA9forx4fHC1utHi1HSfD95dxR6Q2sXwadIvs0Qdk2jOd7FkbpjgZ9qnm+KgsL7xBK1pe3yQXOl20FmvlJta7hVwFY4zy3O49emBQB61RXk8vxfeLTLppvDzQ6xa6m+mS6dLfJuLrGHzGVDGTII4VTjPPHNSeB/iLceMPHWjLZB4ND1Dw3Jqf2aVFLrOt0sR+Yc4A3D0PXFAHqlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADXRZEZHAZWBBB6EVxXwcj+zeBbSwMplk02SXTpMnlWgkaPB98KPr1rt64jws50r4geJtF8mOO3umTV4HB+ZzIAkgPbhoyfXmmgO3rI1y2v7mzuhDJb+WI22wNEX8w46E5GOfTketa9R3LOkDtFEZXA4QEDd+J6UgPFLb4Z358RWo8SeMPEGqXdzZLcD/STbwSTwuPlaJcAp+8XgnPDc88e0WMUcNrEsVuluNoPlIAAvtxxXj/inxf40trVzpHhWGEaRcpG2q6pdYt9jAJvKKA7KA4LEYxtzzXceAbXxJDp8q+KbmFtSXcrmBmaIEsWBjBA+TBwN2W4wTximB19ZviXS11rw/qOmuQv2qB41Y/wsR8rfgcH8K0VXaDyTyTzS0gOV1K4/wCEk+GeoyImJLzTZo3j7pJsZWQ+4YEfhXOeJhGfhHDqVjGpOlNbatGVwQVhkSYkexjDfga6zQUSz13XtNCsI2kS/RWORiYEMB/wONyf96sjwBpcb/DgaHKu0RxS6dIpOcBN0P8AJaYG541jW88Ea9Eo81ZtOuFAXncDE3T65rjPgYb+48NW1xeX1vdRtaQNHtjIZdyZxkkgADaMDjIJwK7vw5E3/CM6bBdR7ZFtY4pU9GCgMPzBryv4JXNxFb6j4UvrSJG0Vn025kncASKhxGVj6kNGUO7gHPA7kQj1vULgJC6RNGJiDtLkbVbHBIyMjPYVzs154uSz8y2g0q9mABCIkkQfrnlyAO2OfX61qPcPpt9DbWejvJbyoztcWwQImNowwznccnHXgHntVC88RavbwDy/DV3POQcKsqgEj8yB7n179KBmLq+teMoNPilu/C9tdoZYSsVterHKX85QFKvleeud4Ax3ri/D+veLNOk8aN/wgF20l9rJM8q6lbMIVaKFcHLAsQuGAAx82MjBrq/EfjjXbK0W5ufBOsta29xGZfsjxzSN8ygKqEqW+ZgMjPTPTmuN8OfE7UBqviWOXwL4qR73WoWJk04yRWy+TbxlZTkYb5dwAzw6n6gHoFhrfjW7Y/aPDLWKH5GUXEUjR+j8sFOO6gsD2YVqrd6nPJGtzFcQCaMxyL5bLGxPAIZSWibrz8w6c55qrbeLNSnVZR4e1dVLlPKktSjfjk8D0boc8hetMufE2tS34hs7A2kPGJLyzkJJ5yMKwGBj7wJHNAF2fStXayFvaXtyvlgbHuZEdmz1V8hhIvbnacHg55rzzwFaSx/EppLxADpun3FzIqSMYxJcThYvLViQg2ROu3PH411niDWNatdFvLmbVtPtmjTJEVv0BYAH5mLZwc4KY9xXFfCbR7nUbzWNVOt6ikd/fpYQvCkUfnQWaMocgxnHzllOPTqaPUD1XxfuuG0SwXrdajEzj/YizMfwzGB+NX7+O3utVsLeeCOYw7rpd4B8tlwqtg9/mOD7VzD+HobjxzapNe6vcCzsZJWZ72RQGldVX7pHaOTpVfXdC02G11i6jtvtF5MyWVn58rSkSnhSN5PR3JPoF9qQGv4Wv7Xy9T1W6uoIl1C8d4mkkC5iQCJCM9iIyw/3q0JPFWgIpJ1rTiBydtwjY/I03SfCeg6VZW1taaRp6LbxLErC2TcQoxycda2Yoo4lCxIiL6KMCgDJi8SabMCbd7mYYzmK0lcHnHBC81JJrSLGWisNSlYY+RbZlJ/76wP1rVooAwv7a1B1Bg8OamSTj97JboB7/wCsJ/SlS91+R1A0ezhQ5y0t+cj8FjP863KKAMQjxHIyYbSLdcfMCskxz7cpWR4si1q10S7urjXLeKGKEsVgsACSBnA3O3UgDHvXZVy/jBzcX2kaSVDx6hcgSKVyBHGDI5J9PlVfq4oQDNA8K3Om6LZWLeINUKwRImEECDIHPSPPJz3rRj8O24Dede6rPk5O++lH6KwGPatqigDM13QtN17QbjRdXthdabcRiKWF3b5lGCPmB3ZyAc5zkVkXXw+8MXWkaPpkmmbLTR+LEQ3EsTwfLtIDqwY5HXJO7vms74teHtR8SW3hi00+OeS1j1uCbURDc+QfsgSQSZIZSR8y8A5PpXmfh74aeKtObSDBDd207Wus2N5LJqRkVInGLJceY3yjORtHHU80AdR4u+B+l6tbWVlol1FounW9k1gVSKaWYxNIzlfM84AjLE4kVwDyMV2f/CvPDLGZpNOMkk0tpPK7TyAvJaqFhY4YAbQo4AAPcGvJrfwv8StSsfINnPolxb+D/wCxo7h9Sjl827SWI7/kYlS6K+G7Z5INWb7wVqsw0l7LwPfW2iW00hv9DOtoXvXaHbHMG8zYAjZ6sCc7sZHIB6bqHw48K6hdS3Vzpjfapbxr9po7qaN/OZAjMGVwQCoAKjCnHIq14c8DeHfDdzZ3Gi6d9mms7JtPgbz5H2QNJ5pTDMc/Pzk89s44rxPxL8PPHtzpvhOF4p9Y1Gy0xLedri8RrQS+axO7MiSq6ptBlTcTgYAxk6qeD/GjfGG2119Ka2to9Xdpbq1u4/JlsihALBpPMZs4yu0KP4QeoAPfKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuL8Xo1j4z8K6rGvyzSS6ZMwOMeYu+Mnnpui2/9tK7SsDx9p1zqng/VbbTmZNQEJmtGXqs8Z3xkf8DVaEBv0Vn+H9STWdB07U4gFS8to7gDOcblDY/DNaH0oA5Lxdr1jDINGudNn1hNUV7Q2ttGrb2KMWRy5VACgPU8Y56isPwRrviHUmgml0W3sLZ0On/6RfedNFPbu6sJVRNuWAJBDdvcV3Fxp0f/AB9NCLq9jO+NnO0gj+FT2HJ4/OvMH8T3J8SMvhLS5kj16VpIZb9jbQTXttt80KQGOJIUIzt2kx5GfmNMD18ZwM8nuQKWqekTXNzYpNeJHFK/JiTJ8v1Uk9SDnnirlIDndVMdl4x0W8ZObyOXTy+ehx5qZ/79uPqfenaKqWHiTWbASDE5TUIo+mA42Pj1G5Nx93qfxhbSz6DPJaR+ZeWhW7gUdWeMhwo/3sFf+BVl+J5Hm0nTvFOiK009kguVjHBuLVwDLHj12gOP9pF96ANq3Btb6WM4WMuWHoQ5z+e8H/vqvMfF2r2vgP4w2+pX6eVp3iC2RPOVdxN1EdhXABOWRosdv3fYZI9Pu3t7i1t9RiKzQBA4ZOQ0bYOR+jfhWB8U/CCeOPBs9hBOLfUIyLnT7tTzDOoO1gfQglT7Me9MDoZtRMAw1vJPMWAMNvh2QHu2SAP84zSXGsWdoge9nitlPQSttOfTBrgPhf4vsNc8OR6HcxPZeJNNBt7/AE1pfLmDR/K0jEEnY3BLZP3hycjPoHkW72jfaTAbZ1A2IAEwcd+/14oA5TxL8SPC+n2LzPrlov2eWJ5UU73MfmIGKoAWbG4ZCgkZHSuF0b4xeDJdS1i0tXutRutR1hHigW3kh3DZEobdIFAIMX3SQTwADmvS/E17oXhfSnv5V0+zgiljed/LUYQSLuOAMkgYPc8Z7V5lo3xT8AatDrVhfa1Hcx3ms+dHHJA6I6AxsnzSKEwTH0zk0gPTLTxra3C7jZXiD5QQFEhBPGMISeOv06ZIIqxHrsd1clba7VZAoYwFA5Vf723IYj3GcdwKztLufA1+PIs4NIikZDMYmt1gcDGScEA8Z5+tblnolnZqsmnHyxjKlz5wx1xlssB04BAp6AcP8VPFf2bR7qwgt5JNTwqW8Co37+eTCxKpIwSSenUbSegzXY+DPDyeHfDul6ezJLPawkSzKu0SSud8rgdtzkt+NcB4LLeKvG+seLLyPzNO0SSa000pJvS4mIw8q/7q4jX0LSA8ivS9T1FdG0N7y8BkkiQfu05aWQ4CovuzEKPqKAKGkSf8TfxLqUpIhSVLdCeAUijBJH/A3cfhVWwha51+wtpQSdNha9uORgXM2Qo46kKZf++lNTWUL6do1pa6pKjTfPe38q8InzGR/wDgO44HsD6Vc8JrNJpX266UpcahIbpkPVFbGxT7hAgPuDSA2qKKKACiiigAooooAR22ozbS2BnA6n6Vy2l3MuqePdVcxstnpMCWcTno80mJJcf7qiIfia6W6mW2tpZ5M7I0LtgZ4Az0rP8ADVo9rpKGcAXNw73M3y4O92LYP0BC/wDAaANWiiigDmPG/iz/AIRptJtrbT5dS1TVbn7LaWqSLGGYKWZmduFUKpJ6n2rhdR+J2paF4o1n+3tPlhtrXSrWaPS0aN5PtMty0IAlHBDfKck8DnGeK9K8TeG9J8TWcVrrdoLiOGUTxMsjxvFIOjo6EMp5PII61jp8N/CYtrqBtIWWK6tVsphNPLJ5kSyGQAlmJ3B2Lb/vZ5zQBzOq/F9NK0a/nv8AQLuLUtP1FNOu7YTBooGZPMWVpgCBGV77c5OMd6z7747WcC232TQ59QkNql3crZ3SSiNGdlAjK5EjYUsR8uOh5yB26/DnwwuljT47GeKH7QbsyR31wk7Sldpdpg4kYkccseMVBL8LvBzw2cUej/ZltIPs0RtLma3YxFixRmjdS4LEkhickk9zQByPij4oalNrlha+G7F4tLi8T2eiXmoysn71nIMsSxEbh8rD5+Oelex1x9z8NfCdzrqaxLpZ+3LdRXoZLqZE8+LGyQxhwhYYHJHPfNdhQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHDeD7g6F4s1jwncsqW5zqek8Y3QSMfNjB/6Zyk8dlkSu5rjfiZYOthY+IrIhNQ8Pz/bQwUEvb4xcRfRo9x/3lX0rrreaK5t4p7eRJYZVDo6HKspGQQe4IoAewDKVYAgjBB71yPie00aK1tLLV4bqUfb0vLEQQuzLcK5kVUKDg5DdcDaSDxmuvqrqNs1xFGYiomikWWMt0yOoP1BI/GgDlPhnr914h0ubUrixezgu53Mcby73hdAI5I3X+AiRHOMnrzg8V2teU6rrOi+GNf1WHRZrieXXZh9ptrJsva37qqRHacJGZcHPmMuWVeuTXonh/UX1LTIZbm2ltLwIv2i2mADxOQCQcEj8QSPegDSrn9F26PqcujMdtvJuubHPTYTl4h/uscgf3WA/hNdBWfrmlx6tYmFpHgmRhJBcR/fhkHR1/qOhBIOQSKAMvSNmgau2ju4Wxuy02ngjARuTJCD04+8o9CwHCVvxKYn8pIwsIXKsG75ORisS2Ka7Z3Ol65biO/tivmhCVBP8E8TdQDgkHOVII6jNWNLW8SCTTtZmSWTlYLhWCPcR4HzFRja4zg447jGcAA4b4n+Cn1HWoPFHhUPbeL9OQMAjBftsIBG0gnazLn5d3B+63ykEV/hn4v0Xxh4YEmowNomp28rQ30BkMEglUlSGcbSpJ6ocEZA6Yz6U0csiCOSTy7qPJimAzuHuPyyPy7V5V8UfAP8AbWrw69oNuun+LbdlEiiY28erRDrH5qch8DCsecfK2VwQwLXibXPhtpNqEvTpJKzRyutxAXG0Sx7pBgYYjI5Gfxwa5rSfiv8ADzUEv9JhuZ75r3WftEFtbWEhZlGxw4DIBjKEEfe9qyYfHtn4d8S2dr4p0PUdCZ7vzzPeQGOISZK/PIoIcdGBBI9+Npj0f4lLqMHi2BrqFr06+8lmLSzkm8xF8pUdfLDjlUYYydwYjjIJAPTrzxV4EWNItTiayjRlMZuYXiUNkhdr9M8njP17Vm+NvE8d00XhLwTcXP8AwkOrJ5ZT5x9hhcENcvuBwqjOACMkrg8iqcy+OfGVpB59ha+GNIifzZbvWY455GQbvu2xyqHp8zlWHvXXeAvCGn6JZFNHFz5ExBuNQuzuvL/H3dz4BEYHAGBx0AHLAG74c0Oz0bRNM0XS4wml6dEkceD/AKxl7nHXn5ie7fjU09va6rq8E0juy6VIx8vjyzMyDDH1Kqxx6b/UDEl/NNvj0/S1VJSBvl2/Lbx+uOhY9Av4ngc3bWGK1thHF8sSZyWPU9SST1Oc5NIDnNfj+2vaaanzPq0wac8/LaR4ZgfY/KmPWU11VYPhtU1C4udeJLC8Ajtty4226k7SM8/OSXz3BX0reoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEZQylWAKkYIPeuB8K/avCfi4+E5pIn0C5t3udFJGJIAjDzLUnPzKoYFO4UEHO0V39QXFpb3E0E00ETz27FoZHQFoyQQSp7ZBI47UAT0UUUAYl3pNtfTatY30G+1v0SQkcHIAXgjoy7UIPUHkdK1bSFoLaKOSVppURUaZwA0mB1OOMnr+NTUUAFFFFAGZrGmvdNFd2Miwalbg+TKwyrA9Y3A6ocDPoQCORUdtPBrlq8U8b217buPMiJHmW8mOGU9x1w3Qj8RWvWfqentPIt1ZyC31CNdqTFchl67HHdT+Y6gigCaOQxeVHetGZM7Uk6Bzj07HrxU08MdxC0VxGksbDDI65B/Cs23u4dSWTT9TthDdBf3ltIchx/eQ/wAS+45HcA1pW8QghSJWdlQYBdizY9yeT+NAFGSxuImLafd7FPWG4Uyp+HII/PHtUQGvCXaTpZiI++BICD/u85/MVoXUzwIHSF5lz84T7wHqB3+nX61UuNQRlVWtL5lkj3oUiZSx5+Q9Cp4/iwOetABqMdiYbYawtvO6OGjDx5zIO6pyc/TOKtWk8lwC7QPBH/CJcBm98DoPrz7Cuf0ouHmfStAktmk4W7vCFLj1YE+ZwexAzjrzmteCzuZVzqlykxP/ACyhQxx/iCSW/E49qAFiVJrnzLXIj5LOv3WY4yfc4GM9BWRft/wkd5JpNqWGj27bL+ZTgTMOtup7j++R2+XqTtWS9ufEDG10KQ2+lo2ybUU6uB1S39fQydB0XJ5XfsLO3sLOG0s4lit4VCIi9h/nvQBMiqiKiKFRRgKBgAUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAId24YI2980tFFABRRRQAUUUUAFFRz+ZtBhwWByQe47ihZkOwE7WfgK3BzjOKAIr+xt7+NUuY92xtyMpKsjeqsOQfcVAIr+3Y+VNHdx9km+Rl/4EBg/iPxq+eRwcGq00txFJny1eLaehOQ3bPt/L37ADY735ws9vPAfV1BX/vpSQPxxVyuY1XxDEq3EEkMrxspXECmR+nIwAQG9AeDkdarW2oalDr/h/S5Cd0mlz3EsWAMurwqN55IwJG6dT9KdgNCSPxTPLJsudGsoSTs/cSXDgds/Ogz+FOPh57uARa3ql5qEZOXhwsMT+xVACV/2WJB75rWaGaSIq9w0bED5olAwR1xnPWi5tFuG+eWcLtxsSQoD78YP60gJY1jiRYolVVQBVRRgADoAOwp9R28EVtEI4I1jQdlGPxqSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqK5h86F1BCuR8rEZ2nse1SKwOQOo6iloAoSXNxbBTcRqwI5MecDHX/AOtUkepWjsVEyBwcbScH8qmnhMiP5crwyEYDpg498HI/Ssq/0ie8I819PlHGWms9zcdOQ49T+dPQCHxHr+kafpNzcX120UUcRl3RMyuQORtxycnjjOTx7VhXGj6rrv8Awh2vI8tnqVkHW4RiFLxSpzuH+8kZxwRz0IxWjb+DbW0vobyC30+S4h+aMzQu3lsepTLkIe2QOnFO8TaDc+Ixpc8V7Pp13YTtIyRSHD8fdJGMjIQ9OmeOaNAuWJNZurWNkubO7kuIwciC2eQN6HIGD07Hv0FV7bXddu5oUj8NXdskgB8+5kiCKD/eUSFw3+ztPXrWla3WppCftVmXkHZWHOOvOce/akbW3EXmNYXSL33oQQfpjp7/AP66YFizu78qwv8ATvJcE4MEwlQjPHJCnOOcY49TVo3SCUR7JtxGc+U2PzxiqVvrthNEz+cFKkqyEHeCDgjb97r7VopIrYC5ORnoakByNuUNgjPYjBpaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAY8YbkEqw6MOtNmEhQbH2uDngZB9j7fSpaKAK0l2sW3zcAkZIBzVOTXtPibE06Rqy7ondgFm4yQvPJ9utauOc96hnFuhSWcRApwjOBkZ7A0AVm1JYoQ88E0bEZWMAOzn0UKTk1zja1d2njvTrXUSbaz1OyuJIIWIJEsbRcMRxu2MWx0wD6VusJLqOO3tLUwWm/948i+X8mckKvXnpyBwSavXVnb3TI08MbvHnY5UFkz1we1ADmtoGlMjQxmQjBYqMn8fwFKkEMZJSKNSRtJCgZHpVMpcxuzRhyFUADIIf2AyMf5+lJ/aflRyPe2lxbRoMmRgHXrj+Ek++SBxTAtR2dtHjy7eFcHPyoBzU9NikSWNZInV42GVZTkEeoNOpAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADWDEjDYHfimC3iE3nFA0oGA7ckD29PwqWooZC7yjKlVbaMdegzn86AJay7rSFnzI13f+eOQY7p4xn02g7cfga0PPi+0G381PP27/AC9w3bc4zj0z3rn/AAfqn9oRa7O8jukGqXFuMnIURkJgegyp49c0AaGmTyweVbXkskzMSqSuoDZAyVfHG7ryBggfnpoyuoZSCp6EVl25F2r4Ykbw6P6LnIP8x+hq9b5WaeM5xu3rn0P/ANcGm0A6KBIeIVEackooAUknJP16/nUtFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAQ89DiqSr9lnQsxCOzjaoJ+ZmyCf15p95OsU9sG5y54B5Hytz9ODUWu6ZHrWlS2Ul1e2qyYImsrhoJUIIIKupz26dD0IIoAzPF9he/6JrWixGbVdN3Fbffs+1wtjzIMngE7VZSeAyLkgZryD4RePrfU/CXiU6fFsuLnX72W0tp5USaYSyLIilMkkkybWAzxnB7j0x/A8aWsq6r4p8SXlhy8yXN8I1KAcqWjVDt4yefXnFeb/ALLFhpDeH7/W7qCP+3HvHhWW4TMsEGxWRVZuQrBi2c8574FCA9w0uxa0sraOeUzTxxKkkhAHmMOrEfXJ/Gn208E8qyQsrb06g8kA8fz/AFqK91FYDiMLJj72D0O5VH8z+VQ+Hb2C/sIp7YHY8UbE4wDuUNx+DCmBrUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCGf5mEYAJYcg5+70P86y7ee5HzQRSPC+8AEEMrBgDjOOPv4zjOB61sbR5gfnIBHX6f4VXtwtnBtk+VTK23j+85I/nTuBy3ibw1qPjK31DTNZvZ9N0OSHyVj0+bbNOxxud3K/KoxgIM5GS2c7R5t8BfCcMx13+00kt7jTZH8PzwRHEV40GC10wI+8RIFGDwoxzxj3yvNNHmOleOPEtvHEzAakl0zBufLngiDDGem5CfwoQHV3Wmm2uYjGJZYXLl9oHy5K7c+w5q94csxY6LZw8ZESZwMDIUD+gps2oiWzhURsk9ztjWNhkgsMnP+6vJrUGMcUAFFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKa6K4YMMgjBFOqOWNmBMTbJMcHGR+I70AY2s6rPpV5Z5TzLPDeftjaSU9AvlquSxBzuAB459jkaldXOt3lnNoNqZYwf30koEagdjnrkemDgMeM108s95CAPsf2jjrDIo5+jEY/M1SlGu3v7sC00yI9ZUczy4/2QVCqfc7voaYFdLeTT2QPILrWLkFI+ywpxuYA5O0cEk8scD0A3raEW9vHEpZgigbmOSfcn1qtp2mwWO5kMks7gCSeZt8j49T6ewwB2FXaQBRRRQAUc59qKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The labial incision is closed in two layers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7857=[""].join("\n");
var outline_f7_43_7857=null;
var title_f7_43_7858="Management of the fetus with compound presentation";
var content_f7_43_7858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the fetus with compound presentation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7858/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7858/contributors\">",
"     Edward R Yeomans, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7858/contributors\">",
"     Clint M Cormier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7858/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7858/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/43/7858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compound presentation is defined as presentation of a fetal extremity alongside the presenting part. It may involve one or more extremities (eg, hand, arm, foot) with the vertex or the breech. The majority of compound presentations are represented by the fetal hand or arm presenting with the vertex [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7858/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compound presentation complicates from 1 in 700 to 1 in 1000 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7858/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. It is more likely to occur when the pelvis is not fully occupied by the fetus because of low birth weight, multiple gestation, polyhydramnios, or a large pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7858/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Rupture of membranes when the presenting part is still high also increases the risk of compound presentation, cord prolapse, or both. Another predisposing factor is external cephalic version [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7858/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. During the process of external version, a fetal limb (commonly the",
"    <span class=\"nowrap\">",
"     hand/arm,",
"    </span>",
"    but occasionally the foot) can become \"trapped\" below the fetal head and thus become the presenting part when labor ensues. In multiple gestations, a possible scenario involves the head of the first twin and an extremity of the second twin within the birth canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compound presentation may be noted on an antepartum obstetrical ultrasound examination or palpated during a cervical examination, typically during early labor. The examiner will feel an irregular shape beside or in advance of the vertex or breech. Compound presentation may not be diagnosed on admission to the labor unit if the cervix is long or closed, but will be discovered as labor progresses and the cervix becomes more dilated. The clinician should consider this condition when the head remains high or unengaged after rupture of membranes or when there is a delay in the active phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LABOR MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of compound presentation is debatable. Some experts recommend attempting to reposition the fetal extremity, while others discourage this practice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7858/abstract/6\">",
"     6",
"    </a>",
"    ]. There is consensus that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    should be avoided.",
"   </p>",
"   <p>",
"    For women with normal progressing labor, we favor observation alone. Occasionally, the presenting part will simply push the extremity aside or the fetus will retract the extremity as labor progresses.",
"   </p>",
"   <p>",
"    However, if descent of the presenting part appears to be slowed or obstructed by the extremity, then gently pushing the small part upward into the uterine cavity while simultaneously applying fundal pressure to effect descent of the vertex or breech can be attempted. We choose not to pinch the presenting part in an attempt to provoke the fetus into withdrawing the presenting part.",
"   </p>",
"   <p>",
"    Failure of the compound presentation to resolve spontaneously or after this gentle maneuver is best managed by cesarean delivery, especially if labor becomes protracted or arrested or the umbilical cord prolapses.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    augmentation in a patient with compound presentation is not advisable and may lead to uterine rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7858/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, labor results in an uncomplicated vaginal delivery. In a case report, a patient with a compound presentation and protracted labor entrapped the fetal arm between the head and bony pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7858/abstract/7\">",
"     7",
"    </a>",
"    ]. The neonate was diagnosed with ischemic necrosis of its arm, which required amputation. This case underscores the need for operative intervention if the compound presentation does not resolve spontaneously or with gentle pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet\">",
"     <li>",
"      Compound presentation is a rare complication of labor. Predisposing factors include fetal-pelvic disproportion, polyhydramnios, external cephalic version, and rupture of membranes at high station. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A compound presentation may be visualized on an antepartum obstetrical ultrasound examination or palpated during a cervical examination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most compound presentations will resolve spontaneously. For compound presentations with normal progressing labor, we suggest expectant management rather than intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the descent of the presenting part appears to be slowed or obstructed by the extremity, gently pushing the small part upward into the uterine cavity while simultaneously applying fundal pressure to effect descent of the vertex or breech may resolve the compound presentation. We suggest cesarean delivery if this intervention is not effective. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Labor management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7858/abstract/1\">",
"      Cruikshank DP, White CA. Obstetric malpresentations: twenty years' experience. Am J Obstet Gynecol 1973; 116:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7858/abstract/2\">",
"      GOPLERUD J, EASTMAN NJ. Compound presentation; a survey of 65 cases. Obstet Gynecol 1953; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     Cunningham, G, Leveno, KJ, Bloom, SL, et al. Williams Obstetrics, 22nd ed, McGraw-Hill Professional, New York 2005. p.511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7858/abstract/4\">",
"      Brost BC, Calhoun BC, Van Dorsten JP. Compound presentation resulting from the forward-roll technique of external cephalic version: a possible mechanism. Am J Obstet Gynecol 1996; 174:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7858/abstract/5\">",
"      Ang LT. Compound presentation following external version. Aust N Z J Obstet Gynaecol 1978; 18:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7858/abstract/6\">",
"      Weissberg SM, O'Leary JA. Compound presentation of the fetus. Obstet Gynecol 1973; 41:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7858/abstract/7\">",
"      Tebes CC, Mehta P, Calhoun DA, Richards DS. Congenital ischemic forearm necrosis associated with a compound presentation. J Matern Fetal Med 1999; 8:231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4462 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2B8F6805EC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7858=[""].join("\n");
var outline_f7_43_7858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LABOR MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_43_7859="Obstructed Roux limb after gastric bypass";
var content_f7_43_7859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Obstructed Roux limb after gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Obstructed, contrast filled Roux limb after gastric bypass with collapse of the common channel on computed tomography (CT) imaging.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7859=[""].join("\n");
var outline_f7_43_7859=null;
var title_f7_43_7860="Ichthyosis linearis circumflexa in Netherton syndrome";
var content_f7_43_7860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Ichthyosis linearis circumflexa in Netherton syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serpiginous, erythematous, pruritic plaques with double-edged peripheral scale develop in patients with Netherton syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7860=[""].join("\n");
var outline_f7_43_7860=null;
var title_f7_43_7861="Acetaminophen and pseudoephedrine: Patient drug information";
var content_f7_43_7861=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/54/16229?source=see_link\">",
"     see \"Acetaminophen and pseudoephedrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ornex&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Ornex&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Contac&reg; Cold and Sore Throat, Non Drowsy, Extra Strength;",
"     </li>",
"     <li>",
"      Dristan&reg; N.D.;",
"     </li>",
"     <li>",
"      Dristan&reg; N.D., Extra Strength;",
"     </li>",
"     <li>",
"      Sinutab&reg; Non Drowsy;",
"     </li>",
"     <li>",
"      Sudafed&reg; Head Cold and Sinus Extra Strength;",
"     </li>",
"     <li>",
"      Tylenol&reg; Decongestant;",
"     </li>",
"     <li>",
"      Tylenol&reg; Sinus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12367 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-EBA391572F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7861=[""].join("\n");
var outline_f7_43_7861=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129653\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129654\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026495\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026497\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026496\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026501\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026502\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026504\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026499\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026500\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026505\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026506\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/54/16229?source=related_link\">",
"      Acetaminophen and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_43_7862="Pseudofractures in osteomalacia";
var content_f7_43_7862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F52768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F52768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudofractures in osteomalacia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A and B) Plain film images of Looser-Milkman pseudofractures of the pelvis and the left femoral neck (arrows) in a patient with osteomalacia.",
"    <br/>",
"    (C) CT of the pubic symphysis from a patient with osteomalacia. There is a pseudofracture (white arrow) in the superior pubic ramus on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     A and B Courtesy of CJ Menkes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7862=[""].join("\n");
var outline_f7_43_7862=null;
var title_f7_43_7863="Methylphenidate: Patient drug information";
var content_f7_43_7863=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methylphenidate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     see \"Methylphenidate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     see \"Methylphenidate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Concerta&reg;;",
"     </li>",
"     <li>",
"      Daytrana&reg;;",
"     </li>",
"     <li>",
"      Metadate CD&reg;;",
"     </li>",
"     <li>",
"      Metadate&reg; ER;",
"     </li>",
"     <li>",
"      Methylin&reg;;",
"     </li>",
"     <li>",
"      Quillivant&trade; XR;",
"     </li>",
"     <li>",
"      Ritalin LA&reg;;",
"     </li>",
"     <li>",
"      Ritalin-SR&reg;;",
"     </li>",
"     <li>",
"      Ritalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methylphenidate&reg;;",
"     </li>",
"     <li>",
"      Apo-Methylphenidate&reg; SR;",
"     </li>",
"     <li>",
"      Biphentin&reg;;",
"     </li>",
"     <li>",
"      Concerta&reg;;",
"     </li>",
"     <li>",
"      PHL-Methylphenidate;",
"     </li>",
"     <li>",
"      PMS-Methylphenidate;",
"     </li>",
"     <li>",
"      ratio-Methylphenidate;",
"     </li>",
"     <li>",
"      Ritalin&reg;;",
"     </li>",
"     <li>",
"      Ritalin&reg; SR;",
"     </li>",
"     <li>",
"      Sandoz-Methylphenidate SR;",
"     </li>",
"     <li>",
"      Teva-Methylphenidate ER-C",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming; avoid long-term use. Use this drug as ordered by your doctor. Tell your doctor if you have a history of drug or alcohol abuse. Misuse of this drug may cause unsafe heart-related side effects. Tell your doctor if you have any heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat attention deficit problems with hyperactivity. It may take 3 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat narcolepsy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702511",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methylphenidate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703511",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Drug abuse, a fast heartbeat, glaucoma, heart disease, nervous problem, structure problems of the heart, tics, or Tourette's syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have small bowel disease, short gut syndrome, peritonitis, cystic fibrosis, long-term bowel pseudo-block, or Meckel's diverticulum, talk with your doctor. Do not take Concerta&reg;.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have chest pain, overactive thyroid gland, recent heart attack, very high blood pressure, or weak heart, talk with your doctor. Do not take Metadate&reg;.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696692",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of heat sources (such as sunlamps, tanning beds, heating pads, electric blankets, heat lamps, saunas, hot tubs, heated waterbeds). Avoid long, hot baths or sunbathing. Your temperature may rise and cause too much drug to pass into your body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698041",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Extra muscle action.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet shell of Concerta&trade; in the stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are new or worse after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablet early in the day to stop sleep problems. Take at least 6 hours before bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take chewable tablet,  immediate release liquid, immediate release tablet, and Ritalin-SR&reg; 30 to 45 minutes before meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take Concerta&reg; once a day in the morning. Take with or without food. Take with water, milk, or juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Methylin&reg; chewable tablet: Take with a glass of water or other liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695369",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Metadate&reg; CD, Ritalin LA&reg;: Take before breakfast. Take with or without food. You may sprinkle contents of capsule on 1 tablespoon of cold applesauce. Do not chew or crush capsule contents.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Metadate&reg; ER: Take before breakfast and lunch. Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4101644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Quillivant&trade; XR: Take in the morning with or without food. Shake bottle for 10 seconds or more before taking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use patches that are cut or do not look right.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bathe, shower, or swim for short periods after putting on the patch. Cover the patch with plastic wrap and tape to help keep it in place.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694484",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin on the hip. Do not put the patch on the waistline.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694472",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on in the morning and take off 9 hours later or as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695471",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the patch site with each patch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695145",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch falls off, put on a new one on some other part of the same hip.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it. Do not take this drug after 6 PM.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4101274",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Quillivant&trade; XR: Throw away any part not used after 4 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705500",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699209",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep patches in the pouch. Use within 2 months of opening tray.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699145",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After you take off a skin patch, be sure to fold the sticky sides of the patch to each other.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away unused patches when they are no longer needed by flushing down a toilet or sink. Take them from the pouch, take off liner, and fold in half.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11797 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7863=[""].join("\n");
var outline_f7_43_7863=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195295\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195296\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023362\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023364\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023363\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023368\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023369\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023371\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023366\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023367\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023372\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023373\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=related_link\">",
"      Methylphenidate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=related_link\">",
"      Methylphenidate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_43_7864="Basic life support in infants and children";
var content_f7_43_7864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic life support in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7864/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7864/contributors\">",
"     Pamela Bailey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7864/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7864/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7864/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/43/7864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early recognition and treatment of sudden cardiac arrest improve survival for children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Basic life support (BLS) involves a systematic approach to initial patient assessment, activation of emergency medical services, and the initiation of cardiopulmonary resuscitation (CPR), including defibrillation. Key components of effective CPR include adequate ventilation and chest compressions.",
"   </p>",
"   <p>",
"    BLS can be performed by trained lay persons, as well as by healthcare providers. This topic will review BLS principles for healthcare providers. Basic airway management for children, neonatal resuscitation, and basic life support for adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link\">",
"     \"Neonatal resuscitation in the delivery room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary arrest among infants and children is typically caused by progressive tissue hypoxia and acidosis as the result of respiratory failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/4\">",
"     4",
"    </a>",
"    ]. Causes of respiratory failure and shock leading to cardiopulmonary arrest in these age groups include accidents, sudden infant death syndrome, respiratory distress, and sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/1,5-7\">",
"     1,5-7",
"    </a>",
"    ]. This is in contrast to adults, for whom the most common cause of cardiac arrest is ischemic cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H2#H2\">",
"     \"Basic life support (BLS) in adults\", section on 'Epidemiology and survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall survival rates vary between 4 and 40 percent for infants and children who have had out-of-hospital cardiopulmonary arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/1,6-9\">",
"     1,6-9",
"    </a>",
"    ]. Increased survival rates occur in pediatric patients who receive early CPR and those with an initial cardiac arrest rhythm of ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT). For example, in one multicenter observation study of 78 children with out-of hospital cardiopulmonary arrest, 50 percent of children who received CPR within four minutes of arrest and 22 percent of children with an initial rhythm of VF or pVT survived compared with an overall survival rate of 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/1\">",
"     1",
"    </a>",
"    ]. In another observational study of 361 patients with cardiopulmonary arrests including 90 children younger than 14 years of age cared for by a regional emergency medical services agency, overall survival rate was 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/9\">",
"     9",
"    </a>",
"    ]. Survival was significantly improved in patients who had a witnessed arrest (OR 13.4), received bystander CPR (OR 3.2), and had an initial rhythm of VF or pVT (OR 9.4). Thus early recognition of cardiopulmonary arrest and prompt initiation of CPR are essential to successful resuscitation of children with cardiopulmonary arrest. &nbsp;",
"   </p>",
"   <p>",
"    Among children with in-hospital cardiopulmonary arrest, acute resuscitation survival approaches 78 percent and survival to discharge occurs in 39 to 48 percent of patients who receive cardiopulmonary resuscitation (CPR) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In one multicenter observational study of 1031 children with in-hospital cardiopulmonary arrests occurring in academic pediatric hospitals over a 10 year period (2000 to 2009), adjusted survival to discharge increased from 14 to 43 percent while the rates of significant neurologic disability remained stable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/11\">",
"     11",
"    </a>",
"    ]. This improvement in survival occurred despite a high prevalence of asystole and pulseless electrical activity (PEA) found as the initial arrest rhythm (up to 85 percent of patients) and was similar regardless of the initial cardiac arrest rhythm (ventricular fibrillation, pulseless ventricular tachycardia, asystole or PEA). The use of extracorporeal membrane oxygenation during resuscitation and postresuscitation care (ECPR) significantly increased from 8 to 14 percent of patients during the study but was",
"    <strong>",
"     not",
"    </strong>",
"    associated with overall survival to discharge.",
"   </p>",
"   <p>",
"    Thus, rates of survival from cardiopulmonary arrest are higher for in-hospital pediatric cardiopulmonary arrests than for out-of-hospital arrests and improved survival among children with in-hospital arrests cannot be attributed to differences in initial cardiac arrest rhythm or ability to perform ECPR.",
"   </p>",
"   <p>",
"    In contrast, if promptly treated, children with a respiratory arrest are much more likely to recover than those with a cardiopulmonary arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. As an example, in an observational study of 95 children with out-of-hospital arrest, 82 percent of children with respiratory arrest were alive at one year compared with 14 percent of patients with a cardiopulmonary arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, the best outcomes in critically ill children occur if cardiac arrest is avoided altogether.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE 2010 INTERNATIONAL RESUSCITATION GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon extensive review of clinical and laboratory evidence, the American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) published updated guidelines for pediatric basic life support (BLS) in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. For the purposes of these guidelines, a newborn is defined as from birth to hospital discharge, an infant is younger than one year of age, and a child is from one year to the start of puberty.",
"   </p>",
"   <p>",
"    The guidelines are designed to be simple, practical, and effective.",
"   </p>",
"   <p>",
"    Changes for infants and children from the previous basic life support guidelines of 2005 include new criteria for the initiation of CPR, compressions prior to airway and breathing for infants and children in cardiac arrest (CAB instead of ABC), and evidence-based reaffirmation of conventional cardiopulmonary resuscitation (CPR) as preferred to compression only CPR. &nbsp;",
"   </p>",
"   <p>",
"    The sequence for neonatal resuscitation is described separately (",
"    <a class=\"graphic graphic_algorithm graphicRef80621 \" href=\"UTD.htm?22/34/23072\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'Overview of resuscitative steps'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BASIC LIFE SUPPORT SEQUENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before beginning basic life support (BLS), rescuers must ensure that the scene is safe for them and the victim (such as by removing the victim from a burning building). The next steps in BLS are activating emergency medical services (EMS), getting an automated external defibrillator (AED), and starting cardiopulmonary resuscitation (CPR).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Activate EMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For activating EMS, the guidelines recommend the following in infants and children for healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For unwitnessed and witnessed cardiac arrests with two or more rescuers present, initiation of CPR, activation of the emergency response system, and getting an automated external defibrillator (AED) occur simultaneously. CPR should be performed for two minutes (five cycles) before using an AED in a patient with an unwitnessed arrest based on limited evidence in adults that even for prolonged arrest from ventricular fibrillation (VF), an initial period of CPR improves the likelihood of successful defibrillation. This approach is the same as for adults with cardiac arrest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H4#H4\">",
"       \"Basic life support (BLS) in adults\", section on 'Phases of resuscitation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For the lone rescuer, the sequence varies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the cardiac arrest is witnessed, the lone rescuer should first activate the emergency response system, obtain an AED, and then start CPR. This approach is the same as for adults with cardiac arrest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H4#H4\">",
"       \"Basic life support (BLS) in adults\", section on 'Phases of resuscitation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the cardiac arrest is unwitnessed, the lone rescuer should first perform two minutes of CPR, activate the emergency response system, and then obtain an AED. CPR is recommended initially for infants and children with an unwitnessed cardiac arrest being cared for by a lone rescuer because most pediatric arrests are likely to be asphyxial. This approach differs from that recommended for adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H4#H4\">",
"       \"Basic life support (BLS) in adults\", section on 'Phases of resuscitation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initiate CPR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The actions that constitute cardiopulmonary resuscitation (CPR) are opening the airway, providing ventilations (rescue breaths), and performing chest compression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link&amp;anchor=H3#H3\">",
"     \"Basic airway management in children\", section on 'Noninvasive relief of obstruction'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Ventilation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Chest compressions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The sequence in which the actions of CPR for infants and children should be performed by health care providers is as follows (",
"    <a class=\"graphic graphic_algorithm graphicRef66803 \" href=\"UTD.htm?17/38/18018\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initiate CPR in an infant or child who is unresponsive and not breathing (or only gasping)",
"     </li>",
"     <li>",
"      If there is no pulse or it is not definitively identified within 10 seconds, then start compressions BEFORE performing airway or breathing maneuvers",
"     </li>",
"     <li>",
"      After 30 compressions (15 compressions if two rescuers) open the airway and give two breaths (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Ventilation'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      If a definite pulse is found within 10 seconds, provide ventilation only",
"     </li>",
"     <li>",
"      If the pulse is &ge;60 beats per minute (bpm), continue ventilation",
"     </li>",
"     <li>",
"      If the pulse is &lt;60 bpm, add chest compressions to ventilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Substantial evidence indicates that healthcare providers are often unable to quickly determine whether or not a pulse is present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/14\">",
"     14",
"    </a>",
"    ]. Consequently, when a pulse is not definitely identified within 10 seconds, CPR should be initiated.",
"   </p>",
"   <p>",
"    High quality CPR focuses on the effective delivery of chest compressions and avoidance of excessive ventilation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Chest compressions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilations can be provided with mouth-to-mouth, mouth-to-nose, or with a bag and mask. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link&amp;anchor=H9#H9\">",
"     \"Basic airway management in children\", section on 'Ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence in adults and animals suggest that hyperventilation is associated with increased intrathoracic pressure and decreased coronary and cerebral perfusion (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H8#H8\">",
"     \"Basic life support (BLS) in adults\", section on 'Ventilations'",
"    </a>",
"    ). These data are the basis for the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each rescue breath should be delivered over one second.",
"     </li>",
"     <li>",
"      The volume of each breath should be sufficient to see the chest wall rise.",
"     </li>",
"     <li>",
"      A child with a pulse &ge;60 bpm who is not breathing should receive one breath every three to five seconds (12 to 20 breaths per minute).",
"     </li>",
"     <li>",
"      Infants and children who require chest compressions should receive two breaths per 30 chest compressions for a lone rescuer and two breaths per 15 chest compressions for two rescuers (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Compression to ventilation ratio'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Intubated infants and children should be ventilated at a rate of 8 to 10 breaths per minute without any interruption of chest compressions (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Compression to ventilation ratio'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CHEST COMPRESSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 international resuscitation guidelines emphasize the importance of hard, fast chest compression, with full chest recoil and minimal interruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/14\">",
"     14",
"    </a>",
"    ]. Evidence in adults and animals suggest that these are the essential elements for effective chest compressions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest compressions should be performed over the lower half of the sternum [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12,14,20\">",
"     12,14,20",
"    </a>",
"    ]. Compression of the xiphoid process can cause trauma to the liver, spleen, or stomach, and must be avoided. The effectiveness of compressions can be maximized by attention to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The chest should be depressed at least one-third of its anterior-posterior diameter with each compression (approximately 4 cm [1 &frac12; inches] in most infants and 5 cm [2 inches] in most children).",
"     </li>",
"     <li>",
"      The optimum rate of compressions is approximately 100 per minute. Each compression and decompression phase should be of equal duration.",
"     </li>",
"     <li>",
"      The sternum should return briefly to its normal position at the end of each compression, allowing the chest to recoil fully.",
"     </li>",
"     <li>",
"      A smooth compression-decompression rhythm, with minimal interruption, should be developed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest compressions for infants (younger than one year) may be performed with either two fingers or with the two thumb-encircling hands technique. No outcome studies have compared these two techniques in children with cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Two fingers",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique is recommended by the American Heart Association when there is a single rescuer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Compressions are performed with index and middle fingers, placed on the sternum just below the nipples (",
"    <a class=\"graphic graphic_figure graphicRef73038 \" href=\"UTD.htm?30/29/31184\">",
"     figure 1",
"    </a>",
"    ). Because of the infant's large occiput, slight neck extension and the placement of a hand or rolled towel beneath the upper thorax and shoulders may be necessary to ensure that the work of compression is focused on the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rescuer fatigue has been raised as a concern with this method and data are conflicting. In one randomized study of CPR on infant manikins by 16 experienced pediatric health care providers, rescuer fatigue did not significantly differ between the two finger and thumb encirclement techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in a randomized crossover study of 20 healthcare providers that compared the two fingers versus the two thumb technique, the two thumb technique was associated with better compression depth, rate, and consistency than the two finger technique [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/23\">",
"     23",
"    </a>",
"    ]. Providers also reported that the two thumb technique was less tiring and that performing compressions on a table rather than on the floor or in a radiant warmer was most comfortable. On the other hand, providers noted that the two finger technique permitted easier transition from compressions to ventilation and allowed the provider to maintain the head tilt during compressions which prevented the need for repositioning for ventilation when performing one-person infant CPR. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Two thumb encircling hands",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two thumb-encircling hands technique is suggested when there are two rescuers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12\">",
"     12",
"    </a>",
"    ]. The thorax is encircled with both hands and cardiac compressions are performed with the thumbs (",
"    <a class=\"graphic graphic_figure graphicRef77050 \" href=\"UTD.htm?16/3/16434\">",
"     figure 2",
"    </a>",
"    ). The thumbs compress over the lower half of the sternum, avoiding the xiphoid process, while the fingers are spread around the thorax [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12,15\">",
"     12,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following evidence supports the recommendation of the two thumb-encircling hands technique:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pediatric animal model, arterial and coronary perfusion pressures were improved with circumferential compression [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a similar study using an infant mannequin, the two-thumb method provided higher blood and perfusion pressures than the two-finger method [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial compared the adequacy of compressions performed on an infant mannequin by healthcare providers using either the two-thumb or two-finger method [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/26\">",
"       26",
"      </a>",
"      ]. Although 71 percent of participants failed to give a sufficient number of adequate compressions by either method, the depth of compression was significantly better using the two-thumb method.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children (from one year until the start of puberty), compressions should be performed over the lower half of the sternum with either the heel of one hand or with two hands, as for adult victims (",
"    <a class=\"graphic graphic_picture graphicRef62171 \" href=\"UTD.htm?34/53/35664\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59710 \" href=\"UTD.htm?39/40/40576\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No outcome studies have compared these two techniques in children with cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/14\">",
"     14",
"    </a>",
"    ]. Evidence to support using two hands to perform chest compressions for children is limited. In a small randomized trial that compared the pressure generated by one and two handed compressions on a pediatric mannequin, significantly higher pressures were generated using two hands [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/27\">",
"     27",
"    </a>",
"    ]. The two hand method for CPR has not been associated with increased rescuer fatigue versus the one hand method in randomized studies that used manikins [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/22,28\">",
"     22,28",
"    </a>",
"    ]. However, the rate of compression slowed significantly more among emergency department staff who used the one hand method versus the two hand method (decrease of 7 versus 3 compressions per minute during one minute, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPRESSION TO VENTILATION RATIO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest compressions in infants and children should always be accompanied by ventilation for infants and children who remain pulseless after the initial sequence of compressions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, every effort should be made to avoid excessive ventilation and to limit interruptions of chest compressions to less than ten seconds.",
"   </p>",
"   <p>",
"    For lone rescuers, two ventilations should be delivered during a short pause at the end of every 30th compression. For two rescuers, two ventilations should be delivered at the end of every 15th compression. The compression to ventilation ratio for newborns is 3 to 1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H21#H21\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'Chest compressions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the trachea is intubated, ventilation and compression can be performed independently. For infants and children, ventilations are given at a rate of 8 to 10 per minute. Compressions are delivered at a rate of 100 per minute without pauses.",
"   </p>",
"   <p>",
"    Experimental evidence in animals indicates that coronary artery perfusion pressure declines with interruptions in chest compressions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Observational reports suggest that long interruptions in CPR occur commonly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Compression to ventilation ratios of 30 to 2 and 15 to 2 are recommended to minimize interruption and for ease of teaching and retention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coordination of compression and ventilation may be facilitated by counting compressions aloud or using an audio-prompted rate guide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Conventional versus compression-only CPR",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that rescuers provide conventional CPR to infants and children with cardiac arrest, regardless of whether the arrest occurs within or outside of the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although compression-only CPR (CO-CPR) for bystanders is suggested in limited situations in adults with cardiac arrest (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link&amp;anchor=H7#H7\">",
"     \"Basic life support (BLS) in adults\", section on 'Compression-only CPR (CO-CPR)'",
"    </a>",
"    ), conventional CPR is recommended in infants and children, because cardiac arrest in this population is more commonly due to hypoxia when compared to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and survival'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One nationwide, observational study of 5158 children &le;17 years of age, who had an out-of-hospital arrest, found that, among the children who suffered arrests from noncardiac causes, those who received conventional CPR were significantly more likely to have favorable neurologic outcomes at one month than those who received COO-CPR (7.2 versus 1.6 percent, OR 5.5; 95% CI 2.5-17.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/8\">",
"     8",
"    </a>",
"    ]. Neurologic outcomes were similar between conventional CPR and CO-CPR for children who suffered arrests from cardiac etiologies (10 versus 9 percent, OR 1.2; 95% CI 0.6-2.7). Favorable neurologic outcome was more common in patients who received bystander CPR compared to no CPR (5.1 versus 1.5 percent, OR 4.17, 95% CI: 2.4-7.3). Infants had poor outcomes regardless of the type of CPR received. Another observational study of 759 children sampled from the same national database also showed significantly improved survival and neurologically favorable survival at one month in children who received conventional CPR [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the cause of an arrest is not typically known in the out of hospital setting and the majority of pediatric arrests are due to noncardiac causes, the available evidence supports conventional CPR as the method that is associated with the best neurologic outcome in infants and children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     AUTOMATED EXTERNAL DEFIBRILLATOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 international resuscitation guidelines recommend that, if a manual defibrillator is not available, an automated external defibrillator (AED) be used as soon as possible for infants and children who experience a witnessed cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. For patients with unwitnessed arrest, CPR should be performed for two minutes (five cycles) prior to using an AED (",
"    <a class=\"graphic graphic_algorithm graphicRef66803 \" href=\"UTD.htm?17/38/18018\">",
"     algorithm 2",
"    </a>",
"    ). For infants and children &lt;8 years of age, an AED with a pediatric dose attenuating system should be used whenever possible. However, if a manual defibrillator or an AED with a pediatric dose attenuating system is not available, then use of an AED without a dose attenuator is advised [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/12,15\">",
"     12,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AEDs are portable devices that have been used extensively to provide prompt defibrillation to adults in cardiac arrest. They are designed to be used by untrained bystanders and are increasingly available in public locations such as airports, athletic events, and the workplace. The device identifies rhythms that should be treated with defibrillation. It then instructs the operator how to use the device to deliver a standard shock to the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link\">",
"     \"Automated external defibrillators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In observational series, 6 to 19 percent of infants and children in cardiac arrest had ventricular fibrillation (VF) as the initial rhythm, indicating that a substantial number of children in cardiac arrest might benefit from early defibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/1,6,7,33,34\">",
"     1,6,7,33,34",
"    </a>",
"    ]. Limited evidence suggests that AEDs can be appropriately and safely used for infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. The American Academy of Pediatrics recommends that lay rescuer AED programs (such as in schools) be implemented as part of comprehensive emergency response plans, rather than as programs focused on a single piece of equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7864/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/50/26402?source=see_link\">",
"       \"Patient information: CPR for children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiopulmonary arrest among children is typically caused by progressive tissue hypoxia and acidosis as the result of respiratory failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shock. Survival rates for children with cardiac arrest depend upon setting (outpatient versus inpatient arrest) and are improved by prompt initiation of cardiopulmonary resuscitation (CPR). &nbsp;(See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) published updated guidelines for basic life support (BLS) and advanced cardiac life support (ACLS) in late 2010 (2010 guidelines). The most important elements of the BLS guidelines are included in the summary below. We suggest the practices described in the 2010 guidelines and summarized below be followed when providing BLS to patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Among the specific elements of the BLS guidelines, we recommend that infants and children with cardiac arrest receive conventional CPR rather than compression-only CPR (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Conventional versus compression-only CPR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial steps in the BLS sequence for infants and children are to initiate CPR and call for help (",
"      <a class=\"graphic graphic_algorithm graphicRef66803 \" href=\"UTD.htm?17/38/18018\">",
"       algorithm 2",
"      </a>",
"      ). Infants and children who have experienced an unwitnessed arrest should receive two minutes (five cycles) of CPR before an AED is used. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Basic life support sequence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A cardiac arrest is assumed in an infant or child who is unresponsive and not breathing (or with only gasping respirations) UNLESS a pulse is definitely identified within 10 seconds by a health care provider. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initiate CPR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest compressions should be initiated BEFORE ventilation in infants and children with cardiac arrest. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initiate CPR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Each chest compression should depress the chest by a minimum of one-third of its anterior-posterior diameter, at a rate of about 100 compressions per minute. The chest should fully recoil at the end of each compression. Interruptions in chest compressions should be minimal (less than 10 seconds). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chest compressions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventilations should be delivered over one second with enough volume to see the chest wall rise. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The compression to ventilation ratio varies depending on the circumstance (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Compression to ventilation ratio'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      30 compressions followed by two breaths for a lone rescuer",
"     </li>",
"     <li>",
"      15 compressions followed by two breaths for two rescuers resuscitating an infant (&lt;1 year of age) or child (&ge;1 year to start of puberty)",
"     </li>",
"     <li>",
"      Intubated infants and children should be ventilated at a rate of 8 to 10 breaths per minute without any interruption of chest compressions",
"     </li>",
"     <li>",
"      The compression to ventilation ratio for newborns is 3 to 1 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H21#H21\">",
"       \"Neonatal resuscitation in the delivery room\", section on 'Chest compressions'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a manual defibrillator is not available, an automated defibrillator (AED) should be used as soon as possible for all infants and children with a witnessed arrest. Those with unwitnessed arrest should receive CPR for two minutes (five cycles) before the AED is used. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Automated external defibrillator'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for the resuscitation of newborns are reviewed elsewhere (",
"      <a class=\"graphic graphic_algorithm graphicRef80621 \" href=\"UTD.htm?22/34/23072\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link\">",
"       \"Neonatal resuscitation in the delivery room\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/1\">",
"      L&oacute;pez-Herce J, Garc&iacute;a C, Dom&iacute;nguez P, et al. Outcome of out-of-hospital cardiorespiratory arrest in children. Pediatr Emerg Care 2005; 21:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/2\">",
"      Samson RA, Nadkarni VM, Meaney PA, et al. Outcomes of in-hospital ventricular fibrillation in children. N Engl J Med 2006; 354:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/3\">",
"      Vaillancourt C, Stiell IG, Canadian Cardiovascular Outcomes Research Team. Cardiac arrest care and emergency medical services in Canada. Can J Cardiol 2004; 20:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/4\">",
"      Young KD, Seidel JS. Pediatric cardiopulmonary resuscitation: a collective review. Ann Emerg Med 1999; 33:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/5\">",
"      Schindler MB, Bohn D, Cox PN, et al. Outcome of out-of-hospital cardiac or respiratory arrest in children. N Engl J Med 1996; 335:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/6\">",
"      Young KD, Gausche-Hill M, McClung CD, Lewis RJ. A prospective, population-based study of the epidemiology and outcome of out-of-hospital pediatric cardiopulmonary arrest. Pediatrics 2004; 114:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/7\">",
"      Herlitz J, Engdahl J, Svensson L, et al. Characteristics and outcome among children suffering from out of hospital cardiac arrest in Sweden. Resuscitation 2005; 64:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/8\">",
"      Kitamura T, Iwami T, Kawamura T, et al. Conventional and chest-compression-only cardiopulmonary resuscitation by bystanders for children who have out-of-hospital cardiac arrests: a prospective, nationwide, population-based cohort study. Lancet 2010; 375:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/9\">",
"      Meyer L, Stubbs B, Fahrenbruch C, et al. Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: a 30-year review. Circulation 2012; 126:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/10\">",
"      Knudson JD, Neish SR, Cabrera AG, et al. Prevalence and outcomes of pediatric in-hospital cardiopulmonary resuscitation in the United States: an analysis of the Kids' Inpatient Database*. Crit Care Med 2012; 40:2940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/11\">",
"      Girotra S, Spertus JA, Li Y, et al. Survival trends in pediatric in-hospital cardiac arrests: an analysis from get with the guidelines-resuscitation. Circ Cardiovasc Qual Outcomes 2013; 6:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/12\">",
"      Berg MD, Schexnayder SM, Chameides L, et al. Part 13: pediatric basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/13\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/14\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Part 10: Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 2010; 122:S466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/15\">",
"      Berg MD, Schexnayder SM, Chameides L, et al. Pediatric basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2010; 126:e1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/16\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/17\">",
"      Part 2: Adult Basic Life Support. Circulation 2005; II2:III5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/18\">",
"      Berg RA, Sanders AB, Kern KB, et al. Adverse hemodynamic effects of interrupting chest compressions for rescue breathing during cardiopulmonary resuscitation for ventricular fibrillation cardiac arrest. Circulation 2001; 104:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/19\">",
"      Kern KB, Hilwig RW, Berg RA, et al. Importance of continuous chest compressions during cardiopulmonary resuscitation: improved outcome during a simulated single lay-rescuer scenario. Circulation 2002; 105:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/20\">",
"      Finholt DA, Kettrick RG, Wagner HR, Swedlow DB. The heart is under the lower third of the sternum. Implications for external cardiac massage. Am J Dis Child 1986; 140:646.",
"     </a>",
"    </li>",
"    <li>",
"     Ludwig, SL, Lavelle, JM. Resuscitation-Pediatric basic and advanced life support. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/22\">",
"      Udassi JP, Udassi S, Theriaque DW, et al. Effect of alternative chest compression techniques in infant and child on rescuer performance. Pediatr Crit Care Med 2009; 10:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/23\">",
"      Huynh TK, Hemway RJ, Perlman JM. The two-thumb technique using an elevated surface is preferable for teaching infant cardiopulmonary resuscitation. J Pediatr 2012; 161:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/24\">",
"      Menegazzi JJ, Auble TE, Nicklas KA, et al. Two-thumb versus two-finger chest compression during CRP in a swine infant model of cardiac arrest. Ann Emerg Med 1993; 22:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/25\">",
"      Dorfsman ML, Menegazzi JJ, Wadas RJ, Auble TE. Two-thumb vs. two-finger chest compression in an infant model of prolonged cardiopulmonary resuscitation. Acad Emerg Med 2000; 7:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/26\">",
"      Whitelaw CC, Slywka B, Goldsmith LJ. Comparison of a two-finger versus two-thumb method for chest compressions by healthcare providers in an infant mechanical model. Resuscitation 2000; 43:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/27\">",
"      Stevenson AG, McGowan J, Evans AL, Graham CA. CPR for children: one hand or two? Resuscitation 2005; 64:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/28\">",
"      Peska E, Kelly AM, Kerr D, Green D. One-handed versus two-handed chest compressions in paediatric cardio-pulmonary resuscitation. Resuscitation 2006; 71:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/29\">",
"      Abella BS, Alvarado JP, Myklebust H, et al. Quality of cardiopulmonary resuscitation during in-hospital cardiac arrest. JAMA 2005; 293:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/30\">",
"      Wik L, Kramer-Johansen J, Myklebust H, et al. Quality of cardiopulmonary resuscitation during out-of-hospital cardiac arrest. JAMA 2005; 293:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/31\">",
"      Berg RA, Sanders AB, Milander M, et al. Efficacy of audio-prompted rate guidance in improving resuscitator performance of cardiopulmonary resuscitation on children. Acad Emerg Med 1994; 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/32\">",
"      Ogawa T, Akahane M, Koike S, et al. Outcomes of chest compression only CPR versus conventional CPR conducted by lay people in patients with out of hospital cardiopulmonary arrest witnessed by bystanders: nationwide population based observational study. BMJ 2011; 342:c7106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/33\">",
"      Mogayzel C, Quan L, Graves JR, et al. Out-of-hospital ventricular fibrillation in children and adolescents: causes and outcomes. Ann Emerg Med 1995; 25:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/34\">",
"      Smith BT, Rea TD, Eisenberg MS. Ventricular fibrillation in pediatric cardiac arrest. Acad Emerg Med 2006; 13:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/35\">",
"      Cecchin F, Jorgenson DB, Berul CI, et al. Is arrhythmia detection by automatic external defibrillator accurate for children?: sensitivity and specificity of an automatic external defibrillator algorithm in 696 pediatric arrhythmias. Circulation 2001; 103:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/36\">",
"      Atkinson E, Mikysa B, Conway JA, et al. Specificity and sensitivity of automated external defibrillator rhythm analysis in infants and children. Ann Emerg Med 2003; 42:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/37\">",
"      Atkins DL, Jorgenson DB. Attenuated pediatric electrode pads for automated external defibrillator use in children. Resuscitation 2005; 66:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/38\">",
"      Jones P, Lod&eacute; N. Ventricular fibrillation and defibrillation. Arch Dis Child 2007; 92:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/39\">",
"      Divekar A, Soni R. Successful parental use of an automated external defibrillator for an infant with long-QT syndrome. Pediatrics 2006; 118:e526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/40\">",
"      Bar-Cohen Y, Walsh EP, Love BA, Cecchin F. First appropriate use of automated external defibrillator in an infant. Resuscitation 2005; 67:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7864/abstract/41\">",
"      Markenson D, Pyles L, Neish S, et al. Ventricular fibrillation and the use of automated external defibrillators on children. Pediatrics 2007; 120:e1368.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6384 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-190.102.30.19-D2DFEA4DB7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7864=[""].join("\n");
var outline_f7_43_7864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE 2010 INTERNATIONAL RESUSCITATION GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BASIC LIFE SUPPORT SEQUENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Activate EMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initiate CPR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CHEST COMPRESSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Two fingers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Two thumb encircling hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPRESSION TO VENTILATION RATIO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Conventional versus compression-only CPR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AUTOMATED EXTERNAL DEFIBRILLATOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6384|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/34/23072\" title=\"algorithm 1\">",
"      Neonatal resuscitation algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?17/38/18018\" title=\"algorithm 2\">",
"      Pediatric basic life support algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6384|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/29/31184\" title=\"figure 1\">",
"      Two finger technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/3/16434\" title=\"figure 2\">",
"      Two thumb technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6384|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/53/35664\" title=\"picture 1\">",
"      One hand technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/40/40576\" title=\"picture 2\">",
"      Two hand chest technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=related_link\">",
"      Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/50/26402?source=related_link\">",
"      Patient information: CPR for children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_43_7865="Management of hyperglycemia in diabetics with end-stage renal disease";
var content_f7_43_7865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of hyperglycemia in diabetics with end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7865/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7865/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7865/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7865/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7865/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7865/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/43/7865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic renal failure is associated with insulin resistance and, in advanced renal failure, decreased insulin degradation. The latter can, in diabetic patients, lead to a marked decrease in insulin requirement or even the cessation of insulin therapy in type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18102?source=see_link\">",
"     \"Carbohydrate and insulin metabolism in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both of these abnormalities are at least partially reversed with the institution of dialysis. As a result, the insulin requirement in any given patient will depend upon the net balance between improving tissue sensitivity and restoring normal hepatic insulin metabolism. Glucose contained in peritoneal dialysate will tend to increase the need for hypoglycemic therapy. Changes in dietary intake and exercise (ie, reduced intake due to anorexia prior to starting dialysis) can also affect the response to administered insulin. Furthermore, the uremic environment can affect methods used to assess glycemic control and the metabolism of most oral hypoglycemic agents is prolonged, making them more difficult to use. The net effect is that one cannot readily predict insulin requirements in this setting and careful individualized therapy is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MONITORING GLYCEMIC CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial measurement of the hemoglobin A1c concentration (HbA1c or glycated hemoglobin) is the most accurate method to assess chronic glycemic control in patients with diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link\">",
"     \"Estimation of blood glucose control in diabetes mellitus\"",
"    </a>",
"    .) However, some of the methods used to measure glycated hemoglobin, such as column- and ion-exchange chromatography and agar gel electrophoresis, are affected by renal failure. This is due in part to analytical interference from carbamylated hemoglobin formed in the presence of elevated concentrations of urea, leading to false elevations in the HbA1c level. Other factors that affect the accuracy of these assays include reduced red blood cell life span, recent transfusion, iron deficiency, accelerated erythropoiesis due to administration of erythropoietin, and metabolic acidosis. As a result, HbA1c levels tend to underestimate glycemic control in diabetic hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Some suggest that measurement of glycated albumin more accurately assesses glycemic control in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations in the accuracy of some HbA1c assays, results in the range of 6 to 7 percent appear to estimate glycemic control similarly to that in patients without advanced kidney disease, while values above 7.5 percent may overestimate the extent of hyperglycemia in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/6\">",
"     6",
"    </a>",
"    ]. Use of Boronate-agarose affinity chromatography [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/3,11\">",
"     3,11",
"    </a>",
"    ] or the thiobarbituric acid method [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/5\">",
"     5",
"    </a>",
"    ] for analyzing HbA1c can be used reliably in end-stage renal disease. It is important to be aware of the specific assay used in each dialysis facility and the extent to which kidney disease and other factors affect the accuracy of HbA1c measurements.",
"   </p>",
"   <p>",
"    In addition, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    and maltose, which are contained in some peritoneal dialysis solutions, can interfere with or cause false elevated glucose results with some self-monitoring methods, possibly leading to inappropriate therapy. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link\">",
"     \"Peritoneal dialysis solutions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glycemic control has been considered to be adequate in diabetic patients on chronic dialysis if the fasting blood glucose is below 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    a one-hour postprandial value of less than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/12\">",
"     12",
"    </a>",
"    ], and the glycated hemoglobin level is between 6 to 7 in type 1 diabetics, and between 7 to 8 in type 2 diabetics.",
"   </p>",
"   <p>",
"    Benefits with better glycemic control in dialysis patients have been reported in several small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. However, several large studies have found no significant correlation between glycemic control and survival and the risk of hypoglycemia is higher with stricter glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As stated in the 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, the HbA1c target that is associated with the best outcome in dialysis patients has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/20\">",
"     20",
"    </a>",
"    ]. We currently have a HbA1c target no lower than 7 percent, although the risks and benefits of using this measure of glycemic control are also uncertain.",
"   </p>",
"   <p>",
"    Excellent glycemic control has not been emphasized as much in diabetic dialysis patients than in those without renal failure. Some possible reasons for this practice include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possible precipitation of severe hypoglycemia with aggressive control, especially with fluctuating dietary intake, such as when patients do not eat prior to dialysis.",
"     </li>",
"     <li>",
"      The lack of symptoms with hyperglycemia.",
"     </li>",
"     <li>",
"      The perceived inability to significantly alter progressive hyperglycemia-induced damage in organs other than the kidney.",
"     </li>",
"     <li>",
"      The perceived lack of accuracy of the glycated hemoglobin level in dialysis patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, since diabetes-related damage is likely to present in varying degrees among different organs, good glycemic control should be a significant treatment goal for diabetic patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/6,20,21\">",
"     6,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring of the plasma glucose is also important in nondiabetic patients since many patients develop diabetes after initiation of dialysis. This is particularly important in patients who begin peritoneal dialysis and are therefore newly subjected to a high daily glucose load. This was shown in an observational prospective study that assessed plasma glucose levels among 252 consecutive nondiabetic patients started on peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/22\">",
"     22",
"    </a>",
"    ]. After one month of being stable on PD, 8 and 19 percent of patients had plasma glucose levels greater than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and between 125 to 200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    respectively. Survival at three years correlated inversely with poor glycemic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ORAL HYPOGLYCEMIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, a large number of drugs as well as types of insulin are available to manage type 2 diabetes mellitus. With oral hypoglycemic agents, a significant number of classes of agents are available. Knowledge of the metabolism of these agents in patients with renal dysfunction is essential, given that significant toxicity, including prolonged hypoglycemia, can be associated with some of the drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sulfonylureas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of sulfonylureas in end-stage renal disease requires careful attention to dosing and routes of elimination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. The sulfonylureas are strongly protein-bound, particularly to albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, elevated plasma drug levels cannot be efficiently reversed by hemodialysis. Furthermore, displacement of these drugs from albumin by beta-blockers, salicylates, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can lead to hypoglycemia due to increased plasma concentration of the physiologically important free drug. Older sulfonylureas (acetohexamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/48/16134?source=see_link\">",
"     tolazamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/49/42774?source=see_link\">",
"     tolbutamide",
"    </a>",
"    ) have been largely replaced by newer agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The basic principles of sulfonylurea metabolism can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"       Chlorpropamide",
"      </a>",
"      is eliminated almost exclusively by the kidney.",
"     </li>",
"     <li>",
"      Active metabolites of acetohexamide (which is no longer available in the United States),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/48/16134?source=see_link\">",
"       tolazamide",
"      </a>",
"      are excreted to a large extent by the kidney. These can accumulate in patients with impaired kidney function and contribute to the development of hypoglycemia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       Glyburide",
"      </a>",
"      has weak active metabolites that are excreted in the urine and accumulate in patients with impaired kidney function.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8823?source=see_link\">",
"       Glimepiride",
"      </a>",
"      is primarily metabolized by the liver, with renal excretion of active metabolites [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"       Glipizide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/49/42774?source=see_link\">",
"       tolbutamide",
"      </a>",
"      are metabolized by the liver and primarily excreted in the urine as inactive metabolites. However, each has one metabolite that may have weak hypoglycemic activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    is the oral hypoglycemic drug of choice in patients with chronic renal failure. The dose for glipizide is 2.5 to 10",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     Glyburide",
"    </a>",
"    can be given at reduced dose if the GFR is above 50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    but should be avoided with more severe renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones enhance tissue sensitivity to insulin and suppress hepatic glucose production via binding to PPAR gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     Rosiglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    are highly protein bound, primarily to albumin, and almost complete metabolized by the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"     24",
"    </a>",
"    ]. Rosiglitazone has inactive metabolites and less than 1 percent of the original compound is excreted in the urine; pioglitazone is associated with three active metabolites. With both agents, the accumulation of the parent drug or the major metabolites does not occur in the setting of renal insufficiency.",
"   </p>",
"   <p>",
"    Hemodialysis does not affect the pharmacokinetics of these drugs.",
"   </p>",
"   <p>",
"    However, they are associated with heart failure and the formation of edema, which may be more frequent in patients also receiving insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"     24",
"    </a>",
"    ]. In an observational study, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    was also associated with increased all-cause and cardiovascular mortality in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/29\">",
"     29",
"    </a>",
"    ]. Given the risk of edema formation and heart failure as well as possible increased mortality with these drugs, they should be avoided in patients with advanced kidney failure, especially if they have preexisting heart failure.",
"   </p>",
"   <p>",
"    The mechanism of edema formation with these agents appears to be related to stimulation of PPAR gamma-mediated sodium reabsorption by renal epithelial sodium channels in the distal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/30\">",
"     30",
"    </a>",
"    ]. Although unproven clinically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , or similar agents may therefore be effective for managing this fluid retention, which may not pose a problem for oliguric or anuric dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alpha-glucosidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-glucosidase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/0/3077?source=see_link\">",
"     miglitol",
"    </a>",
"    , slow carbohydrate absorption from the gastrointestinal tract and reduce postprandial blood sugar peaks. With acarbose, increased levels of the parent drug and metabolites are observed with renal insufficiency, although an increased risk of hypoglycemia has not been documented. Miglitol is absorbed to a greater extent than acarbose and is largely renally excreted, with increased accumulation in patients with decreased renal function. Thus, neither acarbose nor miglitol are recommended in patients with renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Meglitinides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meglitinides, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    are relatively newer agents that stimulate insulin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"     24",
"    </a>",
"    ]. Nateglinide is hepatically metabolized, with renal excretion of active metabolites. With decreased renal function, the accumulation of active metabolites and hypoglycemia has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This drug must therefore be used cautiously in this setting, if at all.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"     Repaglinide",
"    </a>",
"    is principally metabolized by the liver, with less than 10 percent renally excreted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"     24",
"    </a>",
"    ]. Hypoglycemia may be more common among patients with severe renal impairment when starting therapy with repaglinide than subjects with normal or less impaired renal function and maintenance doses tended to be lower in these patients in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/33\">",
"     33",
"    </a>",
"    ]. Initiation of treatment should be with 0.5 mg daily and close careful monitoring of blood glucose levels is essential as the dose is titrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biguanides, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , are primarily excreted unchanged in the urine. Thus, patients with renal dysfunction are more susceptible to drug accumulation and lactic acidosis with these compounds. They should therefore be avoided in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines suggest that, in patients with end-stage renal disease, newer insulin regimens and insulin preparations should be encouraged for glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/20\">",
"     20",
"    </a>",
"    ]. This is due to the lack of adequate data concerning the use of hypoglycemic agents in dialysis patients and the inability to adequately excrete many such agents. However, if such drugs are considered,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    should be used, since it is primarily metabolized by the liver, inactive or only very weakly active metabolites are excreted in the urine, and the risk of hypoglycemia is lower than with other oral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    drug concentration and elimination half life are increased marginally in patients with reduced GFR, dosage reductions are not necessary and this agent may be an appropriate therapy for patients with ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/33\">",
"     33",
"    </a>",
"    ]. However, experience is more limited than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     USE OF INSULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic renal failure is associated with decreased renal and ultimately hepatic metabolism of insulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18102?source=see_link\">",
"     \"Carbohydrate and insulin metabolism in chronic kidney disease\"",
"    </a>",
"    .) As a result, the following dose recommendations have been made for insulin dosage in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/23,24,26\">",
"     23,24,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No dose adjustment is required if the GFR is above 50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      The insulin dose should be reduced to approximately 75 percent of baseline when the GFR is between 10 and 50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      The dose should be reduced by as much as 50 percent when the GFR is less than 10",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important that blood glucose levels be monitored closely and that individually appropriate dose adjustments in insulin therapy be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Subcutaneous insulin in dialysis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of uremia with dialysis will diminish insulin resistance and enhance insulin degradation. The net effect on glycemic control will vary from patient to patient, thereby necessitating individualized therapy.",
"   </p>",
"   <p>",
"    Several different insulin regimens can be used to achieve glycemic control. Examples include twice-daily intermediate-acting insulin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    given before breakfast and before supper or long-acting insulin (ultralente) with two or three times daily supplemental regular insulin given two or three times per day before meals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A consensus approach does not exist to the choice of agents in diabetics with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"     24",
"    </a>",
"    ]. Some suggest that long-acting insulin preparations should be avoided, while others feel that such agents should be used.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intraperitoneal insulin in peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with continuous ambulatory peritoneal dialysis or continuous cycler peritoneal dialysis (CAPD and CCPD) can be treated with intraperitoneal insulin. This regimen has the following potential advantages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/12,37-39\">",
"     12,37-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It provides a continuous insulin infusion.",
"     </li>",
"     <li>",
"      It eliminates the need for injections.",
"     </li>",
"     <li>",
"      It may provide a more physiologic route of absorption, since the exogenous insulin is absorbed into the portal vein which mimics the action of pancreatic insulin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are, however, potential disadvantages with this modality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an additional source of bacterial contamination of dialysate during injection of insulin into the bags [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher total insulin doses are required due to losses of spent dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/37,38,41\">",
"       37,38,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a risk of peritoneal fibroblastic proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/42\">",
"       42",
"      </a>",
"      ] and perhaps of hepatic subcapsular steatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relatively long, 3.8 cm (1.5 in) needles should be used to ensure that the full dose of insulin is injected into the dialysis solution container rather than being trapped in the infusion port. The dialysis solution container should be inverted several times after injection to ensure proper mixing.",
"   </p>",
"   <p>",
"    Several approaches have been proposed for the use of intraperitoneal insulin in CAPD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/34,38,43-46\">",
"     34,38,43-46",
"    </a>",
"    ]. We generally follow the Toronto Western protocol, which is based upon the use of four 2-liter exchanges per day with adaptations as noted below [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/34\">",
"     34",
"    </a>",
"    ]. The first three exchanges are performed approximately 20 minutes before each of the major meals and the fourth exchange is an overnight run performed at about 11 PM. The blood glucose is measured fasting and one hour",
"    <strong>",
"     after",
"    </strong>",
"    each of the major meals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On the first day, one-fourth of the total daily subcutaneous insulin dose is given as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      in each of the four exchanges. This insulin is given to help metabolize dietary carbohydrate intake.",
"     </li>",
"     <li>",
"      An insulin supplement is added to each bag to help metabolize the glucose absorbed from the dialysis solution. Two units are added for each two liter exchange with 1.5 percent dextrose dialysis solution, four units for each exchange with 2.5 percent dextrose, and six units for each exchange with 4.25 percent dextrose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the second day, the insulin regimen is adjusted according to the blood glucose levels obtained the previous day. The fasting blood glucose will reflect the insulin added to the nighttime exchange, while the one-hour postprandial values will reflect the insulin added to the dialysis solution used before that meal. The insulin dose can be adjusted according to the following sliding scale. For each two liter daily exchange:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower the insulin dose by six units if the one-hour postprandial glucose at the same time the previous day was less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Lower the insulin dose by four units if the one-hour postprandial glucose was between 40 and 80",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2 and 4.4",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Lower the insulin dose by two units if the one-hour postprandial glucose was between 80 and 120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.4 and 6.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Do not change the insulin dose if the one-hour postprandial glucose was between than 120 and 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.7 and 10",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Raise the insulin dose by two units if the one-hour postprandial glucose was between 180 and 240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10 and 13.3",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Raise the insulin dose by four units if the one-hour postprandial glucose was between 240 and 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.3 and 16.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Raise the insulin dose by a variable amount if the one-hour postprandial glucose was greater than 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (16.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If, for example, the one-hour postprandial glucose was 220",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (12.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    on day one, then an extra two units of insulin should be added to prebreakfast exchange. A similar sliding scale is used for the nighttime exchange according to the fasting value that day:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower the insulin dose by four units if the fasting glucose was less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Lower the insulin dose by two units if the fasting glucose was between 40 and 80",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.2 and 4.4",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Do not change the insulin dose if the fasting glucose was between than 80 and 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.4 and 10",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Raise the insulin dose by two units if the fasting glucose was between 180 and 240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10 and 13.3",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Raise the insulin dose by four units if the fasting glucose was between 240 and 400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.3 and 22.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Raise the insulin dose by a variable amount if the fasting glucose was greater than 400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (22.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several further adjustments may be made in special situations. The insulin dose should be reduced by one-half the usual dose for a particular exchange prior to a procedure that requires fasting, such as surgery or a diagnostic test. The blood glucose should be checked after the procedure to determine the dose for the next exchange. The insulin dose should also be adjusted to reflect reduced food intake and activity level.",
"   </p>",
"   <p>",
"    The regimen is different in patients treated with CCPD or NIPD (nightly intermittent peritoneal dialysis) in whom most of the dialysis occurs during the night. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=see_link\">",
"     \"Choosing a modality for chronic peritoneal dialysis\"",
"    </a>",
"    .) In these settings, the intraperitoneal dose should be added as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    to any of the nocturnal dialysis containers attached to the cycle. The initial amount added will usually be equal to the total previous subcutaneous dose of insulin (regular plus longer acting). The intraperitoneal dose can then be adjusted according to the fasting blood glucose. A supplemental subcutaneous insulin dose may be required during the day to help metabolize the carbohydrate absorbed with meals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/34\">",
"     34",
"    </a>",
"    ]. An alternative approach can be used in cyclers that infuse a \"final\" long-dwell, daytime exchange from a separate container; addition of regular insulin to this exchange will help maintain glycemic control during the day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Abnormal or variations in peritoneal kinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above recommendations assume that peritoneal transfer kinetics are relatively normal. Diabetic patients on CAPD who have uncontrolled hyperglycemia should undergo a peritoneal equilibration test. High transporters, who can have enormous glucose loads from rapid peritoneal glucose absorption (",
"    <a class=\"graphic graphic_figure graphicRef65815 \" href=\"UTD.htm?1/63/2047\">",
"     figure 1",
"    </a>",
"    ), will usually benefit from transfer to nocturnal peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/37,47\">",
"     37,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .) In addition to raising the blood glucose, the rapid glucose absorption lowers the osmotic gradient between dialysate and blood, resulting in reduced ultrafiltration, diminished urea removal, and fluid retention. A vicious cycle is then created, with generalized edema requiring frequent use of 2.5 and 4.25 percent dextrose dialysis solutions, leading to further hyperglycemia.",
"   </p>",
"   <p>",
"    Another potential concern is that the absorption of insulin may significantly vary among patients or may decline over time in a single individual due to acquired abnormalities in the peritoneal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/48\">",
"     48",
"    </a>",
"    ]. One study of seven patients suggested that the latter is not a common problem as there was no difference in insulin absorption after 30 months of CAPD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CARBOHYDRATE SPARING DIALYTIC REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also carbohydrate sparing dialytic regimens. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       Icodextrin",
"      </a>",
"      , in which carbohydrate absorption is equivalent to a 2.5 percent dextrose bag but is associated with ultrafiltration of a 4.25 dextrose bag.",
"     </li>",
"     <li>",
"      Amino acid dialysate solutions, which are available in countries outside the United States",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link\">",
"     \"Peritoneal dialysis solutions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     APPROACH TO PROBLEM PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some diabetic patients have persistent hyperglycemia, severe hyperglycemia, diabetic ketoacidosis, frequent hypoglycemia, or alternating episodes of hyperglycemia and hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate insulin dose and noncompliance (with diet or the insulin regimen) are the most common causes of persistent hyperglycemia in diabetic dialysis patients (defined as an HbA1c level above 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/50\">",
"     50",
"    </a>",
"    ]. An additional problem is that microvascular disease can cause erratic absorption of insulin from the subcutaneous tissue, particularly if the patient does not rotate injection sites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H15#H15\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Site of injection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Severe hyperglycemia and ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hyperglycemia with serum glucose concentrations occasionally greater than 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (55",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    may be observed among dialysis patients with diabetes. Unlike those without renal failure, however, hypovolemia and marked hypernatremia do not occur since glucosuria is absent in anuric individuals. The net effect is minimal symptoms, even among those with extreme hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/12\">",
"     12",
"    </a>",
"    ]. However, these patients may have marked hyperkalemia due to potassium efflux from cells in response to extracellular fluid hypertonicity, as well as hyponatremia and acute intravascular volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients with type 1 diabetes may also develop diabetic ketoacidosis.",
"   </p>",
"   <p>",
"    Instead of fluid replacement, management is principally dependent upon the administration of low doses of intravenous insulin (commonly beginning at a dose of 2",
"    <span class=\"nowrap\">",
"     units/hour)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/12\">",
"     12",
"    </a>",
"    ]. As with nondialysis patients with severe hyperglycemia and diabetic ketoacidosis, serum glucose and potassium concentrations must be closely monitored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequent or persistent hypoglycemia in diabetic dialysis patients is often due to severe underdialysis with poor calorie intake or occult disease, such as infection or malignancy. Frequent adjustment of insulin dose and evaluation of blood glucose diaries are essential in this setting as is provision of an adequate dialysis dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .) Drugs that interfere with the counterregulatory response to hypoglycemia (such as beta blockers) and long-acting insulin and oral hypoglycemic agents should be discontinued, if possible, until more stable glycemic control without hypoglycemia is achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Alternating hypoglycemia and hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;These patients often have gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/38\">",
"     38",
"    </a>",
"    ], which complicates the timing of insulin injections. Gastric emptying studies will confirm the diagnosis, which can often be effectively treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25476?source=see_link\">",
"     bethanechol",
"    </a>",
"    (urecholine) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/38\">",
"     38",
"    </a>",
"    ]. Improvement in glycemic control may also improve gastric motility. Cisapride, previously commonly used for gastric emptying disorders, is now restricted per the manufacturer's and Federal Drug Administration's recommendations due to the risk of arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7865/abstract/52\">",
"     52",
"    </a>",
"    ]. As of August 2000, prescriptions for the drug can only be filled directly through the manufacturer after providing documentation as to need for the drug and assessment of risk factors for cardiac arrhythmias in the individual patient (including a prolonged QTc on the EKG or use of medications known to alter the drug's metabolism such as macrolide antibiotics, antifungals and phenothiazines). Cisapride is no longer listed in the Physicians Drug Reference (PDR) and is technically removed from the market.",
"   </p>",
"   <p>",
"    Other causes of brittle blood glucose include patient misunderstanding of the timing of insulin injections, poor compliance with dietary restrictions and insulin therapy, erratic eating habits, and poor timing of CAPD exchanges. These problems can often be corrected with patient reeducation. Noncompliance, impaired vision, and a depressive illness should also be sought. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18135?source=see_link\">",
"     \"The adult patient with brittle diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15753507\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic renal failure is associated with insulin resistance and, in advanced renal failure, decreased insulin degradation. The latter can, in diabetic patients, lead to a marked decrease in insulin requirement or even the cessation of insulin therapy in type 2 diabetes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several large studies have found no significant correlation between glycemic control and survival and the risk of hypoglycemia is higher with stricter glycemic control. The HbA1c target that is associated with the best outcome in dialysis patients has not been established. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Monitoring glycemic control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"       Glipizide",
"      </a>",
"      is the oral hypoglycemic drug of choice in many patients with chronic renal failure.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      should not be used in patients with ESRD due to increased risk of rare but potentially fatal lactic acidosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Oral hypoglycemic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin can be used safely with appropriate careful monitoring by the subcutaneous (HD and PD) or intraperitoneal (PD) route. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Use of insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe hyperglycemia in oliguric or anuric ESRD patients is not associated with features of a glucose-related osmotic diuresis as is seen in other patients but is more likely to be associated with hyponatremia, hyperkalemia, and acute intravascular volume expansion. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hyperglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/1\">",
"      Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis 2003; 41:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/2\">",
"      de Boer MJ, Miedema K, Casparie AF. Glycosylated haemoglobin in renal failure. Diabetologia 1980; 18:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/3\">",
"      Scott MG, Hoffmann JW, Meltzer VN, et al. Effects of azotemia on results of the boronate-agarose affinity and ion-exchange methods for glycated hemoglobin. Clin Chem 1984; 30:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/4\">",
"      Wettre S, Lundberg M. Kinetics of glycosylated haemoglobin in uraemia determined on ion-exchange and affinity chromatography: no increase in the rate of glycosylation. Diabetes Res 1986; 3:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/5\">",
"      Paisey R, Banks R, Holton R, et al. Glycosylated haemoglobin in uraemia. Diabet Med 1986; 3:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/6\">",
"      Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/7\">",
"      Freedman BI, Shenoy RN, Planer JA, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010; 30:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/8\">",
"      Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73:1062.",
"     </a>",
"    </li>",
"    <li>",
"     Nagayama, H, Inaba, M, Okabe, R, et al. Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test. Biomed Pharmacother 2008 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/10\">",
"      Freedman BI, Shihabi ZK, Andries L, et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 2010; 31:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/11\">",
"      Bruns DE, Lobo PI, Savory J, Wills MR. Specific affinity-chromatographic measurement of glycated hemoglobins in uremic patients. Clin Chem 1984; 30:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/12\">",
"      Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000; 13:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/13\">",
"      Tzamaloukas AH, Murata GH, Zager PG, et al. The relationship between glycemic control and morbidity and mortality for diabetics on dialysis. ASAIO J 1993; 39:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/14\">",
"      McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002; 40:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/15\">",
"      Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/16\">",
"      Williams ME, Lacson E Jr, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 2006; 70:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/17\">",
"      Shurraw S, Majumdar SR, Thadhani R, et al. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis 2010; 55:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/18\">",
"      Williams ME, Lacson E Jr, Wang W, et al. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 2010; 5:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/19\">",
"      Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial 2010; 23:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/20\">",
"      K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 4(Suppl 3):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/21\">",
"      Tzamaloukas, AH. The use of glycosylated hemoglobin in dialysis patients. Semin Dial 1998; 11:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/22\">",
"      Szeto CC, Chow KM, Kwan BC, et al. New-onset hyperglycemia in nondiabetic chinese patients started on peritoneal dialysis. Am J Kidney Dis 2007; 49:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/23\">",
"      Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 26 Suppl 4:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/24\">",
"      Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/25\">",
"      Skillman TG, Feldman JM. The pharmacology of sulfonylureas. Am J Med 1981; 70:361.",
"     </a>",
"    </li>",
"    <li>",
"     Aronoff, GR, Berns, JS, Brier, ME, et al. Drug prescribing in renal failure: Dosing guidelines for adults, 4th ed. Philadelphia: American College of Physicians, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/27\">",
"      Mujais, SK, Fadda, G. Carbohydrate metabolism in end-stage renal disease. Semin Dial 1989; 2:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/28\">",
"      Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007; 50:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/29\">",
"      Ramirez SP, Albert JM, Blayney MJ, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/30\">",
"      Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/31\">",
"      Inoue T, Shibahara N, Miyagawa K, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003; 60:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/32\">",
"      Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 2003; 59:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/33\">",
"      Hasslacher C, Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003; 26:886.",
"     </a>",
"    </li>",
"    <li>",
"     Tzamaloukas, AH, Friedman, EA. Diabetes. In: Handbook of Dialysis, 3rd ed, Daugirdas, JT, Blake, PG, Ing, TS (Eds), Lippincott, Williams, and Wilkins, 2001, pp. 453-465.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/35\">",
"      Tunbridge FK, Newens A, Home PD, et al. A comparison of human ultralente- and lente-based twice-daily injection regimens. Diabet Med 1989; 6:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/36\">",
"      Freeman SL, O'Brien PC, Rizza RA. Use of human ultralente as the basal insulin component in treatment of patients with IDDM. Diabetes Res Clin Pract 1991; 12:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/37\">",
"      Diaz-Buxo, JA. Blood glucose control in diabetics: I. Semin Dial 1993; 6:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/38\">",
"      Daniels, ID, Markell, MS. Blood glucose control in diabetics: II. Semin Dial 1993; 6:394.",
"     </a>",
"    </li>",
"    <li>",
"     Tzamaloukas, AH, Oreopoulos, DG. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: A review. In: Adv Peritoneal Dial, Vol 7, Khanna, R, Nolph, KD, Prowant, B, et al (Eds), University of Toronto Press, 1991, pp 81-85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/40\">",
"      Selgas, R. Comparative study of two different routes for insulin administration in CAPD patients: A multicenter study. Adv Perit Dial 1988; 4:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/41\">",
"      Maxwell, DR, Prince, MJ. Blood glucose control in diabetics: III. Semin Dial 1993; 6:397.",
"     </a>",
"    </li>",
"    <li>",
"     Selgas, R, Lopez-Riva, A, Alvaro F, et al. Insulin influence on the mitogenic-induced effect of the peritoneal effluent in CAPD patients. In: Adv Peritoneal Dial, Vol 7, Khanna, R, Nolph, KD, Prowant, B, et al (Eds), University of Toronto Press, 1991, pp. 161-164.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/43\">",
"      Beardsworth, SF. Intraperitoneal insulin: A protocol for administration during CAPD and review of published protocols. Perit Dial Int 1988; 8:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/44\">",
"      Flynn, CT. The Iowa Lutheran Protocol. Perit Dial Bull 1981; 1:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/45\">",
"      Khanna, R, Leibel, B. The Toronto Western Hospital Protocol. Perit Dial Bull 1981; 1:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/46\">",
"      Skyler JS, Skyler DL, Seigler DE, O'Sullivan MJ. Algorithms for adjustment of insulin dosage by patients who monitor blood glucose. Diabetes Care 1981; 4:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/47\">",
"      Twardowski ZJ, Nolph KD, Khanna R, et al. Daily clearances with continuous ambulatory peritoneal dialysis and nightly peritoneal dialysis. ASAIO Trans 1986; 32:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/48\">",
"      Fine A, Parry D, Ariano R, Dent W. Marked variation in peritoneal insulin absorption in peritoneal dialysis. Perit Dial Int 2000; 20:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/49\">",
"      Scavini M, Pincelli A, Petrella G, et al. Intraperitoneal insulin absorption after long-term intraperitoneal insulin therapy. Diabetes Care 1995; 18:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/50\">",
"      Tzamaloukas AH, Murata GH, Eisenberg B, et al. Hypoglycemia in diabetics on dialysis with poor glycemic control: hemodialysis versus continuous ambulatory peritoneal dialysis. Int J Artif Organs 1992; 15:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/51\">",
"      Montoliu J, Revert L. Lethal hyperkalemia associated with severe hyperglycemia in diabetic patients with renal failure. Am J Kidney Dis 1985; 5:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7865/abstract/52\">",
"      Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335:290.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1857 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7865=[""].join("\n");
var outline_f7_43_7865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15753507\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MONITORING GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ORAL HYPOGLYCEMIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sulfonylureas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alpha-glucosidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Meglitinides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      USE OF INSULIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Subcutaneous insulin in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intraperitoneal insulin in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Abnormal or variations in peritoneal kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CARBOHYDRATE SPARING DIALYTIC REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      APPROACH TO PROBLEM PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Severe hyperglycemia and ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Alternating hypoglycemia and hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15753507\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1857\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1857|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/63/2047\" title=\"figure 1\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18102?source=related_link\">",
"      Carbohydrate and insulin metabolism in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=related_link\">",
"      Choosing a modality for chronic peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=related_link\">",
"      Peritoneal dialysis solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=related_link\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18135?source=related_link\">",
"      The adult patient with brittle diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_43_7866="Management of infection in acute exacerbations of chronic obstructive pulmonary disease";
var content_f7_43_7866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7866/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7866/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7866/contributors\">",
"     Sanjay Sethi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7866/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/43/7866/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7866/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/43/7866/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/43/7866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Global Initiative for Chronic Obstructive Lung Disease (GOLD), a report produced by the National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO), defines an exacerbation of chronic obstructive pulmonary disease (COPD) as an acute increase in symptoms beyond normal day-to-day variation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/1\">",
"     1",
"    </a>",
"    ]. This generally includes one or more of the following cardinal symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cough increases in frequency and severity",
"     </li>",
"     <li>",
"      Sputum production increases in volume",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      changes character",
"     </li>",
"     <li>",
"      Dyspnea increases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Constitutional symptoms, a decrease in pulmonary function, and tachypnea are variably present during an exacerbation, but the chest radiograph is usually unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In the presence of severe underlying airflow obstruction, an exacerbation can cause respiratory failure and death.",
"   </p>",
"   <p>",
"    The role of infection and antibiotic therapy in acute exacerbations of COPD will be reviewed here. Precipitants, risk factors, and other interventions (eg, bronchodilators, glucocorticoids, oxygen, and mechanical ventilation) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory failure complicating COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 70 to 80 percent of exacerbations of chronic obstructive pulmonary disease (COPD) are due to respiratory infections. The remaining 20 to 30 percent are due to environmental pollution or have an unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/4\">",
"     4",
"    </a>",
"    ]. Viral and bacterial infections cause most exacerbations, whereas atypical bacteria are a relatively uncommon cause [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viruses can be detected in one-third to two-thirds of exacerbations using culture, serology, and polymerase chain reaction (PCR)-based methods. The most common viruses associated with exacerbations of COPD are rhinoviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/7\">",
"     7",
"    </a>",
"    ]. Influenza, parainfluenza, coronavirus, and adenovirus are also common during exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. Respiratory syncytial virus and human metapneumovirus were more recently associated with exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of a virus in the sputum sample of a patient having a COPD exacerbation is relatively common and does not necessarily mean that this is the cause of the exacerbation. In fact, such viruses have been found in up to 15 percent of asymptomatic individuals with stable COPD using sensitive PCR-based assays [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/7,9,13,14\">",
"     7,9,13,14",
"    </a>",
"    ]. Influenza virus is an exception since asymptomatic carriage is unusual.",
"   </p>",
"   <p>",
"    The mechanisms by which viruses induce exacerbations have been partially elucidated. Viral infection of the airway epithelial cells induces inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/17\">",
"     17",
"    </a>",
"    ]. This causes airway epithelial damage, muscarinic receptor stimulation, and induction of inflammatory mediators (eg, cytokines, chemokines) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/18\">",
"     18",
"    </a>",
"    ]. Airway eosinophilia is associated with viral mediated exacerbations, which highlights the importance of the host response to infection and its impact on both inflammation and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infections appear to trigger one-third to one-half of COPD exacerbations. Nontypeable Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae are the bacteria most frequently isolated bronchoscopically from patients having an exacerbation of COPD (",
"    <a class=\"graphic graphic_table graphicRef70203 \" href=\"UTD.htm?28/48/29451\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/19-25\">",
"     19-25",
"    </a>",
"    ]. Pseudomonas aeruginosa and Enterobacteriaceae are also commonly isolated, particularly from patients with severe COPD.",
"   </p>",
"   <p>",
"    Exacerbations of COPD are strongly associated with acquisition of a new strain of H. influenzae, M. catarrhalis, S. pneumoniae, or P. aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. As a result, it has been proposed that acquisition of a new bacterial strain plays a central role in the pathogenesis of an exacerbation. This hypothesis is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exacerbations with new bacterial strains are more likely to be associated with a humoral immune response &mdash; In one study, exacerbations with a new strain of H. influenzae were significantly more likely to be associated with a humoral immune response than exacerbations with preexisting strains of H. influenzae (61 versus 21 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/31\">",
"       31",
"      </a>",
"      ]. These new antibodies were strain specific. M. catarrhalis and S. pneumoniae also induce an antibody response that is measurable following an exacerbation of COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exacerbations with new bacterial strains are associated with a more robust inflammatory response &mdash; Exacerbations of COPD with a new strain of bacteria have been associated with more intense neutrophilic airway inflammation and systemic inflammation than exacerbations not associated with a change in preexisting bacterial strains or recovery of pathogenic bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/35\">",
"       35",
"      </a>",
"      ]. Resolution of the airway inflammation is related to eradication of pathogenic bacteria from sputum and resolution of clinical symptoms. In an animal model, new strains of H. influenzae that were known to be associated with COPD exacerbation caused significantly more airway neutrophil recruitment than colonizing strains of H. influenzae [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the human studies were performed in patients with COPD who had chronic bronchitis because expectorated sputum could be obtained easily. Thus, the degree to which the data can be generalized to exacerbations in patients with COPD who do not have chronic bronchitis is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The idea that exacerbations of COPD are due to acquisition of a new strain of bacteria has largely replaced the older hypothesis that increases in the concentration of colonizing bacteria are the primary cause of exacerbations. The older theory was largely disproven by a comprehensive analysis of the relationship among sputum bacterial concentrations, exacerbation occurrence, and new pathogen acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/37\">",
"     37",
"    </a>",
"    ]. The analysis demonstrated that an increase in bacterial load is not a cause of exacerbation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atypical bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data regarding the incidence of atypical bacterial infection in patients having an exacerbation of COPD. This is related, in large part, to the varying criteria used to diagnose exacerbation and infection. The incidence of Chlamydophila pneumoniae in exacerbations of COPD appears to be 3 to 5 percent (Mycoplasma pneumoniae and Legionella spp are even more rare) if one considers only studies using rigorous methodology that excluded pneumonia and defined infection as a strict fourfold increase in titer or a positive culture [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/10,38,39\">",
"     10,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection is increasingly being considered in studies looking at the pathogenesis of COPD exacerbation. Such studies categorize exacerbations of COPD due to respiratory infection as being caused by viral infection alone, bacterial infection alone, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/14,40,41\">",
"     14,40,41",
"    </a>",
"    ]. Exacerbations were equally distributed across the three categories in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coinfection appears to increase the severity of COPD exacerbations. In a study of inpatients, coinfection was associated with a greater decrement of lung function and longer hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/14\">",
"     14",
"    </a>",
"    ]. In a similar study of outpatients, coinfection was associated with more symptoms, a larger fall in the forced expiratory volume in one second (FEV1), higher bacterial loads, and systemic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It would be advantageous if patients whose chronic obstructive pulmonary disease (COPD) exacerbations are due to bacterial infection could be identified. This would allow antibiotic therapy to be targeted to those who are most likely to benefit. However, detection of such infections is not routinely possible because sputum cultures are unreliable and molecular methods are not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sputum Gram stain and culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sputum gram stain and cultures are often not useful for identifying bacterial infection in patients with COPD exacerbations for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram stain and culture of expectorated sputum are similar during exacerbations and stable disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/8\">",
"       8",
"      </a>",
"      ]. In other words, they do not distinguish between true pathogens and colonizing flora. The molecular typing studies cited in the preceding section that showed that new bacterial strains are more often associated with exacerbations are specialized tests that are not available for routine clinical use.",
"     </li>",
"     <li>",
"      The most common bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae) are frequently difficult to isolate in sputum, which increases the likelihood of a false-negative result. In one study that collected sequential sputum cultures from patients with stable COPD, molecular typing revealed that apparently identical bacterial strains of H. influenzae were intermittently recovered, suggesting that false-negative culture results were common [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/43\">",
"       43",
"      </a>",
"      ]. Support for this hypothesis was provided by the observation that strain-specific H. influenzae DNA was detected in some culture-negative sputum samples. H. influenzae is particularly problematic because H. haemolyticus, which is not a pathogen, is frequently misidentified as H. influenzae [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In recognition of these limitations, the 2007 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines and the 2001 clinical practice guidelines from the American College of Physicians concluded that sputum cultures should NOT be performed during most exacerbations of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/1,44\">",
"     1,44",
"    </a>",
"    ]. A possible exception recognized by the GOLD guidelines is that sputum cultures may be helpful in patients who are strongly suspected of having a bacterial infection, but fail to respond to initial antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/1\">",
"     1",
"    </a>",
"    ]. However, even these cultures should be interpreted with caution because of their unreliability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=see_link\">",
"     \"Sputum cultures for the evaluation of bacterial pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risk factors for Pseudomonas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of sputum gram stain and culture is clearer during exacerbations in patients who have risk factors for Pseudomonas infection. These risk factors include recent hospitalization (&ge;2 days' duration during the past 90 days), frequent administration of antibiotics (&ge;4 courses within the past year), severe COPD (FEV1 &lt;50 percent of predicted), isolation of Pseudomonas aeruginosa during a previous exacerbation, colonization during a stable period, and systemic glucocorticoid use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/1,45,46\">",
"     1,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to H. influenzae, M. catarrhalis, and S. pneumoniae, Pseudomonas spp can easily be recovered from expectorated sputum obtained before initiating therapy. In addition, the susceptibility pattern of Pseudomonas is unpredictable, making the susceptibility results important for guiding the choice of antibiotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sputum purulence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sputum purulence may be a marker of bacterial infection during an exacerbation of COPD. In one bronchoscopic study of 40 patients with COPD exacerbations, more patients with purulent sputum had bronchial infection than patients with mucoid sputum (77 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/47\">",
"     47",
"    </a>",
"    ]. Sputum purulence correlates with increased airway bacterial concentrations and sputum neutrophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/48\">",
"     48",
"    </a>",
"    ]. Based on these observations, we believe that sputum purulence is an important, but not absolute, indicator of bacterial infection in patients with an exacerbation of COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106397380\">",
"    <span class=\"h2\">",
"     Procalcitonin and C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procalcitonin is a peptide precursor of calcitonin that is released by parenchymal cells in response to bacterial toxins, leading to elevated serum levels in patients with bacterial infections; in contrast, procalcitonin is down-regulated in patients with viral infections. Procalcitonin has been evaluated to facilitate the decision of whether to use antibacterial agents in patients with acute respiratory tract infections and when antibiotics can be safely stopped. In a 2012 Cochrane meta-analysis, procalcitonin guidance for antibiotic use was associated with a reduction in antibiotic exposure without an increase in mortality or treatment failure in any clinical setting (eg, outpatient clinic, emergency department) or in patients with any type of acute respiratory infection, including COPD exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of patients with acute exacerbations of COPD, procalcitonin showed poor concordance with sputum purulence, whereas another biomarker, C-reactive protein (CRP), correlated with sputum purulence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/50\">",
"     50",
"    </a>",
"    ]. Further studies are necessary to establish the utility and safety of procalcitonin and CRP for guiding antibiotic use in acute exacerbations of COPD.",
"    <br/>",
"    <br/>",
"    Studies of procalcitonin and CRP in patients with community-acquired pneumonia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Procalcitonin and CRP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of chronic obstructive pulmonary disease (COPD) exacerbations often includes antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antibiotics in exacerbations of COPD is based on placebo-controlled trials and retrospective population studies that found that antibiotics improve clinical outcomes in many patients having an exacerbation of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/51-57\">",
"     51-57",
"    </a>",
"    ]. On the basis of these studies, most clinical practice guidelines recommend antibiotic treatment of moderate to severe exacerbations. There is insufficient evidence to support antibiotic treatment of mild exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258310400\">",
"    <span class=\"h3\">",
"     Hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized trial of 93 patients with severe exacerbations requiring mechanical ventilation, antibiotic therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ) significantly decreased mortality (4 versus 22 percent with placebo) and significantly reduced the need for additional courses of antibiotics, the duration of mechanical ventilation, and the duration of hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/52\">",
"     52",
"    </a>",
"    ]. In a 2012 meta-analysis of 16 placebo-controlled trials, the beneficial effect of antibiotics was clearly demonstrated for severe exacerbations in terms of treatment failure and length of hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/57\">",
"     57",
"    </a>",
"    ]. High-quality evidence from only the single trial described above showed a mortality benefit in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/52\">",
"     52",
"    </a>",
"    ]. Diarrhea was the most common adverse effect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the multivariate analysis of a retrospective cohort study that included 84,621 patients who were hospitalized patients with acute exacerbations of COPD, the risk of treatment failure was lower in those who received antibiotics during the first two hospital days compared with those who were treated later or not at all (odds ratio [OR] 0.87, 95% CI 0.82-0.92); treatment failure was a composite endpoint defined as the initiation of mechanical ventilation after the second hospital day, inpatient mortality, or readmission for acute exacerbations of COPD within 30 days of discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/54\">",
"     54",
"    </a>",
"    ]. In the multivariate analysis of another large retrospective cohort study, receipt of antibiotics was associated with a significant reduction in the risk of in-hospital mortality (OR 0.60, 95% CI 0.50-0.73) as well as a substantial reduction in the risk of 30-day readmission for COPD (OR 0.87, 95% CI 0.79-0.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study examined whether there is additive benefit of antibiotics over that provided by systemic glucocorticoids in the treatment of moderate to severe exacerbations in hospitalized patients not requiring mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/55\">",
"     55",
"    </a>",
"    ]. In this randomized trial of 265 exacerbations,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    provided a significantly greater clinical success rate than placebo at 10 days (80 versus 69 percent). However, this difference was no longer statistically significant at 30 days (61 versus 53 percent). Doxycycline demonstrated limited microbiologic efficacy with only a 67 percent rate of bacteriologic eradication from expectorated sputum, although this was greater than the 37 percent rate seen with placebo. This may explain the substantial clinical failure rate of 39 percent at 30 days, even when patients received both antibiotics and glucocorticoids. Additional trials to address these issues are required.",
"   </p>",
"   <p>",
"    A non-randomized prospective study was conducted in 73 patients with COPD exacerbations admitted to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/50\">",
"     50",
"    </a>",
"    ]. If patients had purulent sputum, they received antibiotics; otherwise, antibiotics were withheld. Clinical outcomes were similar in the two groups. However, the two groups were not matched, since those receiving antibiotics were more ill. Whether antibiotics can be safely withheld from patients with acute exacerbations of COPD admitted to the hospital who do not have purulent sputum is an important question that needs to be addressed in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258310507\">",
"    <span class=\"h3\">",
"     Outpatients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of antibiotics for COPD exacerbations is less well-established for outpatients than for inpatients. In the 2012 meta-analysis described above, in outpatients (with mild to moderate exacerbations), there was low-quality evidence that antibiotics significantly reduced the risk for treatment failure between seven days and one month after treatment initiation (RR 0.75, 95% CI 0.60&ndash;0.94), but antibiotics did not significantly reduce the risk when the meta-analysis was restricted to currently available drugs (RR 0.80, 95% CI 0.63&ndash;1.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest and most rigorous trials was a double-blind, randomized, placebo-controlled trial of 173 patients with 362 exacerbations over a three and one-half year period [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/51\">",
"     51",
"    </a>",
"    ]. Antibiotic therapy increased the likelihood of clinical improvement, defined as resolution of symptoms without additional intervention (68 versus 55 percent with placebo). Improvement was most frequent in patients with a severe exacerbation (63 versus 43 percent with placebo) and was not seen with a mild exacerbation.",
"   </p>",
"   <p>",
"    A randomized trial showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    administration for COPD exacerbations demonstrated both short- and long-term benefits in outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/59\">",
"     59",
"    </a>",
"    ]. When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanate was administered rather than placebo, clinical success at day 10 increased from 81 to 91 percent, whereas clinical cure at day 10 increased from 60 to 74 percent. Median time to the next exacerbation was 233 days with amoxicillin-clavulanate compared to 166 days with placebo.",
"   </p>",
"   <p>",
"    A population-based cohort study evaluated the risk of subsequent COPD exacerbations among nearly 19,000 outpatients treated for an exacerbation with oral glucocorticoids with or without antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/53\">",
"     53",
"    </a>",
"    ]. Median time to the second exacerbation was significantly longer among patients who received antibiotics plus oral glucocorticoids compared with those who received oral glucocorticoids alone (418 versus 321 days); median time between the second and third exacerbations was also longer (240 versus 127 days). Mortality during follow-up was also lower in patients who received antibiotics (hazard ratio 0.82, 99% CI 0.66-0.98).",
"   </p>",
"   <p>",
"    A large trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    in exacerbations of COPD among outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/60\">",
"     60",
"    </a>",
"    ]. The study population was carefully selected to meet the complicated COPD patient criteria; randomization was stratified by systemic glucocorticoid use, patients were followed for eight weeks, and the primary endpoint was clinical failure within an eight-week period. Clinical failure rates with moxifloxacin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanate were similar (21 versus 22 percent, respectively), demonstrating that both antibiotics are good choices outpatients with COPD exacerbations. Failure of bacterial eradication at end of the antibiotic course was associated with clinical failure at eight weeks, demonstrating that bacterial eradication from the airways is associated with clinical benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;To try to maximize the benefit of antibiotic therapy, many clinical practice guidelines recommend antibiotic therapy only for those patients who are most likely to have bacterial infection or are most ill. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend antibiotic therapy for patients who have the following features: a severe exacerbation requiring mechanical ventilation (noninvasive or invasive) or an exacerbation with increased sputum purulence plus either increased dyspnea or increased sputum volume [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We vary slightly from the GOLD guidelines in our clinical practices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend antibiotics in patients with a moderate to severe COPD exacerbation, which is defined as having at least two of these three symptoms &mdash; increased dyspnea, increased sputum volume, or increased sputum purulence &mdash; or requiring hospitalization.",
"     </li>",
"     <li>",
"      We do NOT initiate antibiotic therapy in patients whose exacerbation is mild, which we define as having only one of these three symptoms and not requiring hospitalization or ventilatory assistance (either invasive or noninvasive).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Choice of antibiotic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal antibiotic regimen for the treatment of exacerbations of COPD has not been determined. We use a \"risk stratification\" approach when selecting initial antibiotic therapy. Specifically, we prescribe a broader antibiotic regimen for patients who have risk factors for a poor outcome. Risk factors include older age (&gt;65 years), comorbid conditions (especially cardiac disease), severe underlying COPD (defined as FEV1 &lt;50 percent), frequent exacerbations (three or more per year), and antimicrobial therapy within the past three months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. This approach is illustrated in separate algorithms for selection of antibiotics in outpatients (",
"    <a class=\"graphic graphic_algorithm graphicRef66357 \" href=\"UTD.htm?29/12/29890\">",
"     algorithm 1",
"    </a>",
"    ) and inpatients (",
"    <a class=\"graphic graphic_algorithm graphicRef53537 \" href=\"UTD.htm?39/18/40239\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The risk stratification scheme recognizes that some treatment failures are probably related to ineffective antibiotic treatment and that some patients cannot afford to experience treatment failure. The same approach has been advocated for other community-acquired infections (eg, pneumonia, acute sinusitis) because it addresses concerns about disease heterogeneity, antibiotic resistance, and judicious antibiotic use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/5,6,61\">",
"     5,6,61",
"    </a>",
"    ]. However, this approach has not been shown in prospective controlled trials to improve clinical outcomes.",
"   </p>",
"   <p>",
"    The initial antibiotic regimen should target likely bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in most patients) and take into account local patterns of antibiotic resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/64\">",
"     64",
"    </a>",
"    ]. Pseudomonas aeruginosa and Enterobacteriaceae can occur in patients with severe COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/61\">",
"     61",
"    </a>",
"    ]. Risk factors for P. aeruginosa infection are described above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors for Pseudomonas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Historically favored (ie, first-line) antibiotics based upon randomized trials include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/44\">",
"     44",
"    </a>",
"    ]. However, amoxicillin is no longer considered a first-line agent because it is inactive against most nontypeable H. influenzae and M. catarrhalis.",
"   </p>",
"   <p>",
"    Other (ie, second-line) antibiotics are also logical choices for outpatients based upon in vitro activity and trials showing efficacy that is comparable, but usually not superior, to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . Antibiotics in this category include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/22/14693?source=see_link\">",
"     cefprozil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    , loracarbef, and the fluoroquinolones. In patients with complicated COPD and risk factors for Pseudomonas who do not have indications for hospitalization, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef66357 \" href=\"UTD.htm?29/12/29890\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors for Pseudomonas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority of patients with COPD exacerbations are treated as outpatients. There is a separate treatment algorithm for patients requiring hospitalization (",
"    <a class=\"graphic graphic_algorithm graphicRef53537 \" href=\"UTD.htm?39/18/40239\">",
"     algorithm 2",
"    </a>",
"    ). The antibiotic choice for such patients depends upon the risk of Pseudomonas. For hospitalized patients with risk factors for Pseudomonas, antibiotic choices include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    . Hospitalized patients without risk factors for Pseudomonas can be treated with a respiratory fluoroquinolone (levofloxacin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) or a third-generation cephalosporin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Comparisons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials that compare different antibiotic regimens for the treatment of COPD exacerbations are difficult to interpret without microbiologic data, which are often absent. In addition, since there are many factors other than bacterial infection that play a role in exacerbations, it has been challenging to establish the benefit of antibacterial agents.",
"   </p>",
"   <p>",
"    The efficacy of first-line and second-line antibiotics were compared in a meta-analysis of 12 randomized trials involving more than 2100 patients with exacerbations of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/65\">",
"     65",
"    </a>",
"    ]. Second-line antibiotics were significantly more likely than first-line antibiotics to achieve treatment success, defined as resolution or improvement of symptoms (OR 0.51, 95% CI 0.34-0.75). There was no difference in mortality or adverse effects.",
"   </p>",
"   <p>",
"    Several studies have compared the efficacy of different second-line antibiotics to each other. A meta-analysis of 19 randomized trials (7405 patients with exacerbations of COPD) compared the effectiveness of macrolides, fluoroquinolones, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/66\">",
"     66",
"    </a>",
"    ]. The macrolides included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , while the fluoroquinolones included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    . Antibiotic selection did not affect short-term treatment success, defined as resolution or improvement of symptoms. However, fluoroquinolones were associated with a higher rate of microbiologic success and, in the 26 weeks following therapy, a lower rate of recurrence.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    -clavulanate was associated with more adverse effects (mostly diarrhea) than the other drug classes.",
"   </p>",
"   <p>",
"    In a randomized trial that included 170 patients with acute exacerbations of COPD requiring mechanical ventilation, patients received a 10 day course of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/67\">",
"     67",
"    </a>",
"    ]. Hospital mortality and the need for additional antibiotic prescriptions were similar in both groups, indicating that trimethoprim-sulfamethoxazole was non-inferior to ciprofloxacin. An important limitation of this study is that neither agent has optimal activity against bacteria that are commonly implicated in COPD exacerbations. For example, ciprofloxacin has inadequate activity against Streptococcus pneumoniae, whereas an appreciable percentage of S. pneumoniae isolates are resistant to trimethoprim-sulfamethoxazole. Furthermore, trimethoprim-sulfamethoxazole does not have activity against Pseudomonas aeruginosa. For these reasons, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend either regimen for patients with severe COPD exacerbations requiring hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antibiotic therapy for patients with a COPD exacerbation is usually three to seven days, depending upon the response to therapy. A meta-analysis that compared five days to seven or more days of antimicrobial therapy (fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ) for exacerbations of COPD found no difference in outcome between the two groups, although there were fewer adverse events among patients who received a five-day course [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are initially started on parenteral antibiotics should be switched to an oral regimen when able to take medications orally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose COPD exacerbation was triggered by influenza virus should be treated with antiviral therapy according to current recommendations and based on the predicted susceptibility patterns of the circulating strains. Inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    is contraindicated in this patient population due to the risk of airway reactivity. Several other agents can be used such as oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , or in certain situations, intravenous zanamivir or peramivir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H489947517\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic obstructive pulmonary disease (COPD) should receive influenza vaccine annually and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    once, with a single booster five years later if the patient is &ge;65 years old and was less than 65 years old when the initial vaccination was given [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The utility of influenza vaccine is well established for reducing both the rate and severity of symptoms due to influenza, including respiratory symptoms. A meta-analysis of 11 trials, including six specifically performed in patients with COPD, found a significant reduction in the number of exacerbations per patient compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For pneumococcal vaccine, a meta-analysis of seven trials that assessed the effect on patients with COPD found no evidence of a significant impact on morbidity or mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/72\">",
"       72",
"      </a>",
"      ]. One trial provided data on acute exacerbations of COPD, with no significant effect of vaccination, and a second trial found no significant effect on hospitalizations for acute exacerbations. The recommendation for the pneumococcal vaccine in patients with COPD is based upon studies suggesting a reduced frequency of pneumococcal pneumonia and pneumococcal bacteremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H489947524\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians advocate prophylactic antibiotics for patients with severe exacerbations, especially those that occur seasonally. This approach is largely based upon trials conducted before 1970, some of which showed a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. However, the data supporting its benefit is mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. A 2003 meta-analysis of nine trials that included 1055 patients found a significant reduction in the number of days of disability (mean of one day per month) and a nonsignificant reduction in the number of acute exacerbations (0.12 exacerbations per patient per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of prophylactic antibiotics has been reexamined in carefully selected patients at high risk for recurrent COPD exacerbations using newer antibiotic agents, and, in some cases, intermittent dosing regimens. In one such trial, 1157 patients with COPD were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    or placebo; moxifloxacin was administered intermittently at its full dose of 400 mg orally daily for five days every eight weeks for six cycles for a total duration of 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/78\">",
"     78",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      were less likely to have a COPD exacerbation in both the per-protocol analysis (OR 0.75, 95% CI 0.565-0.994) and in the intent-to-treat analysis (OR 0.81, 95% CI 0.645-1.008).",
"     </li>",
"     <li>",
"      A post-hoc analysis of per-protocol patients with purulent or mucopurulent sputum production at baseline showed a larger benefit with antibiotic prophylaxis (OR 0.55, 95% CI 0.36-0.84).",
"     </li>",
"     <li>",
"      Sustained emergence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      resistant strains was not observed in sputum or in enteric flora.",
"     </li>",
"     <li>",
"      Gastrointestinal adverse effects were more frequent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      , however Clostridium difficile infections were not observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another trial, a significant reduction in the frequency of COPD exacerbations was observed among patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/76\">",
"     76",
"    </a>",
"    ]. In this trial, 1142 patients with COPD were randomly assigned to receive azithromycin 250 mg orally daily or placebo for one year in addition to their usual COPD regimen. Patients with resting tachycardia, hearing impairment, and those with or at risk for a prolonged QT interval were excluded from participating (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    ). The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median time to first COPD exacerbation was significantly longer among the patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      compared with those who received placebo (266 versus 174 days).",
"     </li>",
"     <li>",
"      Patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      had a significant (but modest) reduction in the frequency of COPD exacerbations compared with those who received placebo (1.48 versus 1.83 exacerbations per patient-year; hazard ratio 0.73, 95% CI 0.63-0.84).",
"     </li>",
"     <li>",
"      Patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      had a significantly higher rate of nasopharyngeal colonization with macrolide-resistant bacteria (Staphylococcus aureus [S. aureus], Streptococcus pneumoniae, Haemophilus spp, Moraxella spp) than those who received placebo (81 versus 41 percent). Lower airway and enteric microbiology were not monitored, so the emergence of macrolide-resistant strains in these relevant sites was not assessed.",
"     </li>",
"     <li>",
"      Hearing decrements were more common in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      group than the placebo group (25 versus 20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits of antibiotic prophylaxis must be weighed against concerns about promoting antibiotic resistance and possible adverse effects. For most patients with COPD, we suggest not administering antibiotic prophylaxis. Only carefully selected patients, such as those who continue to have frequent exacerbations in spite of optimal therapy for their COPD with bronchodilators and antiinflammatory agents, should be considered for antibiotic prophylaxis. In such patients, we suggest prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . Azithromycin can be given as 250 mg orally daily or at a lower dose of 250 mg three times per week (the recommended dose for the prevention of cystic fibrosis exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/43/7866/abstract/79\">",
"     79",
"    </a>",
"    ]). Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    has demonstrated efficacy for the prevention of COPD exacerbations, we generally reserve it for the treatment of serious pulmonary infections in order to reduce the risk of selecting fluoroquinolone-resistant bacteria.",
"   </p>",
"   <p>",
"    <br/>",
"    When prophylactic antibiotics are prescribed, careful attention should be paid to contraindications and patients should be closely monitored for adverse effects. Suspected bacterial exacerbations in patients on antibiotic prophylaxis should be treated with antibiotics that are from a different class than the prophylactic agent. Even if the regimen is successful in reducing exacerbations, interrupting treatment after 48 to 52 weeks should be considered.",
"   </p>",
"   <p>",
"    Interventions to prevent exacerbations of COPD that are unrelated to infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An exacerbation of chronic obstructive pulmonary disease (COPD) is an acute increase in symptoms beyond normal day-to-day variation. Specifically, cough increases in frequency and severity, sputum production increases in volume or changes character, and dyspnea increases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most exacerbations of COPD are due to respiratory infection or environmental pollution. Respiratory infections that can cause exacerbations include viral, bacterial, and mixed infections. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sputum cultures should not be performed during most exacerbations of COPD. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic therapy increases the likelihood of clinical improvement in patients having an exacerbation of COPD, particularly in patients with a moderate to severe exacerbation. Among patients requiring mechanical ventilation, antibiotic therapy may provide a mortality benefit. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose exacerbation of COPD is mild (defined as not requiring hospitalization or mechanical ventilation and having only one of the three cardinal symptoms of increased dyspnea, sputum purulence, or sputum production), we suggest that antibiotics NOT be prescribed (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose exacerbation of COPD is moderate to severe (defined as requiring hospitalization or having at least two of the three cardinal symptoms), we recommend antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Choice of antibiotic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal antibiotic regimen for the treatment of exacerbations of COPD has not been determined. We use a \"risk stratification\" approach when selecting initial antibiotic therapy. The initial antibiotic regimen should target likely bacterial pathogens and take into account local patterns of antibiotic resistance. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Choice of antibiotic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The usual duration of antibiotic therapy is three to seven days, depending upon the response to therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with COPD, we suggest not administering antibiotic prophylaxis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients who continue to have frequent exacerbations despite optimal therapy for COPD with bronchodilators and antiinflammatory agents, we suggest antibiotic prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Azithromycin can be given as 250 mg orally daily or at a lower dose of 250 mg three times per week (the recommended dose for the prevention of cystic fibrosis exacerbations). Careful attention should be paid to contraindications and patients should be monitored closely for adverse effects. (See",
"      <a class=\"local\" href=\"#H489947524\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007 file://www.goldcopd.org (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/2\">",
"      Petty TL. Definitions in chronic obstructive pulmonary disease. Clin Chest Med 1990; 11:363.",
"     </a>",
"    </li>",
"    <li>",
"     American Thoracic Society / European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD [Internet]. Version 1.2 file://www.thoracic.org/go/copd (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/4\">",
"      Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax 2006; 61:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/5\">",
"      Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/6\">",
"      Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy. Infect Dis Clin North Am 2004; 18:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/7\">",
"      Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/8\">",
"      Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/9\">",
"      Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/10\">",
"      Smith CB, Golden CA, Kanner RE, Renzetti AD Jr. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980; 121:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/11\">",
"      Tan WC, Xiang X, Qiu D, et al. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med 2003; 115:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/12\">",
"      McNamara MJ, Phillips IA, Williams OB. Viral and Mycoplasma pneumoniae infections in exacerbations of chronic lung disease. Am Rev Respir Dis 1969; 100:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/13\">",
"      Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/14\">",
"      Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/15\">",
"      Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/16\">",
"      Hamelin ME, C&ocirc;t&eacute; S, Laforge J, et al. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/17\">",
"      Papadopoulos NG, Bates PJ, Bardin PG, et al. Rhinoviruses infect the lower airways. J Infect Dis 2000; 181:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/18\">",
"      Mallia P, Johnston SL. How viral infections cause exacerbation of airway diseases. Chest 2006; 130:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/19\">",
"      Bartlett JG. Diagnostic accuracy of transtracheal aspiration bacteriologic studies. Am Rev Respir Dis 1977; 115:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/20\">",
"      Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/21\">",
"      Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/22\">",
"      Mons&oacute; E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/23\">",
"      Rosell A, Mons&oacute; E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/24\">",
"      Bandi V, Apicella MA, Mason E, et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001; 164:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/25\">",
"      Nseir S, Cavestri B, Di Pompeo C, et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008; 76:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/26\">",
"      Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/27\">",
"      Murphy TF, Brauer AL, Sethi S, et al. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis 2007; 195:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/28\">",
"      Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009; 49:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/29\">",
"      Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/30\">",
"      Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009; 15:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/31\">",
"      Sethi S, Wrona C, Grant BJ, Murphy TF. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/32\">",
"      Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/33\">",
"      Murphy TF, Brauer AL, Aebi C, Sethi S. Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun 2005; 73:8161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/34\">",
"      Bogaert D, van der Valk P, Ramdin R, et al. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004; 72:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/35\">",
"      Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/36\">",
"      Chin CL, Manzel LJ, Lehman EE, et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005; 172:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/37\">",
"      Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/38\">",
"      Beaty CD, Grayston JT, Wang SP, et al. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/39\">",
"      Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/40\">",
"      Wilkinson TM, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006; 129:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/41\">",
"      Bandi V, Jakubowycz M, Kinyon C, et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003; 37:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/42\">",
"      Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2011; 52 Suppl 4:S290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/43\">",
"      Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/44\">",
"      Snow V, Lascher S, Mottur-Pilson C, Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/45\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/46\">",
"      Garcia-Vidal C, Almagro P, Roman&iacute; V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009; 34:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/47\">",
"      Soler N, Agust&iacute; C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/48\">",
"      Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/49\">",
"      Schuetz P, M&uuml;ller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9:CD007498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/50\">",
"      Soler N, Esperatti M, Ewig S, et al. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J 2012; 40:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/51\">",
"      Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/52\">",
"      Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/53\">",
"      Roede BM, Bresser P, Prins JM, et al. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 2009; 33:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/54\">",
"      Rothberg MB, Pekow PS, Lahti M, et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010; 303:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/55\">",
"      Daniels JM, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/56\">",
"      Stefan MS, Rothberg MB, Shieh MS, et al. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest 2013; 143:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/57\">",
"      Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12:CD010257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/58\">",
"      Sethi S. Personalised medicine in exacerbations of COPD: the beginnings. Eur Respir J 2012; 40:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/59\">",
"      Llor C, Moragas A, Hern&aacute;ndez S, et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/60\">",
"      Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/61\">",
"      Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10 Suppl B:3B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/62\">",
"      Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J 2001; 17:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/63\">",
"      Wilson R, Jones P, Schaberg T, et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/64\">",
"      Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 346:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/65\">",
"      Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007; 132:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/66\">",
"      Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/67\">",
"      Nouira S, Marghli S, Besbes L, et al. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis 2010; 51:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/68\">",
"      Falagas ME, Avgeri SG, Matthaiou DK, et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008; 62:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/70\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/71\">",
"      Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; :CD002733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/72\">",
"      Walters JA, Smith S, Poole P, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; :CD001390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/73\">",
"      Johnston RN, McNeill RS, Smith DH, et al. Five-year winter chemoprophylaxis for chronic bronchitis. Br Med J 1969; 4:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/74\">",
"      PRIDIE RB, DATTA N, MASSEY DG, et al. A trial of continuous winter chemotherapy in chronic bronchitis. Lancet 1960; 2:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/75\">",
"      Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis. Br Med J 1966; 1:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/76\">",
"      Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/77\">",
"      Staykova T, Black PN, Chacko EE, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003; :CD004105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/78\">",
"      Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/43/7866/abstract/79\">",
"      Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7019 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7866=[""].join("\n");
var outline_f7_43_7866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atypical bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sputum Gram stain and culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risk factors for Pseudomonas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sputum purulence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106397380\">",
"      Procalcitonin and C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H258310400\">",
"      - Hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H258310507\">",
"      - Outpatients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Choice of antibiotic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Comparisons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H489947517\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H489947524\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7019\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7019|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/12/29890\" title=\"algorithm 1\">",
"      AECOPD abx outpatient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/18/40239\" title=\"algorithm 2\">",
"      AECOPD abx inpatient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7019|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/48/29451\" title=\"table 1\">",
"      Bacterial pathogens in AECOPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=related_link\">",
"      Mechanical ventilation in acute respiratory failure complicating COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_43_7867="Treatment of hyperkalemia";
var content_f7_43_7867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of hyperkalemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antagonism of membrane actions",
"of potassium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drive extracellular",
"potassium into the cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin and glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium bicarbonate, primarily if metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;2-adrenergic agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Removal of potassium",
"from the body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loop or thiazide diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cation exchange resin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dialysis, preferably hemodialysis if severe",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7867=[""].join("\n");
var outline_f7_43_7867=null;
var title_f7_43_7868="CF risk couples based screen";
var content_f7_43_7868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Detection of couples at risk by population-based carrier screening",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" style=\"width: 578px; height: 321px;\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Cystic fibrosis mutations detectable,",
"percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Detection",
"of carrier status, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Both parents",
"       </td>",
"       <td class=\"subtitle2\">",
"        One parent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Neither parent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        49.0",
"       </td>",
"       <td>",
"        42.0",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        56.3",
"       </td>",
"       <td>",
"        37.5",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        64.0",
"       </td>",
"       <td>",
"        32.0",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        72.3",
"       </td>",
"       <td>",
"        25.5",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        81.0",
"       </td>",
"       <td>",
"        18.0",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        90.3",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Proportion of high risk couples (couples in which each member carries a CF gene) identified. The proportion of couples identified depends on how many CF mutations are screened. For example, if each member of the couple is tested only for &Delta;F508, accounting for 75 percent of CF cases, only 56 percent of couples who are truly at risk to have a child with CF will be correctly identified; if each member is tested for mutations accounting for 85 percent of the disease, only 72 percent of at-risk couples will be correctly identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Elias, S, Annas, GJ, Simpson, JL. Carrier screening for cystic fibrosis: Implications for obstetric and gynecologic practice. Am J Obstet Gynecol 1991; 164:1077. Copyright &copy; 1991 Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7868=[""].join("\n");
var outline_f7_43_7868=null;
var title_f7_43_7869="Diseases associated with methotrexate pneumonitis";
var content_f7_43_7869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methotrexate pneumonitis: Underlying diseases and dose of methotrexate",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histological study",
"        <br/>",
"        (n = 49)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose of MTX",
"        <br/>",
"        (mg/week)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         RA",
"        </strong>",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        2.5 to 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leukaemia (in remission)",
"        </strong>",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        20 to 80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cancer (breast, lung, other)",
"        </strong>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        15 to 1400*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Psoriasis",
"        </strong>",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2.5 to 37.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Primary biliary cirrhosis",
"        </strong>",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Lymphoma",
"        </strong>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        6.25 to 80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Polymyositis",
"        </strong>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        20 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ectopic pregnancy",
"        </strong>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        12.5 to 88",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Asthma",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5 to 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mycosis fungoides",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pemphigus vulgaris",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        50 to 75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Medulloblastoma",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Polyarticular juvenile RA",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.5",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Psoriatic arthritis",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         COPD",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7.5 to 15",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RA: rheumatoid arthritis; COPD: chronic obstructive pulmonary disease.",
"     <br>",
"      * One patient received ten intrathecal doses of methotrexate at two day intervals.",
"      <br>",
"       &bull;&nbsp;Single intramuscular administration.",
"       <br>",
"        &Delta;&nbsp;mg/kg per week.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of the European Respiratory Society. Eur Respir J February 1, 2000 15:373-381. Copyright &copy; 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7869=[""].join("\n");
var outline_f7_43_7869=null;
var title_f7_43_7870="Amiodarone and SCD mortality";
var content_f7_43_7870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amiodarone reduces total and sudden death mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 276px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A meta-analysis of randomized trials involving 6553 patients with heart failure or a recent myocardial infarction found that, compared to placebo or usual care, amiodarone significantly reduced total mortality by 13 percent and sudden death mortality by 29 percent. There was no difference in treatment effect between heart failure and postinfarction trials.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Amiodarone Trials Meta-Analysis Investigators, Lancet 1997; 350:1417.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7870=[""].join("\n");
var outline_f7_43_7870=null;
var title_f7_43_7871="Wrist drop";
var content_f7_43_7871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wrist drop in vasculitic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 262px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAQYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDIwaUDLKO5OBTgKv6DCk96zOMhMAe1VOXKrlUKXtZ8pTlheGQxyKVZeoIpuK9D1jQo7xXkjKkMgZJFrgp4WhmaJxhlODShJvfcdai6evQh20bSc4BwOtPxilAOCASAetWc5GyZqNoQas4pCKAM+SDPQVUmt/atkqDUUkQIpFJnPS29VJbbrXRyQVVkt+vFA7nNyQEVCyEdRW/Lbe1U5rb2p3KuZWKMVaeAjtUBUjqKdwGYpQxFLikoAlSUg81Zjn96okUoJFAGtHce9W4rj3rBSUirEc3NO4WOgjn461Ms+TWClxxViOf0NUmKxtq4NPB96zIrjHerST8U7isW6MVHHIDxUgpiExSEZ+tOPakJ5pDEC0FD0FKOTTqAIipoqX+dFGgEq4257dat+GLlTezLGc5bNUpB+79iQDSXVpJpF7FeRj/RZcAkfwmuWo+h3YCPvOZ6zYt+5R4/mDA7k9Peub1/SHnn3xxFHJ5PqK1PDV6skaEMM4z9a6x4oJohnaWA4PpUa20Z21lF6SR4tNC0MjRuMMDimYrt/F2loQZY12uvcd64wjitYS5kePWpezfkRnpSHtT2FNI9KsxGkUmKdjmnY60gIygNMaEc1YANLigDOlt/aqktr14rcKAg1C8PFMdznZrX2qjLannIrqJLfPaqc1t14oGmcvJAVNQlSO1dBNa9eDVGW264FFyrmZikIqzJARURUjrTuMjxxQOOlLSUDHK5FSpMRUOKSmI0I5+nNWorjisYMRUyS+9FwN+GbnrVuOfNc/FPVqO496akKxuiTIpC3NZq3HFSpPk9adwsXlPNOB96rxyZ71MGz9KYiQUUinNFMCcjehX1FdBoTwajp0thegEMNufQ9jWBH71KjPBKJoT8w6j1rmkr6m+FrKm7PZljSL19FvZrS6bBhyVY/wASetaOma9f67cbrd/JtIHwpHV/XNcV471NLowFPlkCkFuh+ldl8MIk/seDdyWGTWMo6WPWUuZ2OuhYktY3bb4XAMTnqM9jXJa3pcthMxYEoTwcV6Ncaes0uxiMGP5SPz/SqW2PVLeazuwBdou0g/xD+8KaTg7nFXgmuU8yppFW9QtHs7uSCQcqePcVWA9a6Fqea1Z2Y0CnAU5V9OtOC0CEAowKkxQB+dAhm2kxzUuM0mKAIimaheDI4FXAKVUzxigDJkts9BVWWzJ7V0q24I6UrWYPagOY4yazx/DzWfPaYPSu7msQR0rPudO4PFBSkcPLAQahKle1dNc2OD0rPntMZGKC7mPikxVyW3INV2QimMZimkcU8g5oxQA0MRipUmIxUeOaMUAXEn4qeOfFZgJFPVyDQBuRT8DnmrcU1YEUpz1q9BN05qkxG7C2RnvRVOCYYoqriNWM1ZjqlG3NWo2yK54yJZR1zRI9Tj3Idk46Hsa1/hrdm2i+zXHEkBKEVWvLoWtq0pGSOlYmj6sItdjuWwqTEK49D60ptbHdg5ST12PoSxmW5tF/vr0NUtU01jieDKTKdyuOoNVNGnXykdDx7V0UUoljKDoRUu0jsqR6o898U25vYVukTE8XyzKP51yqgmvQ9UhNtcqzr+5lOyUe3rXMa5o76fc/KMxNyMdqcJW0Z51elbVGOq+1PC808Jinba1OQj28cUYqTFAWgCPFLtPapRGTUqxUCIUjJPSp44fap44ulWY4vQUCuQxw1YWH2qaOMVYVPWncRSa3BHSqk9oMdK2So7VDJHnPSgEzl7qyBzxWTc2GOcV2ksIPYVQntAeQKClI4aezwelZ89ofSu3uLMc8c1l3Fn14oLUjj5Lcr2qBkIrpZ7TB6VRmteuBSKTMbFJirsluRmq7Rle1MdyLHNIakIppFAxoJFTxS4NQEUnQ0Aa0NxxyaKzEkK0UAdsODU0ZpjoQTxSKcEc9a5YsgmvIxNblSM1xurxC1lwp+Vv0rtUPFYuv6M94m+3PzDtWlr6nRh6qheLOo+HviKW7tRBICZI/lJ9R616fpkzPjAIJFeCfD+WbTddMFwpTzBxnua980hlkVHK9qTVmelTmpQLt5aC6hAkHHesK5iS4spI7nJnt/lT3U9P8K7ZId8AI6YrmdctjDOtwiAhOHGOq0pR0OaUtTz+5h8uZlxxnj6VFtNbOt2iw3O6Iq0cg3KRVBYxW0HdHnVY8srIrCPNPEVW1i4qRYqbMyosVTJFjFWViqRY8dqQEUadKsIlCqBTwanmFYcFAp1NBp4GapO4gppqTHFNbApiIWTrVeRcDpVlyKryGqsMozJk9Kz54BzxWnLyaquM0DMea2BB4qhNa8HiuhaPIqJrcGkykzlpbPOeKqyWPtXWva57VA9nnPFIdzj5bL2qrJakV2MtjweKpy2HXigpSOReJl6ioiPWuknsCO1Z89keeKLlXMnFFWXtmU9KKegz0C5iwTVUrz0rWvUANZrDk1ySVmQhFz7VYiNVxUsZwaqMgJprWOVRIFAlT5lYdciu88KXxmhi55IGTXFwdjWp4euvsuoPbnIU/OntmrlqjrwdSzcWe0aafMhAXriqWq2uUc4/+vUPh67JjALdOtal84kTjk0ou6NppqR5zqkIj/wBFIyGBaM+h7ism6t/szKGYFW+6e5/Cun8TQbJIpY/vwtuP9aqC8k0u482CCCRZoiuZU3bc+lVTdm0zDEU7q6MSNeanVAfSo1OAKmU9M1s0eeLswKNvpUinpzT8DnmoaArkUbamK0mOahoaYwCnjjrR0pCacUDHk8dsVDIwpGbFRO1aEjZHqu7Zpzt78VXck8UNlJDHaojzUuKTbU8xSRFj86MelP2j6Ubazch2ECZ4NO8oegpRUgHFCkFiu1uD0FQSWoPatEUbRnpVKQjDksc54qjPp3X5a6sxqahkgB6CqQXOJn0/Dfdorq5bLJziimPmG3uM8VkyfeNa173rKk61jV3CJEaeh5pppV65rEovQNUk8hhlt7heqttP0NVoWqzKN1u3qvzD8Oa1jK6sVTfLNM9D8N6jvhBzhiK6q0m3plz171xvhZo5oI+BuA64rt7O2Dp3BI6ilDc9Wo0YWu7JUZE+bP61l2cJutM8qTmWE4z/ACrrL+yRIjn5gPWudtyLbVQufllGw/XtVPfUyk046HOXEZilIxgHpSK3OK6LXdPABdV4IyfY1zgU5Oa3pyurM8ytDlehMhqVelRRpVlIiapoxEz60xiM1aW2JwaY9tS5QuVS3NMZqklgIqBlIPNFguIzZFQvn8am2Ekml8ukMqEE0eXzVox9TShM9RUtFXKfl+1J5eRV4pxSFOahxGmUDHTGXFXmTrVeROajlKuVsYpQaeUxQV9aFELgOlKKAMmnxrk01cQqqTU0cRqWKPpV2KHjFaxiyGymLfPOKK01h46UVryk3OLuV4wOn1rNmXnpWocMKpXC4Nc1RGqKLdaB0pX601evWuZlE8Zq9CeMHpVBDVmJsYpKVmB1Xgu4wrxZ+aNtp+navT9LmwijPOK8X0a6FnrMRY4S4G0/7wr1fRZgyDnOK2i9bnoKXPBM19QbKYPSuR1SHaXkHDA5H4V2boJEyMdOtc5q9qSpx6/nWr1CLVrBHcJdWqbyNki5P171zOoWbWdxh/8AVt91q0X/ANBIWU/um+6fQ+lJNNHdRNbTHIIyp9DWcZOLuZTgpqxQijyKuQxdKo2jNFKYpuxxWzEoAGK6oyurnnTg4OzCOLHalMQx0qxHipGUHmtEyDKmhB6CqUsHtW1KgqrKo5obAyDFtppXFX3C81VlwKkZAwAHNMzj8aV2FQluaLDJs00t2qIvxTGcetHIFx7tjNQM1NeT8qgaQ54pchVyRmAqMvk0zk09YzmjkC4K2Wq1AMmmRQnIq9BEc801ATZPBH09K0IY+lQQrxV2MY61ooktkixDvRTgeKKqwrnm0LZHPNR3IyM0y2bgVPMAVzXLURsjKkBzTBxU0w5NQ1wyLRIpqVCe3AqFR2qwgqGMi1DP+iMG2kSjBHavVvC1xKY0WTBPr615XqK/6MpPRXU/SvRPC0xKQsDnIwfYitYO8TuwyvBo9It0Z4+i9PWoLiyLgsxy3b2q5pUi7Acc1cuNpRto5IroWqJbs7HGanYLNE0L9SOK48pLbTMGOSvHNd/qahIwQcnIrB1q0V9s6Dg/exUSVylsZSqblBOBll4bFWbWfIZf7tUbWYWc7BeY5OCPelQi2uCrZAbkZ9KcXbQwrw5lc11l98U8XGM1Q3gUx5MVqmzgsXzOD1NVpZRg1TeX3qB5wc81SYWLDydaqyyVE0vvVaSTPQ1QD2aoWbmmljTQcn1ppgKWPSms2RUqQlqsR2ue1UmBQEZIpwgJ6CtaO0HpzVhbTjpVXFcx0gOBxVhLf0FaQtBkHHIqZIAOMUCuUIrfjpVuO3q0kQBqYKPwqkK5AkeKkHFPxTTjFMA3HNFNK0UAeU2s+AKuiUMuK5m3ugAOavJde9cdRnRYvTYLHHWo1HrUIn3dTUisD3rjkVYnRasIveqyGp0k96yYyS4h862kjx94cfWug8D3Z2RbvvA7WB7EVjWqS3DbYULY6nsK17HR5LKVrgOQzfMVHT8qqnJR0Z34WE7N20PXNPmHlqc4z61bLsxwXWuM8MeJITKtreYVjwrdj7GuzVwyligKdmFdEWuhU4uL1RT1OEPavg5P8qzLuNGtFTON4/Ktyfb5bbduCO1cffXzx3Hl4BTPetJLQUFd2OY11pLS4+78h6EetasS/wBq6SJEA+0xD8TVnU7IalbEKRu6g1iaNPLYXLK+QQdrA+lZO6dmNxTVieGYtH8www4INNkfjrVrV4EjIuLc5jfk/Wsl5c9a6ISUkeZVg4SHySVWd6bJIM1Hkk8CrsZis2abyTxzU0cDN1q7Da9OKYmyikJY1bhtOnHFaUFoPSr8NoOOKpIlszIrTpxVlLf2rVS2IA4pTCAMmiwrmcsOO1TqgA5qZgF6VGTSuOwuxcU0oM8UoOakRcmrRLREEOKQqR61fjiz2pzQe1UIzMHFMOQea0Hgx2qJosdqVwKfNFWDF7c0UrjPmuO6296uQXeT1rEcHPHWrFtuFc0ztsdFDOT3q5FLWLbscVdQnHB/OuaSEaqyg/Snibc6IpwXOKyw5FOgnaO9tpByVcHB71Kjc0ppOaTPV9IsntLKLzFWGEjOT941ZmuHkysKhVPBJ5JrIsNUOpsN48sLwEPb3rYUqo2p8zHv6VcKN3c9Pm0977jElsmW6fYSTwc+hr0TwpqD3NuIJX23kY79JF9axdNsQ+ARncckkdasXcRtp0eBtsyAspHany8upM3z6dTo7x+WBBR/bpXO6laK4LEDd6g10lncpdWMckqgPIoJ+tZuoQCDBBwOuO1GqMVKxz9pP9ln2N8wxT7+yW7InhA3D9abqKhf3qKSWOCBVX7U9nMuMmFuCPSk0ym76k2lpHdF4Jn+VeAKxtXtTaXTRjp2rXvLMx7LuybJ6kLUlzGup2wfpIo/WqjJxZjUh7RWOZWEseRVuC1wat29vngjkVfhtx6V1x1VzzJXTsyrBbY7Vow2wx0qWGL2q4iAdqtGbZHDAMDircUQHUUiECpA2aYh+AB0qCUDB4qUvxzUbNnNDBFCZTk1XOQK0JQDVZk5xWbRomVwfmxVu3561WZOc1YgOK0iDNS3VasGMHtVGGUAVcEoIFUzMhkQelVnQd6tyN1NVpD6Vk2NFd1FFDNg0VPMOx8uJDuNW4rfHarVvBnHFaEdt7VMonVcoRxYqbOBVmSHavSqj8GuWSGmKz4qGSTjg49DSs3FUp2xmiJSPSPCc8d7BGeC4GG55Br0HSrNSFAT8zXztpusXGlXYmt24z8y9iK9m8K+LbbULWMM3luR3OM1stDvp1faLzPQYzHaJkDe3T2FUL1x5oGfmbq2O1Y13q7lx5Sb8DqTwKs2c73SiRshhwPYU7cxrycq5mT6bqMtpeC1uQGtZCWUHqp9BW9eRpNAWgclPQ84rndStjLDzw45BHarFhJLHCrbuR8ren1rKSs9TB6mc0jrcmLbkZ7ntUlzAghI4571Y1ZArLdRDayHEiGnRRCeBiec9MVSu0Sn0ZV0OUqMJgqpw6n+Yq1dwiC4E8AzGfvgVmWEEllqLxuc7+ntXQROFPlSrtz+Rqd1cb3KF1bKqC4h5B5Ip0BV0DLirbxG3OFO+Nuo9Ky7+GSzYXFuS0J6r6VUJ8unQ5a9Hn95bl/dinCTtWfBdLMoKHPtUweuhTucLjYub+KUSEdapiT3p3me9WmTYtiSgyZBqoHo34//AF07hYslqZ1NReb60nmj1osBIRxTN+0UwzDFQySZqojuWhOAetWYZ81gtNg9atWs2e9Xa4G9G28etJKvHvUVpICBVxsMtZSgBmuPaippU54ornaZR8+WUYIHFa0cHy1naf2zW7CMpXby6GjZl3ceB0rIuVwc10V0mc1i3icGuSrTKizJlfGeaoTyVPdnBNZc8tYqJqhsz5rd8IaoLe7FvOf3Mh+XPQNXLtJk06OQqwYdQcitUioy5Xc+g9KVJEBQ7fYdK6ayk2qq7gMegxXAeCboXljBIG5KgH613dvBux8ufQ+lVFpnZdmqg81Rnhc/nUsqeSpGMqwwR702zDRnJXO3pntViTDAbzgD1qJq5LV2UtQiLPLjnCgMPUVW0M5XYx+4cDNXJ5ArOzdxz9KxNMnEeqSRk/e5HNStCWjoLyzVwWyPMPIPpUcqO1qpcZAH3qt8NFknOBmpEjD25Xse1Q3d6BbQyIL0xSlJDuQjqafIytFIYxviPUelU44h9skt5DgjJFFrI1tdPA/API96LXHa5l3UDWxMluDsPb0qJLycEbunrW9d2BZvMhJAPVazLy18mHdjr1rLmlF2JlSi9Whsd3J3GQe9Wo7lTgHg1UtUjUqCflPetWfTRLFujPzAVtTqS66nPUoRa00IDLTGl61Sd5IWKSg8d6YZgehFdcZKSujjlBxdmXTNxyajaf3qkZuevFRtKT0qibF4z+9MefIqlvJFAOBRcLEjuSTUtpKQwBNQAZpyjBq1IZ0NpcdOa04pgV5rmLebHetKCfOOaG7kmm7gmiqyEtRWLQ7nhNgeBW7bt8tYVj04rag+7XUjVjplyOlZN9H8praIyKoXycGplG4JnG6iu3OK526Ygmus1OP71cpfJhzXM4WZtEqhqerVCeKAaLFHoHw119LG8+x3LYjc5QnsfSvfdKuoZ0XON3YjvXyMjlWBUkEdCK9Q+HvjeSNksr9ssOEcnrUWs7m8J3Vme+ylI0D4BHtWdLeSSOcgBRWVbX81zHg/PCeeO1XzGGj+XI+tN6m0XbcWSdShDEHNYN/C8dwssWQyc1pSRlRnHToT0NVxP5rlG6jqaiS0sXa+x0GiXsd7Zq4P3eCPetF7gRqR+VcpYk2160cJGyTkj3q+twWkKN1BrKOmjM3HUddR/OLkH5hUN5bPIEnGd45q+Y/Pwg4GOaekZUmJuRjrTlEV7EVleCWEBh846iq97ILhCgQ49aDavBJ5qcjuKtpEJIBIBt9qyd3uXdHPWsJyYX7dDWnY3DRsYZG5HT3qVoFVtxwKqX6JvUxONw96aWl0ZS3LV4qzD5kBrFvLEc+WSCO1a9reoUKyYDClYxSZIZalyaFypnLMksf3hkU0SAYB4NdFLbIwyCDVCbT1fPH5VrHENbmMsPF7FAEHoacOlMnsZYmyp4qP94p+YVvGvF7mEqElsWQaUHFV1kPoacsi5/xrRST2Zk4tbllHweKvW0nTNZe7oatW7+9aIk34JBtoqjHNgcGinYmx45Y9BWxFworGsTwOK14z8tao2ZZVuKrXZBU1KG4qpctwabBGFqi5zXKXyfMa6vUDkGuculySRWEkaxMORcGo6uzx9aqMuDWZYgNORyrAg4YHINMxRQM9Z+HXi5jstryQ7xwGz1r1iK7SRA4z0r5a024NvdxvnAzg17h4Q1N3t0jlO9cfK1Ts7M2i7o6i6ma5l2YZYh79aVgiKqLnjqas2lqszBnbirfkQqGAxjvUtG3MraGbblUug+7n0rRUo8uQwzWFeTJE5WLjPU0WkMoAmMjCocbjbudpDEypkcirSogXc3A9a5aPXBaoTNIDjjBNYeu+PoIImjiYFvaoatqKzeh3N3e29vFudl4965XUfFNvbhlRx9Aa8z1LxVdXzFY2YKarWdleXr5bdg+tYNyexXKludpdeMDyFJINZja7dSSZTP406y8PNtBYVt2nh4nGEqoQb3YWTMuC9vZTljV+N7ochyK6zS/DK7RvFX5/DyqvC1pyxBcidjhxe3sbfeJHvV62vZ9uTk1sXGjhT0qsLMxkgDiocEOSXQqfb9/EgpHkjfG3rVl7EOCdtZd3bSQnKE1HL2M7FkYBOVGKjaIMcgYNVY7iRSFcfjV6IhhkGk+ZEtLqVZCyGkjuirYINW2iDtmmSQI5xVxrziZyowkOW8460VAbQr0JoroWLXVGP1XszzuwPT0rXTpWNYdBWuh4HNekjnZKTwao3TcVbJ4NZ123BpMEZd62QaxpRnNaN5JWazg1kzRFOaOqkkXNaT4NVpAKhotGc6YqJhzVyUVWepKGV2ngvxUNPdILzmMH5X9K4o0opNXHF2eh9KaTrkF1GpjlUqR2NX57wGIrGwJPvXzPZ6hd2n/HvPInsDWtb+K9WiZSbpmx60mrmqqI+hLa3ghjE126+uCa5/xV4qtbSDy7VlJHpXk83i6+u02STsB0qtE8t5JgMXJ71DTWiNIzTdzXv/EN5fSFVZgCegosdIurxtz7jn1ra8PeHujyrk13mlaSARheBWEp9i7tnN6F4WCkGRc12lho6RgBUFbdhpuFAAFatrZ7D8wqSTJt9PC4G2ta0swuMrU7rtPSrMLcdKtCbZNAuwYFTOARzUaBmPAqf7O7DHOaT1IKM8CP6VRlsFbkCtg2jjPGaBatjkVGpVzB+wqBgiqt1pqMDwD3rons3B4FVprWQDGDU6jvc4m60sBjgVAlmUPHFdVcWUhz8uazpoHQ8rxScugWZkPayYytQMGQjeOfX1rfi2tgEVJJaJIvQUJEXObZt2MUVqTaV83y8UU7Bc8asegrXToKxrJulaqvlRXto4GSseDWXetjNXmk4NZN/IMGk2CMe+k61ltJgmrF9L15rIeXk1i2apF0y8VE8lVDLTTIaQyWRqrsaUtmmUhhRSgVLbwSzvtiRmPsKQ7XI8UoGTiup0vwZf3gDOpRTXX6T4Fgt8NcfMw9aylXjEuNNs880zRri8cfIQpr0nw14YS3RWcZauksdHiQgRxgAd8VvWdmFYACuedWUzohBRGaXpvA+WupsNPVFHFTaXYgKCwrXEQXpTjEbYy3iVB0qZgMYAFMAI6VPDEW6iq2JZEtvvbOKs29llhkVchgAPIq7HHjoKVrkN2I4bRVGcVY8lQOg4qVRgUtVYwcmQGIY6U3yR6VZoocUw5mVzbj0qGS0U445q9Rip5ENTZmPYoRyKy77TUIPy10xGarzxAr0qJU0XGpd6nnl5YNE5K5qCORl4YZxXY3loDkYrFutPwTtFZJOJq7MqLhlB4xRSiJkJGOKK1ujPlPm20lwBWiJxjrXN28545q39pOOtelznI0aslwMHmsu9uAQeahe4JB5rOupiQeahzuUolW+lzmstm5NT3Mmaq9TRcoXdS5rU0nQbzUpFEUbBT/ABEV3OnfDyIopuJCW9KznVjHc1jSlI8zA5qxbWk1w4WKNmJ9q9itPAlhDj5N3ua17LQtO05t2xc/SsJYlLZFqj3PL9K8G3E5VrgFV64r0DRPDtlYxAGMF62WRrlwLaPA9hWnYaRNkNNwPQ1g6k5myppEFpAWwkaYUelaP2AIu6T8q0D5VrEAoGaZBBNqEgUA7aI029x3tsUoU3vtiFbum2LKwZx1rZ07Q47eMM45pbrbC2BW6SiK46H5AAKtqd4FZ0chc1o2yHjIPNO9zORNHDuIz0q9DEAORRBHxmrSpinYm4Rx1aUYFMQYqTIp2sZSdwooyKTrSIFooJpNw9aAFoqJ5QoyajNyKClFss1G/PFRrKT3pd4zUtj5WivcJk4weapSRAk8Vptg1UkUBie9Q0ax1M+SyDHgUVfHAooshWZ8MQS1P5pNUIasCupswJXk4qnO/Wp26VUmpIZUlyTXoHgTwV9vjW7vB8h6A1wlsoe7iU9Cwr3/AEKeK10qFRgAKKVWTSsjooQTd2WLbSrWxQLEqqo9BUpuI4gdg6VCssl3JhQStaUGjPPgEHBrhkdd1sZJvJpiUiBP0rT0zQZ7pg9wSB6VvWOiwWgBIGavNdLCMKMCpiiG+wlpptvZIMqMiq99fRr8sQBNV7m7knbavQ+laOkaM0zq0i5Faq62FbuU9M0qfUZgzghM13ml6RHaRDCjNXdNsY7eEAKBTtQukt4jzzWsU92c8ql3ZFDVLgQxnsRXLTTtPIQPWk1PUWuJiqk4qbT7ctgkU3qWtEXNOgyQT1ret7fCg1VtIMY9a1IeF5q4oiT7Cqu2nijrSjAFWQIXxTfM96huJcHA5qEMTyaNAsWvN96ekmazXk+erULYGTSBoss+OtRNNVWe8jwPmGD3qE3KMPlYGgCw8wIIB6VXebDUzzQT14prbXIxSaGnYtRTEn+tWUb1zWaCVIx0qQTkVDQXuaoAIpGi3EYxjvVJLjJA349quxTAgZNITutiKZMHGKKnfD0UrFKWmp8BQ9qnFQwjipxW7MRG6VUm6GrbdKqTd6EBHZ5+2Rexr2fwtaz6pHGoyEAArx7ToTLcrjsa+lvhxBDHpEZAG4ipq66HTR0VzY0nRkt4lBHIq/KwhTCjFSXN0sY64rNecStjPWuZxRuTZdwSTVY2zPIduSCa0bSHzcVt2tigwSBT0WwJWepS0jSYxh2GT711FnFHGOBioLeJYwCcAUl3cogIU1tTijOo76Fu91BLdPlPNchrOoPcZCk1JeytM5AJNNtrAyEZpyaWiIjFIzNPtHkkywNdXYWwRRkU+0slQdKurGAOKcVYJO4+MADgU7fg0gGKQKSeKpkJIlV/WkdielOSOnMgHJoFcoyKc5NNZsLkHpRfTrHxkVQmvVWE5NJySKSbH+aPM5NQahqiW6YLY461zd9rSRTHLgfjXG+MPFMUMJKyZPsanmNOTubPivxHJBGZI5MKBXMaR8SYt5W4fBHHWvMde8W3F9G0Sk7a5MyvknccmrhF9TOc47I+stG8W2moqNkq8+9bkepJn7wNfImk67dacwMbkj612ekfEOUSKlwzAeuarlIufSKajGcZYU6S7UjKtXlmm+Kra7jVvOAJ963bXVg6grJuH1qZRCKO0W6PUde1XIL3GMsBXKW9+HHJqyl18+c8elZNGljsorwEdaK5mK94x3oqQ5UfHkXQVKKji6VIK3ZzA3Sqk3tVpzxUcEXnXUUfUMwFNDRs+HNHllhacgjPIr17wPfmOzEZOCvFQ+G9IjS1jGz5QuKrJF/Z2qyRrkK3IFQ97s7IKysjsNRvvl68mrWjW8k6hz0rjbq6ZpEye9d3oN0q2SYrKcb7Gqep0FrblAuK1oSEUZrGtLoM2K1ogXxmiMBVXbQfJKW6DArOuA7NgVrGMBaZHCGbgVcpWVkYR7syoLQtIvFbtvaBEyQKtWtqqjcRU8g9KUI23JnUu7IonhwKfSOPmqaNM84rXYlsYqE1ZjQAU5UAFRzShByaTdyL30Q58LWVqeoJBGzFhwKravq8dvEzM2MCvHvHXjXAeKCTk8cU4p9ClHqzp9W8W24uCplHFctrvjmKKJhG/Jryi6vbieVnaRsn3qjIWc5Ykn3rT2Pcft0tkbmseK7m5lJQnH1rmL++uLonzXJFPZahdKpQSM3Uctyg61EwxV146gdOaLElY8UmakZaYRSGTwXk0BHlSMuO2a6fQ/F9zauqTsWX1rj6M4osNM988P8Aim3ugoMgBNdjb3iSKCrZFfLlpeTW0gaJyMe9d54a8aPGyR3DfnWcomsZXPchMSBRXM6brkFzFuVwTj1orKxdzwBRgCnUAcUVocoj9Kv+F4RcaxEpBPNZ8h4rsvhfpxudSabbkLR0NKavI9l0S0K26L7VheLoVg1W3YdWGK7SxiEcYHtXEeNWJ1iBc5xUnaiG8snkt/MQZI5q3oWolE8tjgit3Q4lntlVxwRWD4k0ebT7g3NuD5fUgVTiZqWtjqdOvxuGTXWafeKyjmvIrS9faHB5rqNE1jJALfnWbVin7x6SG8zoav2cQAyea5zTb5ZFHNbMdyQBg0oq5lJO1jWFMkPFVBdkjmopbn3rRRMFBpjypMtW1IRapxyDGe1VL/VI4FIZsUm0acrloX7m8SJTk1yHiHxJDaRuWkAI965rxd40htY2CSAn61414g8SXGpTMA5CVcIOQ3y01qdF4u8azXUjRwOceua4GeeSeQvKxJNNCvISQrNTGVl+8pH4V0xSjoc85SlqJmjrSZozVmYxkqNkqekPNFgKbp7VC8ftV9lz0qJkqXEaZnPFVd48dq03jqB46hopMzytMIq48dQumKmwyEUoYqcjgilIpCKQzZ0zX7qzUqGJGMdaKxKKLD5maCzCgy8VniX3pwkqOUkuFizADkmvc/hPpQj0hZSnz9TXhGnzBL2Fm6BhX1B8LzHJpvzAAMOKUkb0lo2dC0e1RgcV574jYS6+qnsK9Jvk2LtHUV5prilPEXz9xxWV9TrS0udh4ZwAoxXSahZx3Nm6MgORXP8AhZASpzzXbGINFxWqOee54lNAbHVZLd1+QnirL28kLCSEHHXitjx7YeVdpOgwc80uiss0QSQA5FJK+ho3azRHpmrSxFQxOa6vTtc34DHmuc1PSdi+bDx3rPinaMd9w61PLYd1JanqEN4JFzmiSbuK4zStVLYRjzW/FKWXOabehnyWZbn1Mwqd3SuC8Z68FgcK+Dg1v6mZHBAGa888U6RcXYbbkVktXqbqKSujzjVLyS7uXLsWGeBmtLQdBlvyHdSE7Vu6X4LLlWkbmuz0bThY4hMZ6Zz2rplV0tExp4e8uaZmaZ4dhijCmIH3IqTUPDFpNEcRgNXZiACLCDtWdqk8dlau8pAwKwSZ3tRtseG+INP/ALNvmi/h7Vl5rU8R3/2/UpJB90HArKrvhflVzxKtud8o6kpDRVGYoPFBxTe9GaBCMoNROlTUGlYZTdPaq0ie1aLqDVd0oUbjuZzpTCp9KutHk4xSmDPak6Y0zOKn0orR+zZ7UVnysdzDBpQaSipAkjbDqT2NfR/w51VG0e1W3bPyjJr5uFenfBzUDHeSWzNwOQprOotLo6MPKzsfRCu9xgkrXn3xABg1a1m24zwTXX213heg5rk/iGfMsI24yG61ipHaonSeD5ldUOc130ci+V+Ga8k8EXR8pVzyK9D+0stmzr1A/KtebQ55xuzB8Ybbm2dgOBzXJaHfIHC5wQcV1uouZrV0kHUda881TQry2mFxZOWBPKjtRTu2OraMT063kjmhCkgk8Vn+I/D0lhALtShUjJANYHhjSNf1G5jghPldGZ36IPWvXb3RbeTR/IvJXkKJ80rHqfpWz5VucntJJ6bHk9kFZw6GuktZWCgZrm7+ym0qZmwwhJ+XPpV7TtTVgu6spR6HUpX1Oh3AjlaxdYXePlXmtJbpHTg1X+SSUE9KzcSoy1I9MtFaHLCr7WkYwMdOlMaeOPAXAxVO61TnbH8zUK7NXIu3ciQQnnFeZ+PJby7gYWwOzviuvfz7t/3xKqO1VruCJIXMmAuO9NJp3RdrxszwVwVYhhg9803NavigRLq0vkFSp9KyM12xd0eRNcsmh2aM03NFMgdSZpAaKAFzRmkzSHmmIXNIQDRmjNCdgIynOamjjB5plSRvtq1JMCURDsKKmjkBHTminZAcPS0oFKBXGaCCuh8DXv2HxDbMThWO01z+KfE7RSK6nDKcik1cqLs7n1xpbpJEpPQjOaxfHkIfSn2DO3msz4da0NT0iFmPKja31rqtQhS5tHVgCCMVzs9KHRnG+DZ/kQ5xXqFnLm3HfivJobafRp3DozW5bKsO1dlo2uRvGi7wQe9UmE4GvdbQZVb7pJrmb+0u4pd1rIWTrtauv+yxugbOcjNC2AfB61EZOL0BqElZnJ+HvG99o9863FoJARtPOM119t4rbVJBJc7UUfdiB4H19TWZqmh21whBUB+xFctNbXWmyHepKjuK3VS+rMHh4fZO+1ZItStyDjpxXES2cljck4Pl5pI/E/2RQJFbFMuvEtvKhLgge4pOVxxhKOljYt7mHYMPz6U5pJJBiBfxrmLbXdMeTO8L7E1rHxVp0EXyyoMe9FmLmS2L8dpM7ZlfA9KtvDBbsCCMjua4698eWMRO19x9q5PXfHVxdgpa5QetChJj9rGOrO/1/wATWenRN5kgL9gDzXl+v+LrzUyyIxih9B1Nc9c3MtxIXmcu57k1Bmt4wsjnqYiUtFsOLEkknJNNz+dITQDitDmFJozSZpKAHUU3NGaAHdqTNJmigB2aSkH1ozQAuc0Z5puTz6UZ96AH7iOh4opmaKdxHPKtPC04LUqrkVjY0IdlN21bKcUxk9qLAdX8OvEA0m+8mZysUnQ56Gvcra9Se3VhJuB7ivmEKQcjiu08JeLZ7Ipa3bF4s4VielYzhfVHZQrW91nuUqxvBhsMMeleaeLYptO8y5sJCm35to6Gut07VEuYhg4zzg1ieNnjXR7huM7cVlZ7nf7vKxngz4im48u21FtrgYBPevVtP1OO4jUxuCCO1fJEJKsCCQR6V2XhrxlfaUVR2MsQ9eoFbSp9jzY1ujPpFyhGc5qC4tUmi+YZFcFoXjyyvQqyybHPZjXX2+rRTINjqR9azS5TdO+xha5oschBRenNYj6ZGykFa7icrKSFOCarSWcKgYILGs5K51052Vmea6t4dheNtqlH7MK4HULeWznaKUt7E9694u7VZAdwwBXnfjrSx9mM6j5krSlNxdnsZYmjGpDmjujgM0hPNNzSZrsPHHE0ZpM+1FMBc0H2pKSgQtGaQnFRs9AyTNLmq5kpyyZouFiajOaYGBpaBDs0lGaTNMBaQmjNFACj3opO9FIDMC81IoFApwqChQODTStPFFOwEe3nFKFp+BSgUrBc6vwz4m+yoltf5MQ+7IOq1P431YzQR28Dq8L/ADb1OciuP7Uvt2qXDW5sq0lHlI1XBqdeDTacKoxuSq2DkHBrZ0zxFf2GBHKWX0asLNLn0oaTKjJx2PQLP4g3Ea4mjJPqDVxfiEnVo2zXmgbPSlzUeziarEzR6zB42trlfnkVfY1U1bVrDUtNuBJdRoQpwueTXmOaQmn7KJTxU2rDm6nHSkzSE0VocouaKTNGeKAFzQKSjNMBrmq0j4qeQ1Tl5qWNDGl96cstVm60gbFK4zQSWplkzWYsmKmSXmmmI0QwpTVRJamV807isSd6M00EUUxDs0U2imB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient has suffered bilateral peripheral nerve infarction, leading to a complete wrist drop on the left and significant dorsiflexion weakness on the right. The patient's underlying diagnosis is the Churg-Strauss syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_43_7871=[""].join("\n");
var outline_f7_43_7871=null;
